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Abstract
Outcomes for muscle-invasive bladder cancer (MIBC) have changed little
over recent decades, with long term survival remaining around 50 % [1]. Standard
radiotherapy treatment for MIBC involves resection of tumour followed by uniform
radiotherapy to the whole bladder, as the residual tumour is not readily visible
on conventional computed tomography (CT) imaging. This thesis investigates the
use of diffusion-weighted MRI (DW-MRI) to enable a dose-escalated radiotherapy
treatment, aiming to improve local control of MIBC.
Geometrical distortion in DW-MRI was investigated via bladder-mimicking
phantoms, and positional differences were quantified between DW-MRI, standard
T2-weighted MRI, and CT. Deformable registration within a commercial radiother-
apy treatment planning system was tested to see whether it could mitigate distor-
tion. All markers were located within a maximum discrepancy of 5 mm (mean 3
mm). Open-source software designed to correct geometric distortion in DW-MRI
was tested and produced improved results with a maximum of 1.8 mm (mean 1.3
mm).
Tumours were simulated in 6 locations within the bladder on a CT dataset of
a previously-treated MIBC patient. Expansions producing planning target volumes
incorporated the findings from the phantom investigations, aiming to mimic the use
of DW-MRI registered to CT. Escalated dose distributions were compared against
the standard, using established dose-constraints for nearby sensitive organs. Maxi-
mum dose-escalations to 70 - 78 Gy were possible depending on tumour location.
Poisson-based tumour control probability (TCP) models were fitted to MIBC
trials data for radiotherapy-only and radio-chemotherapy treatments, and used to
calculate TCP for all dose distributions. TCP increased 9.0 - 19.2 % depending on
tumour location and model used. The feasibility of delivery of the dose distributions
was assessed via dose-accumulation using cone beam CT.
This work showed that the use of DW-MRI for planning and pre-treatment




This thesis presents a series of investigations into a potential improvement of radio-
therapy treatment for bladder cancer. The work involved assessing a specific type of
magnetic resonance imaging (MRI) called diffusion-weighted MRI (DW-MRI), which
provides additional information to conventional imaging methods regarding tumour
cell density. DW-MRI would be used within the design of radiotherapy treatments
to enable an increased dose to areas of tumour highlighted by the images to con-
tain tumour, rather than basing treatment on standard computed tomography (CT)
imaging in which the whole bladder is targeted as the tumour is not consistently
visible. DW-MRI is already in clinical use for the diagnosis of some cancers, but is
not yet used within the design of radiotherapy treatments. The assessment of the
use of DW-MRI within the design of radiotherapy treatments for bladder cancer was
performed by developing models to quantify the probability of control of bladder
tumours. The models were then used to compare a standard radiotherapy technique
with the proposed new technique, quantifying the expected increase in probability
of tumour control. A range of scenarios were tested, and the feasibility of delivering
the technique in clinical practice was also assessed. The aim was to provide a basis
upon which a future clinical trial could be developed.
Section 1.1 explains the motivation underlying the work described in this
thesis, and begins with a brief background to bladder cancer and its treatment
using radiotherapy, to provide a context for the subsequent outline of the different
sections of work. An overview is given in section 1.2 of the contents of each chapter.
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1.1 Motivation underlying this thesis
Bladder cancer is the 4th most common cancer in males in the UK [2] and is as-
sociated with poor survival, with around 50 % surviving for 5 years post diagnosis
[3]. It is the most expensive cancer to care for from diagnosis to death [4]. The
historical standard treatment is the surgical removal of the whole bladder (cys-
tectomy) to control disease spread [5], however this obviously causes significant
long-term morbidity in patients, even if their cancer is cured. Relatively little im-
provement in outcomes has been seen for patients with bladder cancer in recent
decades, unlike for several other cancer sites such as breast or prostate [6]. Some
clinical trials of alternative treatments to cystectomy have shown similar outcomes
for patients who received combined therapies including tumour resection, radiother-
apy and chemotherapy [7, 8]. Current trials are investigating ways to maximise the
effectiveness of such bladder-conserving treatments via the use of either technical
improvements in the delivery of radiotherapy [9] or improved imaging within the
diagnostic pathway [10]. The work presented in this thesis fits within this context
of the use of technical developments within radiotherapy and related imaging to
improve outcomes and reduce morbidity for patients with bladder cancer.
1.2 Overview of the chapters
The current chapter provides an introduction and overview of the thesis as a whole,
including the main aims and sections of work. Chapter 2 introduces background
information regarding radiotherapy treatments and the types of imaging used within
the radiotherapy process, and which is required for the context of this project to be
understood. This includes the effects of radiation on cells and how they are exploited
in the design of radiotherapy treatments. An overview of radiotherapy treatment
design and the relevant imaging modalities used within the process is presented.
Finally, in section 2.3, the limitations of radiotherapy treatment are discussed in
order to underpin the efforts to overcome or mitigate these problems later in the
thesis.
Chapter 3 provides background information on bladder cancer, including its
incidence and diagnosis as well as common treatment techniques, with particular
reference to radiotherapy and patient outcomes. Some important previous clinical
trials and their impact upon current standard treatments are presented, as well as
some current clinical trials. This leads on to the aims of the current work and the
rationale for this investigation.
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The first set of results are presented in Chapter 4, which covers the work
performed in designing, producing and imaging two model bladders using DW-MRI.
The purpose of this work was to quantify the effects of distortion seen in DW-MRI,
as this is a known issue and potential limitation to the ability to use this imaging
method within radiotherapy treatment design. The aim of this section of work
was to provide a ‘worst case’ but realistic prediction of the amount of geometric
distortion which could be seen in DW-MRI of the bladder, in order to be able to
assess the clinical effect of such distortions within the later work in this thesis.
The next section of work is presented in Chapter 5, in which two models are
developed to fit clinical trials data of bladder cancer radiotherapy. These models can
therefore be used to predict the probability of tumour control. One of the models
follows a standard method, using Poisson statistics to fit data in which patients were
only treated using radiotherapy. The second model is not a standard approach, but
builds upon the previous model and aims to provide an additional, ‘best estimate’
of the effects of treating patients with chemotherapy as well as radiotherapy. Both
models were designed to be used to enable comparison of the likely effects of a
standard bladder radiotherapy treatment with a variety of alternatives based upon
the use of DW-MRI within their design.
The central results of this thesis are presented in Chapter 6; this details the
systematic investigation of increases in dose to simulated bladder tumours. In this
study, tumours were simulated to mimic the range that might be seen using DW-
MRI within the BladderPath Clinical Trial [10]. Standard radiotherapy treatments
were compared with dose-escalated treatments, with a wide range of doses tested.
The models produced in Chapter 5 were then used to predict the probability of
control of the tumours using both the standard technique and the dose-escalated
techniques. The resulting predicted increases in probability of tumour control from
the dose-escalated treatment design based on DW-MRI are presented.
The feasibility of clinical delivery of the radiotherapy dose distributions dis-
cussed in Chapter 6 was assessed using daily imaging of a patient showing the day-
to-day movement of the bladder and other anatomy. The results of this feasibility
study are presented in Chapter 7.
Finally, Chapter 8 draws together the implications of the results seen in
Chapters 4-7 and sets out a vision of how this change in radiotherapy treatment




This chapter introduces the concepts and background knowledge about radiother-
apy and related imaging that is relevant for the chapters which follow. It begins
with a brief history of the development of the use of ionising radiation for medical
treatment, in order to set the context for this project. The methods of production
and shaping of x-ray beams for radiotherapy treatments, and their interactions with
cells and resultant effects are then discussed. This leads on to the introduction of
tumour control probability (TCP), which is fundamental to the practice of radio-
therapy, and which is investigated further in Chapter 5. Section 2.1.4 then provides
an overview of the techniques used in current radiotherapy clinical practice, and sec-
tion 2.1.5 presents the limitations of radiotherapy treatment including toxicity and
treatment failure. Section 2.2 introduces the imaging methods currently required
for accurate calculation and delivery of 3-D dose distributions to a patient, as well
as other imaging of relevance to this thesis.
2.1 The use of radiation for medical treatment
The information presented within sections 2.1.1, 2.1.2 and 2.1.3 can be found in
many radiotherapy physics textbooks; where not otherwise stated information was
taken from The Handbook of Radiotherapy Physics [11] and Radiotherapy physics
in practice [12].
2.1.1 Historical context
High energy x-rays have been routinely used for decades for the treatment of cancer,
and remain one of the main forms of radiotherapy. A variety of techniques are
used to image the patient prior to radiotherapy treatment in order to accurately
4
delineate the volume of tumour which requires irradiation. Over the last few decades,
the imaging techniques used to determine the tumour volume, and the ability of
radiotherapy treatment machines to deliver radiation accurately to these volumes
have been refined and developed [13].
Figure 2.1: Picture of a modern Elekta linac.
Technological developments from the initial use of radioactive sources (par-
ticularly Cobalt-60) and cathode-ray x-ray generators, through to modern linear
accelerators (linacs) have systematically improved the ability to deliver radiation
doses more accurately, and with corresponding decreases in doses to healthy tissues.
An example of a modern linac is shown in figure 2.1. These technological develop-
ments have led to improvements in both survival and patient quality of life following
treatment, owing to the ability to deliver higher doses of radiation to tumours, with
lower doses to nearby healthy organs. Improved conformality of regions of high dose
to the desired volume have been possible via the development of multi leaf colli-
mators (MLCs). These consist of multiple narrow pieces of high-Z metal such as
tungsten which can be rapidly moved and interleaved to produce complex-shaped
x-ray beams (for a schematic example, see figure 2.4). Developments in computer
systems in conjunction with MLCs has enabled the calculation of sculpted radiation
dose distributions and the treatment machines to accurately deliver them. The pro-
gression has developed from basic 2-D to 3-D and even 4-D radiation delivery, so
that in the latter, the effects of positional changes with respiration can now be ac-
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commodated. At the present time, there is widespread clinical use of 3-D sculpted
dose distributions which are accurately calculated and delivered using such tech-
niques as intensity modulated radiotherapy (IMRT) and volumetric modulated arc
radiotherapy (VMAT). These techniques may also be gated to enable delivery at
specific parts of the breathing cycle for greater accuracy of dose delivery to tumours
in 4-D [13].
It could be argued that some of the current limitations of radiotherapy treat-
ment are due to limitations in imaging capabilities, rather than dose delivery, and in
the ability to accommodate patient anatomical variations at the time of treatment
relative to the snapshot previously seen during initial imaging of their anatomy.
Much current research and development aims to address these issues, particularly
with regard to the use of MRI both prior to, and during the delivery of radiother-
apy treatments, in order that radiation doses are conformed as closely as possible to
the required volumes. As the technological developments discussed above enabled
improvements to radiotherapy treatment delivery, it is anticipated that further tech-
nological advances incorporating developments in MRI could lead to future improve-
ments in patient outcomes. This could be via enabling improved identification of
tumour volumes and individualisation of treatments such as adaptations to response
as evidenced by MRI during treatment.
2.1.2 Radiation - production and interactions
X-rays used for modern radiotherapy treatments are generally produced using linear
accelerators (linacs), which produce a spectrum of energies in the megavoltage (MV)
range. Figure 2.2 shows a nominal 6 MV spectrum, which may have a mean x-ray
energy of around 2 MeV. This energy range exhibits the ‘build-up’ effect, as seen in
figure 2.3, in which the absorbed dose is higher a short distance beneath the skin
compared to the surface. The effect is due to a lack of electronic equilibrium, as it
requires a short distance for the electrons generated (principally via the Compton
effect) by the incident x-ray beam, and which tend to travel along the direction of
the incident beam, to reach an equilibrium level. The range of secondary electrons
produced via interactions in tissue will be around 16 mm [11], but the dose deposited
will decrease after reaching electronic equilibrium as the beam is attenuated. Doses
are usually measured in Gray (Gy) where 1 Gy is equivalent to 1 J/kg.
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Figure 2.2: Spectrum of a nominal 6 MV linac.
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Figure 2.3: Variation of absorbed dose with depth for a nominal 6 MV x-ray beam
produced by a medical linear accelerator. The variation of dose with depth is shown
for an idealised beam with no attenuation and a realistic beam in which dose beyond
the depth of dose maximum decreases approximately exponentially.
This ‘build up’ effect is exploited in radiotherapy treatments, as the dose to
the skin would otherwise limit the achievable dose at depth. A schematic showing
a linac and patient positioning system is shown in figure 2.4.
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Figure 2.4: Schematic showing a linac and patient positioning system, allowing
delivery of shaped beams of x-ray radiotherapy from all angles as required.
Medical linacs such as these are designed to enable x-ray beam delivery from all
angles around a patient, allowing multiple beams to intersect at the desired location,
and spreading out the radiation dose to healthy tissues. In the case of commonly-
used VMAT treatments, the linac rotates continuously around the patient with
positional adjustments to the MLC occurring whilst x-rays are delivered. Figure 2.5
shows a schematic of the effect of delivery of shaped beams of radiation of varying
intensities from around the patient via a cross-sectional diagram through a patient.
High dose gradients are achieved at the intersection of the beams (referred to as the
‘isocentre’). This is usually chosen such that it is located within the tumour volume
to be treated.
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Figure 2.5: Schematic showing a cross-section through a patient and the intersection
of beams of varying intensity from all angles around the patient. The variation of
beam intensities with gantry rotation is indicated schematically below the patient
cross-section.
2.1.3 Cellular responses to radiation and TCP
When radiotherapy is used to treat tumours, both tumour cells and healthy (nor-
mal) cells are exposed to ionising radiation. The proportion of cells killed depends
on many factors including the sensitivity of the exposed cells to radiation (radiosen-
sitivity). For each individual cell the likelihood of cell kill if exposed to a certain
dose occurs with a particular probability, i.e. it is a stochastic process. However, for
a large number of cells it is seen as a deterministic effect, and so there is a threshold
below which no clinical effect is observed (and similarly a threshold above which
an effect will always be observed). Figure 2.6 illustrates this; the curve on the left
shows tumour control probability (TCP) i.e. the probability that the tumour will
be controlled by that dose of radiation. The curve on the right shows normal tis-
sue complication probability (NTCP), which is the probability that healthy tissue
will experience a particular complication as a result of the radiation dose received.
Successful radiotherapy treatment is more likely when the TCP curve lies far to
the left relative to the NTCP curve, as it is possible to deliver a larger dose to the
tumour and achieve a higher probability of tumour control with a lower probability
of unacceptable side effects.
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Figure 2.6: Probability of tumour control and normal tissue complication against
dose. D0 is the intended treatment dose. Adapted from Williams and Thwaites [12].
The tissues of the body retain their function via renewal of the cells within
them, which occurs due to the ability of stem cells to reproduce. Tumours contain
cells which reproduce rapidly, and can proliferate beyond the body’s normal control
mechanisms, leading to overgrowth and resultant complications. Not all cells within
a tumour retain this ability to reproduce, however, and indeed many cells within
a tumour remain normal functional cells. The intention of the use of radiation to
treat a tumour is to ‘kill’ tumour cells whilst minimizing damage to normal, healthy
cells nearby. Although the term ‘kill’ is often used when talking about the effects
of radiation on cells, in fact it is not that the cells will necessarily immediately
die, but that they lose the ability to reproduce and proliferate. Tumour stem cells
can be detected via assays in which cells are placed in a growth medium, and those
which are able to reproduce and form colonies are referred to as ‘clonogenic’, ‘colony-
forming’ cells, or ‘clonogens’. When clonogenic assays are performed, the proportion
of surviving cells or colonies can be compared for variations in dose. The results
from such experiments are often presented as cell survival curves, such as those seen
in figure 2.7, which shows typical cell survival curves for irradiated cells.
11
Figure 2.7: Schematic cell survival curves, plotted on a logarithmic scale. The green
curve shows cells which are more radiosensitive and which would have a higher α/β
ratio than those shown by the blue curve.
Study of cell survival curves has led to the development of the linear quadratic





where the survival fraction (SF) is the fraction of cells which survive the irradiation,
d is the radiation dose and α and β are parameters which determine the shape of the
curve. Often, the shape of cell survival curves are referred to via a single parameter,
the α/β ratio. The α value determines the initial slope of the curve, and the β value
determines the degree of curvature. The curves in figure 2.7 illustrate the effect of
variations in α/β, with the green curve having a higher α/β ratio than the blue
curve. In general, tumours are thought to have high α/β ratios (e.g. ∼ 10 Gy)
and normal tissues low α/β ratios (e.g. ∼ 3 Gy), although there is much variation
between different tissue and tumour types, and some tumours have low α/β ratios.
For the purposes of comparing the effects of different types or doses of radi-
12
ation, it can be more appropriate to consider the effect (E) of radiation, instead of
the surviving fraction of cells. In this case equation 2.1 becomes
E = αd+ βd2, (2.2)
i.e. here E = -ln(SF). Historical practice of radiotherapy led to the development
of fractionation of treatments, that is, for the dose to be delivered in several equal
portions, often with a portion given each day for 5 days over several weeks. This
was found to produce a greater tumour response and reduce side effects to healthy





= αD + βdD, (2.3)
where total dose D = number of fractions (n) × dose per fraction (d). This can be








The quantity E/α is also known as the Biologically Effective Dose (BED), which
indicates how much damage a particular fractionation scheme will do. This is the
total dose which, if given in infinitely small fractions, is equivalent to the actual
fractionation scheme with a dose per fraction of d and total dose D. The practice of
fractionation can then be understood as the different α/β ratios between tumours
and healthy tissues leading to the different effects of fractionation, where healthy
cells tend to be less affected than tumours.
The BED is one way of comparing fractionation schedules; another commonly-
used quantity for this purpose is to convert to the dose which if given in 2 Gy





Tumour control probability modelling
In theory, it should be possible to eradicate every clonogenic cell within a tumour,
and if this were achieved, would enable control of the tumour. This is often referred
to as ‘local control’, i.e. in the locality of the tumour the disease is controlled,
although distant spread elsewhere (metastasization) may have ocurred and not yet
be apparent.
However, total eradication of all clonogenic cells is difficult to achieve. Each
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gram of a tumour may contain ∼ 109 cells, of which only around 1 % will be
clonogenic [11]. At the time of radiotherapy treatment, a tumour may be many
grams and therefore the total number of clonogenic cells to be eradicated may be
greater than 109. If, for example, a tumour contains 1010 clonogenic cells, then
assuming a constant effect per fraction which results in a surviving fraction of around
0.5, then 30 fractions of 2 Gy will reduce the number of surviving clonogenic cells to
around ten (0.530 ≈ 10−9). However, although this number of surviving cells may
not be visible on any imaging used to assess response, it does not necessarily mean
that complete regression has been achieved.
From equation 2.1, and replacing SF by Ns/N0, we can now write










where D is the total dose, d is the dose per fraction, N0 is the initial number of
clonogens, and Ns is the surviving number of clonogens.
Munro and Gilbert [14] originally modelled TCP using a combination of
Poisson statistics and the linear-quadratic model of cell survival. They assumed
that tumours are only controlled if there are no surviving clonogens at the end of
treatment, and that for a population of identical tumours the number of surviving
clonogens after irradiation has a Poisson distribution, i.e.




where P is the probability of the occurence of y events when the mean number of
events is N. Therefore the probability of y = 0 (no clonogens survive) is
TCP = P (N, 0) = exp(−N). (2.8)
If an experiment were performed in which identical tumours were irradiated and
there was, on average, a single clonogenic cell remaining then the probability of no























This approach to the modelling of TCP has been taken by many authors,
and different models have aimed to incorporate the various effects of tumour cell
radiosensitivity, changes in tumour volume, or inhomogeneities in dose distributions
amongst other effects.
2.1.4 Overview of radiotherapy treatments
In general, a patient attending a radiotherapy department will have had diagnostic
imaging to confirm cancer diagnosis, which will likely have included a computed
tomography (CT) scan. In conventional radiotherapy treatment of most cancer
sites, the patient will ordinarily have further CT imaging performed within the
radiotherapy department which is often referred to as a ‘planning CT’, as it is used
for planning and calculating the radiation dose distribution to the patient. Further
details of CT scans are discussed in section 2.2.1, however in essence they are a
3-D image of the patient which shows good contrast between soft tissues (such as
muscle) and bony anatomy. The image intensities within CT allow not only the
visibility of many internal tumours and organs, but also the accurate calculation
of radiation dose from x-ray beams. The dose calculation procedure is referred to
as ‘radiotherapy treatment planning’, and may take place over the course of one
or more days as it requires the input of several members of the radiotherapy team,
in order to calculate and check all aspects. The radiotherapy treatment is then
delivered over the course of several ‘fractions’ over several days, as discussed in
section 2.1.3.
A difficulty which arises from planning treatments on a set of images from
one snapshot of anatomy, and then fractionating treatment delivery, is that there
will always be some changes in patient anatomy between the acquisition of the
planning CT and delivery of each fraction. Some differences originate from the
positioning of the patient, whilst others are due to internal changes such as variations
in bladder filling. Where possible, all differences are minimised via the choice of
reproducible patient positioning and assisted with immobilisation devices at the
time of acquisition of planning CT. Nevertheless, dependent upon the anatomical
treatment site and previous analysis of reproducibility of positioning, some imaging
may be performed immediately prior to the delivery of radiotherapy. This is done
with the aim of performing small shifts to the patient position so as to reproduce
the original position as well as possible. The imaging used for this purpose is often
cone beam CT (CBCT), which is very similar to standard CT but uses a cone beam
of x-rays and a single rotation of the beam, and can be directly attached to the linac
(see section 2.2.1).
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2.1.5 Complications and limitations of radiotherapy treatments
Imaging limitations
Radiotherapy treatments can be limited by the visibility of tumour on the imaging
used to determine the volume to be treated, There may be infiltration of nearby
tissue by tumour which is not yet large enough to be visible owing to the limitations
in resolution of any imaging method. There also may have already been metasta-
sization of the tumour (distant spread around the body) which means that even if
the local tumour is adequately treated, the disease elsewhere limits the long-term
response of the patient. There is also the basic limitation of the anatomy located
close to the tumour which limits the dose which may be prescribed to the tumour,
as the proximity of other sensitive organs means doses must be limited for safety.
This is a particular problem in mobile organs such as the bladder, where the margins
required to ensure that tumour is treated are quite large and so nearby organs such
as the bowel limit the dose that can be prescribed. Historical developments in both
imaging and techniques to deliver radiation have enabled safe dose increases in some
cases, or the reduction of side effects.
Side effects and toxicity
As tumours can infiltrate and also contain normal functioning tissue, the require-
ment to deliver a tumouricidal dose to volumes containing normal tissue means that
side effects from radiotherapy treatment is to some extent unavoidable, even if the
dose is highly conformed to the volume which requires treatment. Side effects of
radiotherapy are very dependent upon the dose received and the tissue of the body
receiving the dose. Some effects are short term ‘acute’ effects, which generally sub-
side with time, and others can be long-term chronic or ‘late’ effects. Although the
acute effects can be clinically significant as they may limit the deliverability of the
treatment, the late effects are obviously also of concern as they are long-term and
not necessarily reversible.
Side effects of particular relevance for bladder radiotherapy include those
caused by irradiation of the bowel such as malabsorption, diarrhoea, ulceration and
occasionally obstruction. The bladder itself can also be affected, with cystitis being
the most common side effect but possible shrinkage or ulceration can occur [15].
This is not a complete list of the potential toxic effects of bladder radiotherapy but
rather an indication of the many possible undesirable effects, most of which increase
in likelihood with dose and the volume of tissue irradiated. The tolerance of the
various different tissues can vary significantly, and in general the dose to the bowel
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will be the limiting factor regarding the dose which is deliverable to the bladder
owing to its proximity. These potential side effects can be generally referred to as
the ‘toxicity’ of treatment. Technical developments in radiation delivery such as
IMRT and VMAT have meant that doses have often been increased (‘escalated’) to
small tumour volumes, whilst doses to nearby organs have been kept low. Sometimes
this has been referred to as the development of ‘isotoxic’ dose escalation strategies,
i.e. for tumour sites where there is an acceptable level of toxicity, the probability
of local tumour control has been increased by a change in treatment technique, and
clinical trials have compared the change against the standard technique with the
aim of keeping the rates of toxicity constant.
Chemotherapy
Some tumours respond better when chemotherapy is given in addition to radiother-
apy. It can be prescribed prior to (neoadjuvant) or during (concurrent) radiotherapy
treatments. As chemotherapy agents are essentially toxic (although ideally prefer-
entially affect tumour cells), the effects of chemotherapy can increase toxicity of
radiotherapy treatments, as well as improving response.
2.2 Use of imaging within radiotherapy
Prior to the introduction of CT imaging, radiotherapy treatments were planned on
the basis of external measurements of anatomy and 2-D (planar) x-rays of internal
anatomy. Over recent decades, the use of CT to provide 3-D anatomical informa-
tion about tumour and nearby organ locations has become ubiquitous. Current
developments involve the use of other imaging modalities such as MRI and PET,
which provide additional information regarding either improved soft tissue contrast
or functional information. This section provides an overview of the imaging modal-
ities relevant for radiotherapy treatments with respect to this thesis.
2.2.1 Computed tomography
The background information about computed tomography (CT) described here can
be found in many textbooks on medical physics and imaging; unless otherwise stated
this section refers to information from An Introduction to Medical Physics [16].
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Figure 2.8: Example of a CT scanner.
Figure 2.8 shows an example of a CT scanner, with the patient couch and
ring of detectors through which the couch is passed for image acquisition. A CT
scanner produces cross-sectional images of the internal anatomy of a patient, via the
use of a fan beam of x-rays which is rotated around the patient as they are moved
along the axis of rotation (see figure 2.9 for a schematic). Detectors on the opposite
side of the patient are used to detect the radiation which has passed through the
patient. Images are then formed via back-projecting and reconstructing what must
lay within each ray-path to have produced the images acquired.
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Figure 2.9: Schematic of a CT acquisition, showing the movement of the patient
along the axis of rotation of the x-ray source and a simplified cross-sectional image
slice with contrast between bones and the rest of the pelvis.
CT images are displayed as transaxial ‘slices’, i.e. a set of 2-D images each
showing the cross-sectional view of internal anatomy. The display of these images
is via an array of pixels (picture elements), the shade of which varies from white
to black. The shade displayed varies according to the CT number, measured in
Hounsfield units (HU), which depend upon the inferred x-ray absorption coefficient
of that pixel. Figure 2.9 shows this idea with increased absorption shown in the
cross-sectional view of the top of the femur (thigh bones) compared to the rest of
the pelvis. As there is a stack of slices, each slice has a finite thickness, and therefore
each pixel has an associated volume. This small volume element is called a voxel,
and is often around 2 mm in each dimension [16].
Use of CT for radiotherapy treatment planning
CT is used for the dual purposes of delineation of tumours and nearby sensitive
structures, as well as to allow accurate calculation of radiation doses. Patient geom-
etry can be determined from CT due to good contrast between the various tissues
of the body, and no geometric distortion of the reconstructed images. CT data is
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readily converted from Hounsfield units to relative electron densities; this is useful
as the x-rays used for radiotherapy treatments are of high energy (several MeV) and
predominantly interact in the body via the Compton effect. Since the probability
of Compton interaction is directly proportional to electron density, CT scans can
therefore be used to calculate dose distributions which account for inhomogeneities
in tissue [12].
Radiotherapy treatments require the delineation of the tumour volume, with
subsequently reliable and accurate delivery of radiation to this tumour volume. This
must be achieved by taking into account the various uncertainties in the process of
imaging and repeatedly setting up the patient for multiple treatment fractions. The
process is aided by the definition of specific 3-D volumes within the CT of the
patient. These volumes are illustrated schematically in figure 2.10 and include the
gross tumour volume (GTV), clinical target volume (CTV), internal target volume
(ITV), planning target volume (PTV), and organs at risk (OARs). These volumes
are defined by the International Commission on Radiation Units and Measurements
(ICRU [17]).
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Figure 2.10: Schematic showing the relationship between the gross tumour volume
(GTV), clinical target volume (CTV), internal target volume (ITV), and planning
target volume (PTV) as defined by the International Commission on Radiation Units
and Measurements (ICRU [17]). Note that the margins around each volume may be
anisotropic, depending upon known positional variations and treatment techniques
used. An organ at risk (OAR) is also shown for context.
The GTV is the gross palpable, visible or demonstrable position and extent
of the malignant growth, and the CTV is the volume of tissue that contains the
GTV and any subclinical microscopic disease (if there has been surgery to remove
the GTV, there will remain a CTV but which no longer contains the GTV). This
CTV is the entire volume which must be treated using radiotherapy in order for
the local control of the disease to be achieved. An ITV may be produced in order
to accommodate the internal motion of a CTV relative to bony anatomy of the
patient. Variations in size and location of a CTV may occur due to breathing or
other organ motion, and so is formed from the CTV plus a margin to accommodate
the variations.
The PTV is a geometrical definition which is used for the purposes of treat-
ment planning, and contains the CTV but with additional margins which vary in
order to account for variations in daily positioning and motion-related uncertainties.
The purpose of the PTV is to enable delivery of the prescribed radiation dose to
the whole GTV/CTV with an acceptable (high) probability.
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In the case of bladder cancer, the GTV is the tumour volume itself, but the
CTV is usually the whole bladder, as there may be microscopic disease spread and
distinguishing GTV from healthy bladder wall is not always possible using CT (and
particularly CBCT). The PTV is therefore constructed via a margin around the
outside of the whole bladder. The margins may be isotropic, or anisotropic in order
to take into account the known variations in movements of the bladder in different
directions (this is discussed in greater detail in Chapter 6, section 6.3).
Cone Beam CT
An imaging technique similar to CT is cone beam CT (CBCT), in which instead of
using a fan beam of x-rays for imaging the patient whilst the patient is moved, a
cone beam is used, and rotated around the patient a single time with the patient
remaining stationary. Equipment which can be used to do this is often attached to
the linear accelerator used to deliver the radiation treatment, enabling rapid imaging
of the patient immediately prior to treatment delivery. Figure 2.1 in section 2.1.1
showed a linac with CBCT attached.
Small alterations in the patient position may be made on the basis of the
acquired CBCT images which show internal anatomy, so that margins used to create
the PTV can be minimized, resulting in minimisation of doses to OARs and the
volume of healthy tissue irradiated around the tumour. CBCT produces images
with poorer image quality than is possible with conventional CT, owing to the
increased scatter from the use of the cone beam of x-rays, but is adequate for many
tumour sites. The field of view (FOV, i.e. cross-sectional area in which images are
acquired) of CBCT may also be smaller than for a conventional CT scan.
2.2.2 Magnetic resonance imaging
The background information about magnetic resonance imaging (MRI) described
here can be found in many textbooks on medical physics and imaging; unless oth-
erwise stated this section refers to information from An Introduction to Medical
Physics [16] or MRI From Picture to Proton [18].
Whilst CT is the predominant imaging modality used within radiotherapy,
other modalities can provide supplementary information. Sometimes contrast be-
tween different tissue types is insufficient using CT, or information about the func-
tionality of the tissues rather than gross anatomic differences may be desirable. MRI
is one of the most commonly-used of these other modalities. In general, where MRI
is used within radiotherapy treatment planning, the images are acquired in addition
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to the planning CT and fused with or registered to the CT, such that the visibility
of anatomy can be compared between the two datasets [16]. This image registration
means that the information from the MRI can be incorporated into the radiotherapy
treatment planning, and dose calculation still performed using the CT dataset.
MRI can contain spatial distortions and other artefacts and so care must be
taken when using this modality for the purposes of radiotherapy, as whilst these
effects may not be significant when the same images are used purely for diagnosis,
they could result in significant effects within the radiotherapy process. It is not
straight-forward to use MRI for volumetric radiotherapy dose calculation, as the
electron density information acquired from CT is not simple to infer from an MRI.
However, this is an area of much research and is starting to be used clinically in some
sites [19]. This use of MRI without fusion to CT is referred to as MR-simulation
or MR-sim. The use of MRI for MR-sim and radiotherapy treatment planning is
likely to be developed further in the future as MR-linacs become more widespread
(MR-linacs are combined linacs and MRIs used for radiotherapy treatments with
the MRI used to image patients prior to and even during delivery of radiation [20]).
Generation of an MR image
MRI involves putting the patient inside a strong magnetic field (usually 1.5 or 3.0
T) to induce a magnetic field within the patient. This field is then perturbed in a
variety of ways by using radiofrequency (RF) pulses, and as the system returns to
equilibrium by a process called ‘relaxation’, small RF signals are produced. The RF
signals can be detected and converted into images using a fast Fourier transform
(FFT) which converts the frequency information detected into positional informa-
tion. The frequency information is referred to as ‘k-space’ and is essentially an array
in which each cell contains information about how much of that particular signal
frequency occurs in the image. The appearance of MR images can vary widely de-
pending on the sequence of applied RF pulses and additional gradients in magnetic
field used for its acquisition.
In the presence of an external magnetic field, protons will align either parallel
or anti-parallel with this field, and precess around it. A slight excess of protons
are aligned parallel with the field and so this results in a net induced magnetic
field in the patient, in the direction of the applied field (usually referred to as the
longitudinal direction). This net induced magnetization can be referred to as the
net magnetization vector (M0). The precession frequency ω0 is described by the
Larmor equation,
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| ω0 |=| γB0 | (2.11)
where γ is the gyromagnetic ratio which is a constant for each nuclear isotope and B0
is the external magnetic field. When an RF pulse (B1) is applied which has the same
or very similar frequency as the precession frequency, the amount of longitudinal
magnetization is decreased and the protons also become synchronized (i.e. begin to
precess in phase with each other). We can say that
B1 =| B1 | cos(ωRF t+ φ), (2.12)
where | B1 | is the magnitude of the RF signal, ωRF is the frequency of the applied
RF, t = time and φ is an arbitrary offset. The resonance offset, Ω, is the difference
between the applied RF and the Larmor frequency, i.e.
Ω = ωRF − ω0, (2.13)
which must be sufficiently small for resonance to occur.
The application of the RF pulse results in a transverse component to the
magnetic field (i.e. perpendicular to the original longitudinal direction of the mag-
netization). Figure 2.11 (a) illustrates this movement of M0 from longitudinal (z)
direction into the transverse (x-y) plane. This is often pictured via a rotating frame
of reference, as can be seen in (b) where the frame of reference rotates at ωRF . The
angle through which M0 is moved is often specified in terms of the RF pulse which
caused it - e.g. a 90◦ pulse causes M0 to be ‘tipped’ or ‘flipped’ such that it rotates
in the x-y plane at ωRF .
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Figure 2.11: Diagram showing movement of M0 into the transverse plane following
application of an RF pulse at ωRF . (a) shows the effect in the laboratory frame of
reference, and (b) a frame of reference rotating at ωRF .
If the RF pulse is switched off, the system begins to revert to the initial
state, and the rates at which longitudinal magnetization is regained and transverse
magnetization are lost are independent from each other. The former depends on
energy exchange with the surroundings (or lattice, so this is sometimes referred to as
‘spin-lattice’ interactions) and are described by a time constant denoted T1. The rate
at which transverse signal is lost depends on the rate at which synchronicity in the
phase of precession is lost, and this in turn depends on inhomogeneities in both the
external magnetic field and in the local environment. This can therefore be referred
to as ‘spin-spin’ interactions, and these are described by a time constant denoted
T2. Images acquired in which the timings of excitations and signal measurement
are chosen so as to maximize either the contrast resulting from differences in T1
or T2 relaxation times are referred to as T1 or T2 ‘weighted’ images (T1W or T2W
respectively).
Sometimes the RF pulse used is referred to as ‘tilting’ the magnetization, as
what can be seen on the macroscopic scale is a net shift in direction of magnetization,
for example from longitudinal to transverse (which would be called a 90◦ pulse).
Other RF pulses can be used, and are similarly named based on the angle through
which the net magnetization is changed. Combinations of pulses can be used so as
to maximise the differences in signals generated between tissue types, according to
their relative relaxation times. For example, a ‘spin-echo’ pulse consists of a 90◦
pulse and one or more 180◦ pulses (for T2 weighted imaging) and can be used to
highlight differences in rates of loss of phase coherence between different tissue types
[21].
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Figure 2.12: An example MR scanner showing the various typical axes and direc-
tions, and the location of the different parts of the scanner.
Gradient fields are produced in MRI by the gradient coils, such that the
strength of magnetic field varies linearly along the length of the scanner (figure
2.12 shows the location of the coils and the axial directions referred to here). The
gradient fields allow positional information in terms of the ‘slice’ (or z-direction
for axial slices) along the patient length to be selected. To determine positional
information within a given slice, other gradients are applied; these are the ‘phase
encoding’ and ‘frequency encoding’ gradients.
In order to fill k-space with sufficient data to form an image, these processes
are repeated multiple times in quick succession. The repetition time, TR, is the
time between two excitation RF pulses, and the echo time (TE) is the time between
an excitation pulse and the MR signal sampling. The number of excitations (NEX)
and echo train length (or number of echoes) may also be specified when describing
a particular MR sequence. Whereas in CT scanning, the FOV of the scanner is
generally fixed, this can be manually set for MR scans in order that the region of
interest can be imaged with sufficient resolution in a reasonable time.
Conventional MR imaging produces images in which there is excellent con-
trast between various soft tissues of the body; this can be useful within radiotherapy
both for delineation of tumours (GTVs) as well as for OARs. An advantage of an
MR-linac is that this kind of imaging is then possible both immediately prior to and
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even during treatment, with no additional radiation dose to the patient unlike with
the use of CBCT. As there is improved soft tissue contrast, some tumours are much
more visible against local soft tissues using MRI than with CT, and particularly
with the reduced contrast seen in CBCT.
2.2.3 Biological imaging: DW-MRI
Biological imaging does not have a precise definition, but can broadly be divided
into functional and molecular imaging (although there is no consensus on these def-
initions) [22]. Functional imaging can refer to imaging of physiological processes
such as blood flow, and may be performed using MRI, CT and ultrasound. Molec-
ular imaging generally refers to imaging of molecular and cellular processes and
can be performed using positron emission tomography (PET), magnetic resonance
spectroscopy and others.
Of interest for the purposes of this thesis is a particular type of biological
imaging which can be performed using MRI, in which the sequences chosen produce
images which are sensitive to the degree of diffusion of water molecules within the
body called diffusion-weighted MRI (DW-MRI). In addition to the conventional
forms of MRI discussed in section 2.2.2, an MR scanner can also be used to produce
images in which contrast is produced between regions of high diffusion of water,
and regions where diffusion is restricted. This provides information beyond pure
anatomic information (indeed, the detailed anatomic information normally acquired
in MRI is lost when using this technique). However, when multiple types of MR
images are acquired in a single session they can provide a range of information
about the relevant part of the patients’ anatomy; this is often referred to as multi-
parametric imaging (mpMRI). DW-MRI is a form of biological imaging which is
often one of the acquired datasets of mpMRI.
DW-MRI techniques show signal intensities that vary according to the aver-
age distance water molecules are displaced through diffusion. The signal decreases
with increase in speed with which the water molecules travel in the direction of an
applied gradient. Where the geometry of the environment on a cellular level pre-
vents free movement of water, as in the proliferation of tumour cells, the diffusion
is reduced.
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Figure 2.13: Schematic showing the application of RF pulses and diffusion sensitizing
gradients to generate a DW-MRI signal.
In order to create an image in which the contrast is sensitive to the diffusion
of water, a pair of (very high amplitude) gradients can be applied before and after
the 180◦ RF pulse. This is illustrated schematically in figure 2.13, which shows an
initial 90◦ RF pulse (which tips the signal from alignment with the applied magnetic
field) followed by a later 180◦ pulse which is used to rephase the protons. The signal
is then detected following the time allowed for rephasing. On either side of the
180◦ pulse are the applied diffusion gradients. The effect of this is essentially that
if all protons were to remain stationary the effect of the applied gradients would
cancel. However, if there is movement (due to the diffusion of the water containing
the protons) then the protons will experience different magnetic fields and therefore
there will be resulting signal loss. Hence there is greater signal where there is
restricted diffusion, and reduced signal where there is a high rate of diffusion.
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Figure 2.14: Cross-sectional imaging of the bladder and an internal tumour as shown
using CT, T2-weighted MRI (T2W-MRI), Diffusion-weighted MRI (DW-MRI) and
Apparent Diffusion Coefficient (ADC) mapping. Images reproduced from Maurer
et al. [23], arrows added.
An example of the various types of imaging discussed can be seen in figure
2.14, which shows a cross-sectional image of a bladder and an internal tumour
highlighted with an arrow as it appears on each image modality. The thickening of
the bladder wall at the location of the tumour is visible on the CT image. Similarly
on the T2W-MRI, although there is improved contrast between the bladder wall
and its contents, it remains difficult to clearly see the extent of the tumour. On
the DW-MRI it can be seen that, although anatomic information is reduced, the
tumour volume is highlighted clearly. This is because the proliferation of cells in a
tumour restricts the diffusion of water molecules that would normally occur in the
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intracelluar spaces, and so the information contained within the image shows what
is occurring at the cellular level (although obviously the resolution is far less than
this). From the perspective of the designing of radiotherapy dose distributions, it
would be useful to be able to accurately overlay the information from all of these
images, so as have knowledge of tumour proliferation (from the DW-MRI) as well
as electron density (from the CT) and nearby soft tissues and organs at risk (from
the T2W-MRI).
Apparent Diffusion Coefficient (ADC) maps
The final image in figure 2.14 is an apparent diffusion coefficient (ADC) map, which
is generated via the acquisition of multiple DW-MRIs of the same volume, but with
different amounts of diffusion weighting applied each time (i.e. different gradient
strengths or applied for different times). The different amounts of diffusion weighting
are applied by altering the amplitude and duration of the gradients and are referred
to as the ‘b-value’. An ADC map is a parametric map, in which the greyscale of
each pixel of the image is a display of the ADC value according to the equation
I = I0e
−b.ADC , (2.14)
where I = intensity and b = b-value. The b-value depends on the strength and
timing of the diffusion gradients applied - the higher the b-value, the stronger the
diffusion effects. The value(s) of b can be chosen prior to imaging, and this choice
controls the degree of observed diffusion weighting. Typical values available on MRI
scanners range from 0 - 4000 s.mm−2, although those used are generally in the range
0 - 1000 s.mm−2. Using the original Stejskal-Tanner pulsed gradient method [24],
the b-value is given by
b = γ2G2δ2(∆− δ/3), (2.15)
where γ = gyromagnetic ratio, G = gradient amplitude, ∆ = interval between
gradient pulses and δ = duration of each pulse (and as illustrated schematically in
figure 2.13).
Calculation of b varies, however, depending on the sequence used, and mod-
ern techniques often use trapezoidal or sinusoidal pulses rather than the rectangular
Stejskal-Tanner technique. In any case, larger b-values are achieved by increas-
ing the gradient amplitude (G) and/or duration (δ) and by widening the interval
between gradient pulses (∆).
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Figure 2.15: Illustration of the calculation of ADC maps from multiple DW-
MRIs of the same volume. Highlighted blue and red volumes on each im-
age correspond to the plotted blue and red circles. Images reproduced from
http://xrayphysics.com/dwi.html.
Figure 2.15 illustrates how the parametric map is produced, with bright
areas on the ADC map produced where the gradient of the log(intensity) against
b-value curve is highest. Similarly, darker areas on the ADC map are produced from
regions where the gradient of the graph is flatter. In theory, any two b-values could
be used to fit the straight line in the b-value against log intensity graph. However,
the behaviour of the curve can deviate from linearity, particularly at lower b-values
as microcapillary perfusion effects can also cause changes in the apparent diffusion
coefficient [25]. There may be optimal b-values to use to fit the ADC curve for a
particular anatomic site [26], or a greater number of b-values than two may be used
for acquisition.
The ADC map is a useful tool, as an individual DW-MR image may have ‘T2
shine-through’, where a bright area of the image is not necessarily due to reduced
diffusion but due to a long T2 relaxation time. The ADC is independent of such
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effects and shows only the change in response with diffusion weighting. Therefore
it is quantitative, and ranges of expected ADC values can be measured for various
tissues, either to note differences between patients or changes for a given patient
over the course of time.
Unfortunately, the acquisition of DW-MRI and the resulting ADC maps can
be strongly affected by geometric distortion, to a far greater extent than conventional
MRI. One of the known main causes of this, is the way in which the signal is read
out for this type of sequence. As the images must be acquired rapidly, in order
that the effect of the diffusion of water is seen, the acquisition of all of the signal
frequency information is performed for each cross-sectional slice much more rapidly
than for conventional MRI.
A representation of the spatial frequencies acquired over the whole slice is
referred to as the ‘k-space’ of that slice, and for conventional imaging this may be
read out a line (of k-space) at a time. Echo-planar imaging (EPI), is a frequently-
used method to rapidly read out the signal for DW-MRI and other techniques which
require fast acquisition. In this technique, k-space is read out in a ‘raster’ pattern,
as represented in figure 2.16 following a single 90◦ pulse. In this figure, the mag-
netic field map is illustrated as non-uniform owing to the distribution of magnetic
susceptibility in the patient to be imaged within the bore of the MR scanner. (The
magnetic susceptibility may be thought of as the readiness of a material to be mag-
netized, i.e. how magnetized a material will become in an applied magnetic field).
Also illustrated is the way in which one direction of k-space is read out rapidly, and
the other is read out more slowly (kx and ky respectively in 2.16). The interaction
of this readout of k-space and the resulting potentially misplaced signal in k-space
is what leads to distortions in physical space, and which occur predominantly in the
‘slow’ direction of k-space readout.
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Figure 2.16: Representation of the effect of EPI readout of k-space on distortion in
images. Images adapted from http:/users.fmrib.ox.ac.uk/∼mchiew/teaching/.
Figure 2.16 illustrates a ‘blip up’ image acquisition, in which the raster pat-
tern of k-space readout is performed from bottom up - the image could also be
acquired in a ‘blip down’ direction, i.e. with the acquisition of k-space from top-to-
bottom. The effects of this change are discussed further in chapter 4 and particularly
section 4.2.9.
The use of biological imaging within radiotherapy treatment design
Biological imaging modalities such as DW-MRI could provide important, additional
information regarding the functionality of tissues and the changes in functionality
over the course of treatment. Adaptations could then be made to treatments based
on individual patient response as indicated using these types of imaging. Some stud-
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ies have been performed investigating these possibilities, for example Shaverdian et
al. [27] assessed the feasibility of the use of DW-MRI within an integrated MRI-
radiotherapy system for response assessment in rectal cancer, and Yang et al. [28]
reported their preliminary experience in the use of an MRI-guided cobalt 60 radio-
therapy system for three head and neck and three sarcoma patients. The results of
these studies showed the incorporation of DW-MRI into the radiotherapy treatment
pathway is feasible, and that larger studies are warranted.
One major potential limitation to the use of DW-MRI within radiotherapy
treatment design is the difficulties in acquiring geometrically accurate images, as
discussed in the previous sections for DW-MRI and ADC. These effects are gen-
erally not important when the images are acquired for diagnostic purposes, as the
distortions are unlikely to affect the visualisation of a tumour or other area for med-
ical concern. However, they do pose a potential limitation to the use of this type of
imaging within the workflow of radiotherapy treatments, as the geometric fidelity
of images are paramount for accurate treatment delivery.
Methods of distortion correction in DW-MRI
There are established methods for distortion correction of DW-MRI, and an overview
of a commonly used open-source toolkit to do so is included here as it is subsequently
used for the work reported in Chapter 4.
The Functional MRI of the Brain Software Library (FSL) [29] is an open-
source toolkit which, amongst other processing packages, implements a method de-
scribed by Andersson et al. [30] to estimate and correct susceptibility-induced dis-
tortions in DW-MRI. Section 2.2.3 discussed the reasons for the increased distortion
seen in DW-MRI and how these primarily originate from the interaction between
the readout of the image slice and the field map (i.e. the non-uniform magnetic
field in the patient caused by variations in the magnetic susceptibility within the
patient). This is sometimes referred to as the susceptibility-induced off-resonance
field, where the resonance offset Ω may be insufficiently small owing to the variations
in ω0 caused by the variations in magnetic susceptibility (see equation 2.13). The
field map will be approximately constant for all acquired images, and the method
used by FSL uses two acquisitions in which the distortions go in different directions.
Typically this is referred to as the phase enoding blips having opposing polarities,
and can be thought of as reading out the k-space in figure 2.16 in opposing raster
patterns (the ‘blips’ being the steps between the horizontal line readouts in this
diagram).
The typical use of this software is for diagnosis and the overlaying of mpMRI
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information onto anatomic (T1 or T2W-MRI) images within a diagnostic setting. It
is not CE marked (which would indicate conformity with health and safety stan-
dards for products sold within the European Economic Area), unlike the imag-
ing/processing and treatment calculation software usually used within radiotherapy.
There are also potential difficulties or short-comings in its use within a radiotherapy
treatment pathway, as FSL requires input of Neuroimaging Informatics Technology
Initiative (NIfTI) format images, rather than the Digital Imaging and Communi-
cations in Medicine (DICOM) format produced by MR scanners and required by a
radiotherapy treatment planning system (TPS). Therefore any use of FSL requires
image format conversion prior to use and then back to DICOM afterwards in or-
der to proceed within the radiotherapy pathway. Hence there are possible practical
and safety issues regarding image orientation for example which would require rig-
orous testing should it be used for clinical (rather than non-clinical, research-only)
purposes.
2.2.4 Image registration for radiotherapy treatment planning
The design and calculation of radiotherapy dose distributions is usually performed
using a CT dataset. However, sometimes it is useful to be able to overlay an imaging
dataset acquired using another modality, in order to visualize the location of volumes
which are visible on that imaging modality in relation to the dose distribution. This
is usually done via the use of image registration algorithms. The most commonly
used modalities for this purpose are conventional (T1 or T2-weighted) MRI, or PET.
Regardless of the care taken to set up the patient in the same position,
the two different image datasets will have been acquired with the patient anatomy
in slightly different positions. Therefore, whatever method is used to overlay the
images, there will always be limitations in the accuracy with which the location of
volumes visible on one dataset can be located within another dataset.
Rigid and Deformable Registration
Commercial radiotherapy treatment planning systems (TPS) commonly provide
methods to geometrically register two (or more) image datasets to a common co-
ordinate system (image registration). This can be done either by rigid registration
(RR) methods where only one global transformation for translations and/or rota-
tions of all points in one dataset with respect to the other are performed, or by
deformable registration (DR) in which a point-to-point transformation of the spa-
tial correspondence between image datasets is found [31]. Whichever method is
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used, the result is the establishment of a common coordinate system that will be
used for the subsequent radiotherapy treatment plan. Any remaining spatial errors
due to the imaging methods, as well as the registration procedure will propagate
through the radiotherapy treatment process and therefore must be understood and
accounted for in the design of the radiotherapy dose distribution.
As well as a RR algorithm, the RayStation TPS (v.5.0.2.35, RaySearch Lab-
oratories AB, Stockholm, Sweden) offers two DR algorithms: a hybrid DR and a
structure-based DR. In the hybrid DR the registration is performed via a non-linear
optimization and can use a combination of image intensity and anatomical infor-
mation (regions of interest (ROIs) and points of interest (POIs) - both defined by
the user). The structure-based DR requires an intermediate step to convert the de-
lineated ROIs into triangular mesh structures. It allows the assignment of different
linear elastic material properties to the structures associated with the images and
registration is performed using a finite element method.
Figure 2.17: The Dice similarity coefficient (DSC), which varies between zero for no
volume overlap and one where there is complete overlap of two volumes.
One common method for assessing the similarity of delineation of volumes
used within radiotherapy is the Dice similarity coefficient (DSC) [32]. This is a
simple method for quantifying the similarity of volumes and the degree to which
they overlay, and can be useful either for assessing the variation in a given volume
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over the course of sequential imaging sessions, or across different imaging modalities.





where V1 is the volume of volume 1 and V2 is the volume of V2. The DSC will
therefore vary between zero (where there is no overlap) and 1 (where the two volumes
overlap perfectly) as illustrated in figure 2.17.
2.2.5 Direct radiotherapy treatment planning on MRI
Although radiotherapy treatments are conventionally designed and calculated us-
ing the electron density information contained within CT images, there is a move
towards the use of MR to replace CT within the pre-treatment workflow of radiother-
apy. In such an ‘MR-sim’ workflow, the patient is imaged with MR in the required
treatment position, with care taken to ensure the use of RF coils does not deform
the patient anatomy. Additional checks are performed on an MR scanner used for
this purpose to ensure potential distortion and other imaging parameters are within
acceptable limits for radiotherapy purposes. The dose calculation in the MR-sim
workflow will be performed either assuming bulk density information of water, bone
or air from the MR images, or on a ‘pseudo-CT’. These are image sets created from
the MR(s) such that the image intensities are converted to what would have been
produced by imaging the same anatomy using CT.
One potential advantage of the use of MR-sim may be that, as the various
MR sequences can be acquired in a single patient imaging session, there will be
less variation in patient positioning between the different image sets than there
would currently be between a planning CT and additional (separately-acquired)
MR image set. Therefore the errors which propagate through the system from
image registration may be reduced.
It is anticipated that clinical use of MR-sim will increase and that direct MR-
based radiotherapy treatment planning will become more widely used, particularly
as the use of MR-linacs becomes more routine.
2.3 Adaptive radiotherapy and personalised medicine
The prescribed dose of radiotherapy treatment for a particular type of cancer may
vary between centres for reasons of historical development or clinical differences in
opinion. However, in general, the dose prescribed is standardized either locally or
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nationally, and is not tailored to an individual patient. So far all discussion of radio-
therapy treatment has also implied that the intended delivery of the radiation dose
distribution remains constant throughout all fractions of a course of radiotherapy.
However, there is increasing interest and research into ways of individually adapting
radiotherapy treatment, both based on day-to-day variations in patient anatomy
(for example the RAIDER clinical trial, discussed in section 3.2.2), and/or based
on knowledge acquired about the individual patient’s tumour (e.g. hypoxia, gene
sequencing and radiosensitivity), or response as seen on imaging during the course
of treatment. These developments are referred to as adaptive radiotherapy, i.e. ra-
diotherapy in which the treatment is adapted in some way which is individualised
to the patient.
Of particular interest for this thesis, is the use of imaging acquired prior to
and during the course of radiotherapy treatment of the bladder. The development
of MR-sim and MR-linacs means that it is becoming possible to image the bladder
both prior to and at the time of radiotherapy treatment delivery. This would enable
visualization of the internal tumour using various MR sequences, which at present
is not possible using CT/CBCT. The use of such imaging may therefore enable the
reduction of margins used for radiotherapy treatment of bladder cancer: currently
margins are used around the bladder to facilitate delivery of a uniform dose to the
whole bladder, as this is what is visible using CBCT prior to treatment. Multi-
parametric MRI, used prior to treatment delivery, could enable targeted treatment
to the tumour itself, with smaller margins owing to the reduced uncertainty in
tumour location. This could reduce complications from treatment, and/or enable an
increase in dose delivered without unacceptable increase in side effects, i.e. widening
the gap between the TCP and NTCP curves seen in figure 2.6. Further individual
adaptations could be based on changes in these images seen through the course of
therapy, either escalating or de-escalating doses prescribed to an individual patient




The previous chapter discussed the treatment of bladder cancer with radiotherapy,
and the limitations and problems encountered within the radiotherapy process. This
chapter provides relevant background information on bladder cancer, including an
overview of its incidence, diagnosis and treatments (including placing the use of
radiotherapy into context), and prognosis. Some previous and current clinical trials
are discussed, before developing the questions which will then be addressed through
the rest of this thesis. The aim of the work presented in this thesis was to facilitate
improvements in prognosis for bladder cancer patients and quality of life following
treatment with radiotherapy.
3.1 Overview of bladder cancer
3.1.1 Incidence and development
The urinary bladder is a hollow, muscular bag located in the pelvis, into which
the ureters drain urine from the kidneys. Urine collects in the bladder before being
excreted from the body via the urethra. Figure 3.1 shows a schematic of the bladder
with an inset showing its location within the body. A healthy bladder can store up
to ∼400 ml of urine [33] and has a bladder wall thickness of up to 3 mm depending
on the volume of urine stored [34].
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Figure 3.1: Diagram showing the bladder and its location within the body [33] (not
to scale).
Basic stages of bladder cancer and its development are illustrated schemat-
ically in figure 3.2. The early stages of bladder cancer do not invade the muscular
wall of the bladder, and are called non muscle-invasive bladder cancer (NMIBC).
Around 75 % of bladder cancers are non muscle-invasive, and treatments are aimed
at preventing further tumour development and muscle invasion [4].
Higher grade tumours are those which have begun to invade the bladder mus-
cle and this is diagnosed as muscle-invasive bladder cancer (MIBC). MIBC accounts
for around 25 % of bladder cancer diagnoses [4] and is associated with poor survival,
with less than half of these surviving 5 years post diagnosis [3].
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Figure 3.2: Diagram showing the development and stages of muscle-invasive bladder
cancer [35].
3.1.2 Diagnosis, treatment modalities and outcomes
The required treatments and their prognoses differ considerably between NMIBC
and MIBC, as well as the individual stage of progression. Therefore, the early ability
to distinguish between the two is of great importance. Standard practice in the
UK may involve, depending upon individual requirements, cytological testing (the
assessment of cells from the inside of the bladder under a microscope), visualisation
of the interior of the bladder via cystography, histological testing of biopsies taken
from suspicious areas, CT imaging, and trans-urethral resection of bladder tumour
(TURBT) [5]. TURBT is illustrated schematically in figure 3.3, which shows how
for NMIBC, the procedure is a primary treatment as all visible tumour is removed
(although further, adjuvant treatments may also be used to reduce the chance of
recurrence). The diagnosis of muscle-invasion is strongly influenced by the findings
of the TURBT procedure, but it is not a primary treatment in this case as gross
tumour will still remain owing to the invasion of muscle (as shown in figure 3.3). For
these patients, the TURBT will be followed by cystectomy, chemotherapy and/or
radiotherapy depending upon various factors including staging and other patient-
specific factors [35].
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Figure 3.3: Diagram showing schematic of trans-urethral resection for bladder tu-
mours (TURBT).
Historically, the standard treatment of MIBC is surgical removal of the whole
bladder (cystectomy) to control disease spread [5]. This obviously causes significant
long-term morbidity in patients, even if their cancer is cured. An alternative treat-
ment is TURBT followed by chemotherapy and/or radiotherapy to the whole blad-
der. Although there has not been a randomised controlled trial directly comparing
cystectomy with combined TURBT, radiotherapy and chemotherapy treatments,
the BC2001 trial demonstrated that modern treatments with TURBT followed by
both chemotherapy drugs and radiation can achieve outcomes comparable to cys-
tectomy whilst preserving bladder function [7]. It is possible that developments in
techniques could lead to this bladder-preserving approach replacing surgical removal
as the gold standard, as has been seen in other sites such as breast cancer [35].
3.1.3 Prognosis
In a recent paper in the Lancet, patient cancer outcomes in England and Wales were
analysed by cancer site for trends over the 40-year period from 1971-2011 [6]. The
authors showed that survival at 1, 5 and 10 years post diagnosis had increased for
both men and women across all cancers, but that there was great variation between
cancer sites. They divided the sites into 3 broad clusters: firstly those cancers with
high survival in 2010-11 and for which the absolute increase in survival since 1971-
72 was progressively larger for survival at 1, 5 and 10 years. This cluster includes
breast, prostate and testicular cancers. The second cluster was those cancers with a
moderate level of survival in 2010-11 and generally smaller increases since 1971-72.
This cluster includes bladder cancer, as well as cervix, ovary and colon. The final
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cluster is those cancers for which survival for patients who were diagnosed in 2010-11
was low and for which there has been little improvement since 1971-72. This group
includes pancreatic and oesophageal cancers.
Figure 3.4: Graph showing the net survival adjusted for age and sex for each cancer
in 2010-11, and absolute change since 1971, all adults in England 5 years after
diagnosis. Reproduced from Quaresma et al. [6].
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Figure 3.4 shows a reproduction from Quaresma et al.’s paper illustrating
the three clusters for 5-year net survival, with bladder cancer highlighted. This
illustrates well the way in which bladder cancer outcomes are better than some of
those cancers with the poorest prognoses, but still much poorer than the cancers
with the best prognoses. Bladder cancer’s position towards the left of the graph
shows that the improvements in outcomes since 1971 are lower than many other
cancer sites.
Figure 3.5: Graph showing the 5 year age-adjusted net survival after diagnosis for
bladder cancer in England [6].
Figure 3.5 shows the trend in 5 year age-adjusted net survival after diagnosis
for bladder cancer in England, as tabulated by Quaresma et al. A similar trend is
seen also for the equivalent data regarding 1- and 10-year net survival respectively
(presented in the Quaresma et al. paper but not shown here). In all cases, there is
an increase in survival between patients diagnosed in the 1970s and 1980s, but this
improvement does not continue beyond the 1990s. The subsequent apparent slight
decrease in survival is likely due to changes in the definitions of bladder cancer (the
staging definitions changed from the Jewett-Marshall-Strong classification system
following the introduction of the TNM sysytem in 1983 [36]).
In their discussion of the three clusters of cancer sites, Quaresma et al. rec-
ommend that “...for the cancers in [the second] cluster that have shown no evidence
of improvement, efforts should be made to achieve earlier diagnosis, and to focus on
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stricter guidelines for improved treatment, such as increased use of surgery, radio-
therapy with curative intent, neoadjuvant therapies, or a combination of the three.”
Bladder cancer can be considered to fall in this category, as although there has been
some improvement it has been limited, as is readily seen in figure 3.5.
3.2 Radiotherapy treatment of bladder cancer
3.2.1 Current techniques and their limitations
Standard radiotherapy treatments for MIBC usually use one of two dose fractiona-
tion schemes, as shown in table 3.1. The BC2001 trial showed that these schemes
were equivalent in terms of both local tumour control and toxicity [7].
Table 3.1: Standard fractionation schemes for MIBC used in the UK [7].
Prescription dose (Gy) No. of fractions
55 20
64 32
In both standard fractionation schemes the dose is delivered as a uniform
treatment to the whole bladder. This is partly because there is the expectancy
that there will be some degree of microscopic spread of tumour which is not visible
on imaging. However, it is also because the residual tumour remaining within the
bladder wall is not readily visible on the planning CTs used to design radiotherapy
dose distributions, and visiblity is poor on the daily CBCT used for pre-treatment
positioning of the patient. As the amount of bladder filling, shape of the bladder and
therefore the exact location of the tumour will vary from one fraction to another,
this lack of visibility means there is greater uncertainty in the tumour location. For
these reasons, a uniform dose is prescribed to the whole bladder and large margins
are generally used to expand the CTV (outer bladder wall) to create the PTV used
for radiotherapy treatment planning. This is illustrated in figure 3.6 which shows a
schematic of a bladder and surrounding PTV along with residual tumour following
TURBT.
The size of the margins used to create the bladder PTV limits the maximum
dose that can be prescribed, due to the proximity of radiosensitive OARs such as
the bowel. Radiation doses prescribed for bladder cancer are therefore lower than
for other cancers such as the prostate [37], and improvements in tumour control are
thought to be possible should dose be increased (escalated) [7].
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If imaging of the bladder could be achieved with better visibility of residual
(post-TURBT) tumour volume to be treated, doses could be escalated to the tu-
mour alone rather than to the whole bladder. Indeed, it would also no longer be
necessary to deliver the current standard dose to the rest of the bladder (as there
would be increased confidence that the volume did not contain tumour). Therefore,
with improved imaging, better outcomes could potentially be delivered with a sim-
ilar toxicity to that currently accepted. One current clinical trial called RAIDER
[9] is investigating the potential of dose escalation of the residual tumour, whilst
decreasing the dose prescribed to the rest of the bladder (see section 3.2.2). A ques-
tion which arises from this approach to dose escalation is the degree of microscopic
spread and therefore the dose to which the rest of the bladder should be treated.
The BC2001 trial provided some encouragement that a reduction of dose to the
bladder wall to 75-80 % of the planned tumour dose did not reduce the effectiveness
of the treatment [38].
Various MRI techniques allow excellent visualisation of bladder tumours, and
there has been considerable work showing that it may improve diagnosis of MIBC
compared with TURBT [39, 40]. Another current clinical trial called BladderPath
[10] (see section 3.2.2) is aiming to show that the use of multi-parametric MRI,
including T2-weighted and DW-MRI can be used in place of TURBT to more accu-
rately and rapidly diagnose MIBC.
3.2.2 Current clinical trials: RAIDER and BladderPath
The two MIBC clinical trials most relevant to this thesis are RAIDER [9] and
BladderPath [10], which are described here.
RAIDER
RAIDER is a Randomised phase II trial for Adaptive Image guided standard or Dose
Escalated tumour boost Radiotherapy in the treatment of the bladder cancer [9].
The objective of RAIDER is to define a feasible and safe adaptive dose-escalated tu-
mour boost radiotherapy schedule for MIBC. It is investigating the ability to deliver
daily adaptive bladder radiotherapy and will assess the impact of doing so. Patients
are randomised (1:1:2) between (i) standard whole bladder radiotherapy (WBRT)
which is the control arm of the study, (ii) adaptive standard dose tumour-focused
radiotherapy (SART), and (iii) adaptive dose-escalated tumour boost radiotherapy
(DART). All groups are permitted to receive chemotherapy, and both standard frac-
tionation schemes of 55 Gy in 20 fractions and 64 Gy in 32 fractions are permitted
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within the trial, although only the latter is referred to in this thesis for clarity
and relevence to later work. All RAIDER patients are treated with radiotherapy
following performance of the TURBT procedure.
Figure 3.6: Diagram showing the radiotherapy treatment in the standard arm (arm
(i)) of the RAIDER clinical trial. In the case illustrated the whole bladder receives
64 Gy in 32 fractions.
In arm (i) of the trial, the whole bladder is delineated on a CT scan which is
performed after patient voiding of the bladder, and treatments will also be delivered
following patient voiding. This arm is illustrated diagrammatically in figure 3.6.
In arms (ii) and (iii) of the trial the bladder is partially-full, with patients
following a specified drinking programme prior to the performance of the CT and
all radiotherapy treatments. This means the bladder is partially distended, moving
OARs such as the bowel away from some of the bladder and, owing to the stretching
of the bladder wall, reducing the volume of bladder wall contained within the high
dose treatment volume. The variability in bladder filling is accommodated via the
production of 3 radiotherapy plans which are generated for each patient, with small,
medium and larger versions. On each day of treatment the smallest plan will be
used which adequately covers the required bladder/tumour volumes. Figure 3.7
illustrates arms (ii) and (iii) of the trial. In arm (ii), the dose to the tumour volume
remains at the standard dose (i.e. 64 Gy for the 32 fraction scheme), whilst the
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dose to the whole bladder is reduced to 52 Gy. In arm (iii) of the trial the dose
prescribed to the tumour is escalated to 70 Gy (for the 32 fraction scheme) and the
dose to the bladder is again reduced to 52 Gy.
Figure 3.7: Diagram showing the radiotherapy treatment in the trial arms of the
RAIDER trial, where in arm (ii) the whole bladder receives 52 Gy and boost volume
receives 64 Gy and in arm (iii) the whole bladder receives 52 Gy and the boost
volume receives 70 Gy (both for the 32 fraction scheme).
It is hoped that the RAIDER trial will show that adapting radiotherapy to
the daily imaged position and volume of the bladder is feasible, as well as that the
reduction in dose to the low risk volume of the bladder and increased dose to the
tumour results in improved control of the tumour without increased toxicity.
BladderPath
Another current clinical trial of relevance to the later work presented in this thesis
is the BladderPath trial. BladderPath is the image-directed redesign of Bladder
cancer treatment Pathways [10]. Rather than changing the treatment received by
patients, it instead seeks to test how a change in the clinical pathway for patients
with suspected MIBC affects outcomes by expediting their route to definitive treat-
ment. At present, the requirement for the TURBT procedure for the diagnosis of
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muscle-invasion can cause a delay between patient presentation with symptoms at a
haematuria clinic, and their receipt of treatment with the aim of cure (radiotherapy,
chemotherapy and/or surgery). Often clinics can need to refer to a different hospital
for the TURBT procedure, and then afterwards a further referral for treatment is
required. BladderPath is intended to improve staging, accelerate treatment and re-
duce tumour spread for MIBC patients by avoiding TURBT, ultimately improving
clinical outcomes.
A schematic showing the intended differences in patient pathway being tested
in the BladderPath trial is shown in figure 3.8. The MRI step highlighted in red
in the new pathway replaces the TURBT procedure with multi-parametric MRI
including DW-MRI for patients with suspected MIBC. This trial does not change
the other aspects of the patient treatments; therefore, once diagnosed the patients
will proceed to treatments with radiotherapy, chemotherapy and/or surgery as would
ordinarily be the case. MRI can accurately diagnose bladder cancer [39, 40, 41] and
whilst not yet widely used in the UK for this purpose, it is routinely used for other
cancer sites.
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Figure 3.8: Schematic showing the differences in patient pathway being tested within
the BladderPath Clinical Trial. The highlighted MRI step tests the use of multi-
parametric MRI including DW-MRI to more rapidly diagnose MIBC, removing the
requirement for TURBT for patients with suspected MIBC.
3.2.3 Potential developments in bladder cancer radiotherapy
Developments and improvements in imaging have the potential to enable better
stratification of patients and personalisation of treatments. Along with the ability
to better target radiotherapy treatment delivery using modern intensity modulation
techniques, these developments could lead to improvements in outcome for some
patients with bladder cancer. The technical difficulties which would need to be
overcome include the significant mobility of the bladder and poor visibility of (in
particular post-TURBT) tumours on pre-treatment CBCT.
The excellent soft tissue contrast afforded by MRI is becoming more widely
available for radiotherapy simulation and treatment planning, and is starting to
become available at the time of treatment delivery via the use of MR-linacs. This
means that the possibility is raised of addressing the difficulties in visualisation of
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residual bladder tumour at the time of both radiotherapy treatment design and its
delivery. The use of an MR-linac potentially allows real-time information of cellular
function to be acquired, enabling treatment not only of conventional, anatomically-
defined tumour volumes, but also ‘biological’ tumour volumes. These ‘biological’
tumour volumes (BTVs) could have associated prescriptions which could vary in
intensity over the volume itself, and/or over the course of treatment based on re-
sponse.
This possibility of biologically-adaptive radiotherapy (sometimes called ther-
agnostic imaging), has potential to transform the way radiotherapy is delivered to
patients. The current ‘one-size fits all’ approach would become one in which treat-
ments are individually adapted based on patient response to treatment, during the
course of treatment.
Theragnostic imaging and biologically-adaptive radiotherapy
Theragnostic imaging within radiation oncology is the use of molecular or functional
imaging (i.e. imaging which provides underlying biological information rather than
purely structural, anatomical information) to prescribe radiotherapy which varies
in intensity in 3-D, and also varies over time. It was highlighted by Bentzen [42]
as the upcoming revolution in radiotherapy, owing to its ability to visualize cellular
or biochemical processes by various imaging methods and enable treatments to be
individually tailored from this information, minimizing radiation damage to nearby
healthy tissue. As Fowler noted [43], the use of ionizing radiation for this purpose
has the virtue over drug or gene-based therapies that it unambiguously reaches the
cells that the physical radiotherapy plan encompasses.
There is increasing interest in the use of multi-parametric MRI including DW-
MRI and resulting ADC maps for informing radiotherapy treatment and assessing
tumour burden or response [44, 45]. The next step in the use of this modality is to
assess the feasibility of using the information it conveys to directly influence radio-
therapy planning, i.e. acting as theragnostic, rather than purely diagnostic imag-
ing. This has also been referred to as biologically-adaptive radiotherapy (BART)
or biology-guided adaptive radiotherapy (BiGART) [46]. In all of these approaches
to radiotherapy treatment, the tumour volume to be treated is not purely informed
by the anatomic tumour volume but by some biological (or functional) information,
which may also be adjusted or adapted during the course of treatment based on
response.
As discussed in section 2.2.3, DW-MRI is able to highlight areas of restricted
diffusion which occur in regions of increased cellularity including tumours, and has
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also been recommended for testing in clinical trials as a biomarker for cancer [47].
Its use to generate ADC maps allows the quantification of the degree of diffusion,
and has been investigated for the ability to predict clinical aggressiveness in bladder
cancer [48]. This ability to produce images which quantify the degree of diffusion
could potentially enable a ‘dose painting’ technique [42, 49], allowing the radio-
therapy treatment to be intensified or focussed where the tumour burden is higher.
Moreover, changes in ADC values during treatment could be used as a means to
assess response and predict efficacy. This would enable individualised adaptations
of radiotherapy treatments, and enter the realm of personalised medicine. However,
these approaches would be limited by any geometrical distortion present in the ADC
maps, particularly if this is greater than the spatial uncertainties associated with
the CT scan that is used for radiotherapy treatment planning.
Use of DW-MRI in radiotherapy treatment planning
Imaging that is used within radiotherapy requires stringent quality control, which
may differ from that required for diagnostic purposes. In particular, any geometric
distortion in images used for determination of treatment volumes could have signifi-
cant impact on achievable accuracy in delivery of the required radiation dose to the
appropriate volume, whereas this level of distortion may be of less significance if the
same images were used for diagnosis alone.
As discussed in section 2.2.1, CT is conventionally used for treatment plan-
ning - both for delineation of all relevant anatomical volumes and for calculation
of dose distributions using the electron density information contained within the
CT images. Investigations into the use of MRI-based treatment planning have been
ongoing for many years [50, 51, 52], and some centres now use MRI to produce
pseudo-CT images and calculate dose distributions directly upon these images, al-
though this practice is still not yet widespread. Multi-parametric MRI, and other
imaging modalities such as PET, if used at all within the radiotherapy pathway,
tend to be used to provide supplementary information regarding the tumour. How-
ever, the prescription of dose and delineation of volumes is conventionally confined
to planning CT (or MRI pseudo-CT) images only.
Progressing the use of DW-MRI from use within diagnosis alone to use for
directly informing tumour volume and even dose prescription, would rely upon the
ability to produce images of the required quality for radiotherapy purposes. If this
were shown to be possible, then DW-MRI could be used either via registration with
a conventional planning CT, or via the acquisition of other MR sequences within
the same image acquisition session as DW-MRI to produce a pseudo-CT for use in
52
dose calculations and delineation of OARs. This second method would have the
advantage of reduced differences in patient positioning between image acquisitions.
This project aimed to investigate the possibilities of using DW-MRI and
resultant ADC maps within the treatment pathway for MIBC.
3.3 Developing the use of DW-MRI as biolological imag-
ing for adaptive bladder radiotherapy
This project used data from a previously treated MIBC patient to simulate the
possibilities regarding the adaptation of radiotherapy treatments using DW-MRI
information in conjunction with standard planning CTs. The aim was to mimic
what would be achievable with additional bladder imaging information similar to
that acquired through the BladderPath trial, but with dose escalation strategies
similar to those used within the RAIDER trial. The overall aim of this project was
to investigate and predict the effect on patient outcomes from escalation of absorbed
dose to bladder tumours treated with radiotherapy.
3.3.1 Project sections
There were 4 main sections within this project:
1. The magnitude and effect of distortion in DW-MRI was assessed with respect
to its effect upon tumour definition within radiotherapy;
2. Models were developed which could be used to predict TCP when escalating
the dose to bladder tumours, and which allowed the effect of variations in
both tumour volume and dose to tumour and bladder wall to be taken into
consideration;
3. Tumours were simulated and dose distributions calculated to mimic the clinical
situation if DW-MRI were used to inform tumour volume, with standard and
escalated dose levels used to enable comparison. The TCP models previously
developed were used to assess the expected effect of dose escalation;
4. The feasibility of delivery of the radiotherapy treatment plans was assessed via
accumulation of dose on pre-treatment CBCTs which were acquired for the
patient at the time of treatment. The doses which would have been received
were summed and compared to the original planned doses.
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Firstly, in order to assess the magnitude of distortion in DW-MRI under con-
ditions similar to those for clinical images of a bladder, a phantom (i.e. model) was
designed and constructed to mimic the bladder and a tumour. This enabled imaging
to be performed under reproducible conditions with DW-MRI, conventional T2W-
MRI, and CT. Geometric distortion was measured via reference markers within the
bladder and tumour across the imaging modalities. Potential mitigation strategies
to correct distortion were tested, and estimates made of additional margins required
for creation of PTVs using this strategy.
The second section of work involved the development of two models to predict
TCP when provided with the doses received by bladder tumours. The models were
based on published work which used a logistic model, but were refitted with a Poisson
model so that tumour volume could be explicitly controlled. One model was fitted
to clinical trials data involving treatment with radiotherapy alone, and the other
used data in which patients received both radiotherapy and chemotherapy.
The third section of the project required the development of a method for
simulating tumours on a previously-treated patient CT, in which tumour location
and volume was varied. Once tumour volumes were simulated, margins used to
produce PTVs were informed by the first section of work. This was intended to
simulate a situation where the tumour volume had originated from an ADC map
which was registered to the planning CT. Prescription doses to tumours and the
rest of the bladder were systematically varied, along similar lines to the RAIDER
trial, but with a wider range of doses tested. The dose distributions produced were
used to calculate TCP with each of the two models which had been developed.
Finally, the feasibility of delivery of the calculated dose distributions in prac-
tice was assessed by recalculating the dose on the daily CBCTs of the previously-
treated patient, as if these treatment plans had been delivered instead. The dose
accumulated over the course of treatment was summed and compared with the orig-
inal planned dose. These recalculated dose distributions were then used to predict
TCP as before, and compared with the original predicted TCP.
3.3.2 Project summary
The central aim of this project was to systematically investigate the increase of
radiation dose to bladder tumours, and determine the expected effect this should
have on the probability of tumour control. Tumour positional information from
ADC maps was quantitatively assessed for accuracy relative to current methods.
These results were used within the simulation of tumour target volumes and the
calculation of dose distributions for radiotherapy treatments. Previously acquired
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patient images were used to quantatively assess the feasibility of delivery of the
calculated dose distributions, and the effect of variations in day-to-day volume and
location of the bladder upon TCP.
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Chapter 4
Investigations of distortion in
DW-MRI for radiotherapy
treatment of bladder tumours
4.1 Introduction
This chapter reports on work done to assess the magnitude of distortion in DW-
MRI under conditions similar to those used for clinical imaging of the bladder within
the BladderPath clinical trial. This work was designed in particular to determine
the margins which might be required should DW-MRI of the bladder be used for
tumour volume (GTV) delineation if these images were registered with a planning
CT, although it would also be relevant if MR-sim were used instead of CT.
Clinical images of patients suffer from limitations in the reproducibility of pa-
tient position between different image acquisitions, and this is particularly significant
for imaging of the bladder due to temporal variations in bladder filling. Therefore,
this research required the design and construction of a model bladder to mimic what
would be seen when imaging a patient bladder so that any changes between image
acquisitions would be due only to differences between CT and DW-MRI rendering
of the images rather than changes in the ground truth between acquisitions. Such a
model or phantom should be appropriately constructed to produce adequate visibil-
ity of landmarks across all imaging modalities to enable measurement of distances
and quantify geometrical uncertainties in and between the associated images.
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4.1.1 Commercial MRI phantoms
The American College of Radiology (ACR) MRI phantom is commonly used to
assess the magnitude of distortion in MRI using a 2-D grid. Figure 4.1 shows a
photograph of the phantom and MR image of the 2-D grid contained within it.
Figure 4.1: (a) Photograph of the ACR phantom and (b) MR image of the 2-D grid
contained within the phantom [53].
Figure 4.2 shows transverse images of an ACR phantom as it appears when
imaged using (a) CT, (b) DW-MRI and (c) following rigid registration of the CT
and DW-MRI (i.e. these images are overlaid). The extent of the distortion that can
be present in DW-MRI is apparent by comparison with the undistorted CT image,
and the schematic of the grid shown in figure 4.1 (b).
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Figure 4.2: Cross-sectional 2-D images of the grid section of an ACR phantom as
it appears using (a) CT, (b) DW-MRI (with a b-value of 300 s.mm−2), and (c)
following rigid registration of CT and DW-MRI.
The ACR phantom is not representative of any relevant anatomy, and its 1
cm thick grid for evaluation of distortions in 2-D is of limited use for the volumetric
evaluation of distortions required here. There are also other commercially-available
phantoms, some of which allow quantification in 3-D such as the QUASAR MRID
(Modus Medical Devices Inc., Ontario, Canada). However, in common with the
ACR phantom, these have a uniform pattern of objects which are often aimed at
testing aspects of image quality within MRI, usually T1W- or T2W-MRI rather than
DW-MRI. Publications regarding in-house design of phantoms for testing DW-MRI
image quality exist [54, 55, 56] but these are generally aimed at testing ADC value
consistency with time or between scanners, rather than geometric distortions, as
these are the parameters of greater relevance in diagnostic use of DW-MRI.
Testing of geometric distortions within DW-MRI for the purposes required in
this thesis, would be best achieved in a phantom which mimics the anatomy of the
bladder rather than a generic phantom, as the distortions generated will be affected
by the construction of the phantom itself and the inhomogeneities contained within
it. Ideally, therefore, this work would use a phantom which mimics the situations
of tumours within the bladder. Such a phantom could also have the advantage that
it could be constructed so as to enable visibility of both tumour and bladder on all
imaging modalities, unlike the clinical situation where tumour is not readily visible
on CT.
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4.2 Bespoke bladder phantom for quantification of dis-
tortion
4.2.1 Phantom design
A phantom designed for the purposes of assessing distortion in DW-MRI of bladder
tumours would need to:
1. Be constructed using synthetic (non-metallic) components with a geometrical
shape that approximates a urinary bladder containing an internal tumour,
2. Produce sufficient contrast on all relevant image modalities to allow the delin-
eation of volumes of clinical interest,
3. Contain positional markers for spatial reference,
4. Allow production of artefact free images,
5. Produce no additional distortion beyond that expected for similar clinical blad-
der images.
6. Ideally enable the investigation of different sizes and shapes of bladder/tumour.
Construction of a phantom using non-metallic components is important for
use within MRI, as any metal will cause loss of signal and artefacts. The production
of adequate contrast across all modalities is difficult to achieve, however, particularly
whilst also trying to ensure that there is limited distortion created within the DW-
MRI. The following section discusses the types of materials investigated for these
purposes.
4.2.2 Phantom materials
Within the clinical use of CT and MRI, it is common to produce in-house phantoms
for the purposes of testing specific situations relevant to the local use of the equip-
ment. Often materials used for the construction of phantoms used for CT include
water, acrylic, wood and air. For MRI these may typically involve the use of water
or oils, and perhaps the addition of clinically-administered contrast agents such as
gadolinium in order to alter the T1 or T2 relaxation times of the solution, and de-
pending upon the specific parameters to be tested. Air is not usually used but if
present in the phantom will produce regions of minimal signal. If DW-MRI is to
be tested, however, it is less straightforward to produce a phantom which will have
adequate contrast between different components, particularly if there must also be
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good contrast on other imaging modalities as well. In particular, if there are even
small volumes of air (such as bubbles), this can produce significant distortion in the
DW images. One compound which is frequently used within MRI phantoms is a
cryogel called polyvinyl alcohol (PVA), as it is a non-toxic, stable compound which
is simple to produce and handle within the hospital environment [57].
Cryogels
Cryogels are substances which can be dissolved in water and then the process of
cycling through freezing and thawing changes the properties of the material. PVA
is a commonly-used cryogel in MRI, which is used as a tissue-mimicking material
and which becomes more solid as it is subjected to more freeze-thaw cycles. This
change also affects the degree to which the water molecules are able to diffuse within
the material, and therefore the signal produced when imaged using DW-MRI is
also changed [57]. In this way it is possible to produce contrast within DW-MRI,
particularly if other materials with differing degrees of diffusion are included - e.g.
water, which has high rates of diffusion and solids such as wood or plastics (which
will produce little or no signal if imaged using DW-MRI).
4.2.3 Phantom I construction
The process of development and construction of a phantom which would achieve
all of the purposes listed in section 4.2.1 was iterative. Therefore, this section of
work details the first main phantom (‘phantom I’) developed and tested, in order to
show the various issues encountered, and section 4.2.7 discusses the developments
and alterations made based upon findings from this phantom.
Figure 4.3 shows (a) a photograph of phantom I produced to model a urinary
bladder with internal tumour and (b) and (c) schematic diagrams of the cross-
sections of the phantom construction. Information regarding the materials used are
reported in table 4.1. Two bladder inserts were constructed for this phantom, with
cross-sections of diameter 5.5 cm and 6.5 cm, which are later referred to as the small
bladder (SB) and larger bladder (LB), respectively.
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Figure 4.3: Phantom I: first main phantom designed and constructed to model a
bladder and internal tumour shown in (a) photograph, and (b) and (c) schematic
cross-sectional diagrams of the phantom internal construction.
Features of the construction of phantom I were:
• The main phantom volume was filled with water.
• Two bladder volumes were produced to mimic post-micturition (SB) and
partially-full bladder (LB) containing internal spherical tumours of the same
size. No attempt was made to replicate a full bladder as it is not typical
practice for radiotherapy treatments.
• The bladders were made of hollow plastic spheres containing solidified gelatine
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solution. Seventeen markers were positioned on the outside of each of the
bladder spheres.
• The tumours were solid spheres made from polyvinyl alcohol (PVA) gel, held
in position inside the bladder by the solid gelatine solution.
• Care was taken during construction of the bladder and tumour to ensure no
air bubbles were introduced as they would cause additional distortion when
imaged using DW-MRI.
• Each bladder was suspended inside the container using a wooden dowel glued
to the bladder and clamped at the other end by an acrylic attachment inside
the phantom.
• Strings saturated with gelatine solution (to ensure no introduction of air) had
been passed through each tumour in three perpendicular directions prior to
fixation within the bladder. This enabled identification of 6 points of intersec-
tion of string with the tumour surface.
• Wooden location aids were affixed on either side of the bladder. Their trape-
zoidal shape enabled accurate registration between image modalities in 3 or-
thogonal directions as well as 3 axes of rotation. They also prevented the
generation of dielectric artefacts on MRI.
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Table 4.1: Construction of phantom I










PE sphere 6.5 cm diameter,
wall 1 mm thick
Sphere 143.8 cm3
Tumour PVA gel with
gadolinium (Gd)
contrast agent
3.5 cm diameter 10 % PVA cryogel so-














2 x 2 x 2 mm
Attachment
rod
Wood 0.8 x 0.8 x 4 cm
Localisation
aids
Wood Upper end 7.0
x 3.8 cm; lower
end 9.3 x 3.8 cm
The tapering shape of
these wooden blocks
enabled accurate RR
between CT and MRI




4.2.4 Phantom I imaging, processing and registration methods
Phantom I was imaged using CT, T2W-MRI and DW-MRI with each bladder re-
maining in position for all imaging modalities. CT was performed using a GE
HiSpeed CT scanner (GE Inc., New York, USA) with a 2.5 mm slice width. Multi-
parametric MRI was performed using a GE 3T Discovery MR750w scanner (GE
Inc., New York, USA) with the settings as shown in table 4.2. An axial DWI Focus
sequence was used for the DW-MRI, and ADC map generation was performed au-
tomatically using the scanner software. These imaging parameters were chosen as
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they are those used clinically for imaging of the prostate at the centre at which this
work was performed.
Table 4.2: Settings used for T2W- and DW-MRI of phantom I.
Parameters T2W-MRI DW-MRI
Repetition time (TR) (ms) 6237 2851
Echo time (TE) (ms) 120.4 65.9
Slice thickness (mm) 2.5 2.5
Slice gap (mm) 0 0
Matrix size 352 x 288 140 x 70
Field of view (FOV) (cm) 24 x 24 24 x 24
Echo train length 19 -
No. of excitations (NEX) & b-values† -
b = 50, NEX = 1
b = 300, NEX = 2
b = 700, NEX = 4
b = 1000, NEX = 6
†b-value is calculated using equation 2.14.
All DICOM image sets were transferred to the RayStation TPS (v. 5.0.2.35,
RaySearch Laboratories AB, Stockholm, Sweden). The bladder outer surface, tu-
mour, location aids, positional markers and string were manually delineated on the
CT, T2W-MRI, and ADC maps. The locations of the centres of the bladder posi-
tional markers were projected to the inner surface of the plastic sphere (of approxi-
mately 1 mm thickness) and marked with points of interest (POIs). The delineation
of the outer bladder surface as a region of interest (ROI) and the placement of POIs
on its internal surface ensured all POIs were inside the bladder ROI for consistency,
as this contour was used to control all subsequent deformable registrations (DR).
POIs were also placed at the intersection of the tumour surface with the strings (6
points).
Phantom I - Rigid and deformable image registrations
Rigid and deformable registrations (RR and DR, respectively) were introduced in
section 2.2.4. For both bladder sizes, RR of the T2W-MRI to CT was performed
manually using the trapezoidal location aids to position accurately in 3 orthogonal
directions and with respect to 3 axes of rotation. The same transformation was then
applied to the ADC map resulting in RR of the ADC map to CT. DRs between ADC
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map and CT were then performed with this underlying RR and using the bladder
delineation alone to control the algorithm. This mimics the clinical situation in
which tumour would not be adequately visible on CT.






RR Rigid - -
DR1 Deformable Hybrid Image intensities not used
DR2 Deformable Hybrid As DR1; ROI focus set to bladder
and IL setting† applied
DR3 Deformable Hybrid As DR1; ROI focus set to bladder
DR4 Deformable Structure based Structure based, ‘fixed’ setting
DR5 Deformable Structure based As DR4; ‘sliding’ setting
†IL setting is usually used for internal lung to accommodate changes in lung volume between image sets.
Five different DRs were produced, as detailed in table 4.3. These DRs cor-
respond to the available default settings in the TPS, although the intensity-based
information was not utilized as this is designed for registration of CT-CT datasets.
Only the default settings of linear elastic properties were investigated (i.e. the de-
fault value of 0.48 for Poissons ratio in linear elasticity was used for the bladder).
The three default settings of the hybrid DR algorithm were tested: all used
the bladder delineation to control the registration, two also used the bladder as a
focus region (DR2 & 3). The two default settings of the structure-based algorithm
were tested: fixed, in which vertex-to-vertex correspondence of the triangular mesh
structures was required between the reference (CT) and target (ADC map) datasets
(DR4), and sliding, in which some latitude or slippage was permitted in the mapping
of vertices from one dataset to the corresponding vertices on the other dataset (DR5).
The positions of pairs of POIs which had been identified on CT and ADC
maps were compared. The expected position was taken to be that on the CT dataset,
and the actual position was that identified on the ADC map. The distances between
the two locations were recorded. The delineated volumes were compared via their





where VCT is the volume of the ROI delineated on CT and VADC is the correspond-
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ing volume delineated on the ADC map (as discussed in section 2.2.4).
4.2.5 Phantom I: Results and discussion
Images of phantom I
Representative transaxial CT and T2W-MR images of phantom I are shown in figure
4.4 for corresponding central slices. These images both show minimal distortion and
good contrast between the relevant parts of the phantom.
Figure 4.4: Imaged phantom I showing cross-sectional images with CT and T2W-
MRI.
Figure 4.5 shows the equivalent slices as shown in figure 4.4 but from the
DW-MRI (with b=300) and ADC maps. The distortions in these images relative
to CT and T2W-MRI are apparent, but the various phantom parts are still visible
across all modalities, enabling delineation of the various ROIs and positioning of
POIs for quantification of the distortions.
Figure 4.5: Imaged phantom I showing cross-sectional images with DW-MRI
(b=300) and ADC map.
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Delineated images of phantom I
Greater distortion was noted in the ADC maps of the small bladder (prior to DR)
compared to those for the larger bladder; this effect is shown in figure 4.6. This
figure shows the delineation of a central slice of the SB and LB following RR only
(i.e. the images are simply overlaid with no DR performed) to allow comparison
of the CT (solid line) and ADC map (dotted line) delineations of bladder (yellow)
and tumour (green). Note that a representative distance between ADC bladder
delineation and that on the CT is 1.1 cm for the small bladder and 0.8 cm in a
similar location for the larger bladder. This indicates that the subsequent use of the
DR had to deform the ADC maps further for the small bladder images than for the
larger bladder images.
Figure 4.6: Delineations of bladder wall (yellow) and tumour (green) after RR only.
Images show small and large bladder, from CT (solid lines) and ADC (dotted lines).
Dice similarity coefficients
Dice similarity coefficients (DSCs) were calculated according to equation 4.1 for each
registration for both bladders and their tumours as shown in table 4.4.
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Table 4.4: Dice similarity coefficients for all image registrations between CT and
ADC maps.
Dice similarity coefficient:
RR DR1 DR2 DR3 DR4 DR5 DR (mean)
SB 0.81 0.99 0.99 0.99 0.96 0.96 0.98
Tumour 0.67 0.92 0.92 0.93 0.92 0.92 0.92
LB 0.85 0.99 0.99 0.99 0.97 0.97 0.98
Tumour 0.67 0.90 0.90 0.91 0.89 0.89 0.90
The application of all of the DRs reduced the distortion seen in the ADC
maps significantly, with all algorithms producing similar results. After RR alone,
DSCs were 0.81 and 0.85 for SB and LB respectively, whereas after DR, the DSCs
ranged from 0.96 - 0.99 for both bladder sizes. Similarly, after RR alone DSCs
were 0.67 for both tumours, which improved to 0.89 - 0.93 after DR. As DSCs
would be expected to vary between 0 if there were no overlap, and 1 if there were
perfect overlap of the volumes (as shown in figure 2.17), these results indicate good
agreement following the DRs. The DSC was higher after DR for bladder (mean
0.98 for both bladder sizes) than tumours (mean 0.92 and 0.90 for SB and LB
respectively). This is further illustrated in figure 4.7, which shows the intersectional
volumes for the small bladder and tumour shown on ADC maps and CT respectively,
for both RR and DR3. In this case the DSC of 0.81 for the bladder following RR
increases to 0.99 following DR3; for the tumour these values are 0.67 and 0.93,
respectively.
Both visually and numerically, these results show that the use of DR produces
good agreement in the volume of both bladder and tumour. However, the use of
the DSC as a metric does not provide any information regarding the location of
individual points within either the bladder or tumour volumes. The following section
addresses this via the measurement of positional markers and their locations within
each image dataset.
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Figure 4.7: Diagram showing intersections of bladder and tumour volumes for the
small bladder (SB) visualised on ADC maps and CT using rigid registration (RR)
and deformable registration (DR), respectively. Bladder and tumour are shown
in yellow and green, respectively. ADC map and CT delineations are shown with
dashed and solid lines, respectively. Intersections between ADC maps and CT vol-
umes are shown shaded in yellow (bladder) and green (tumour). These diagrams
illustrate the SB results in table 4.4 where RR produced a DSC of 0.81 for the
bladder and 0.67 for the tumour, and DR3 produced a DSC of 0.99 (bladder) and
0.93 (tumour), respectively.
Differences between locations of positional markers
The locations of the 17 bladder positional markers and 6 tumour markers had been
denoted with POIs for each bladder size as described in section 4.2.4. The mean
and one standard deviation in differences between expected positions of POIs and
their actual positions were recorded for each registration, and are shown in figure
4.8. The values were recorded in mm for all POIs and are shown as the mean and
range of 17 POIs for each bladder size and 6 for each tumour.
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Figure 4.8: Mean and standard deviation of positional differences between expected
and actual positions of POIs following registrations of ADC maps to CT of phantom
I, for small bladder (solid colours) and larger bladder (hashed colours).
The mean differences between expected and actual bladder POIs were re-
duced by approximately 50 % using DR rather than RR alone (6.2 to 2.9 mm and
4.8 to 2.8 mm for SB and LB respectively). The spread in differences between ex-
pected and actual POIs was similarly reduced with the maximum decreasing from
12.4 to 5.9 mm and from 10.1 to 5.2 mm (SB and LB respectively). The mean dif-
ferences between expected and actual bladder POIs were slightly lower than those
for the tumour POIs (2.9 and 2.3 mm for bladder compared to 3.4 and 2.7 mm
for tumours for SB and LB respectively). These results might be expected as the
delineation of the bladder was used by the TPS to control all DRs, and so POIs
close to this delineation (i.e. bladder POIs) would be more likely to be correctly
mapped than POIs further from the controlling structure.
More importantly, for the purposes of estimating the realistic worst case
scenario of positional information transfer from DW-MRI to CT, are the results
shown in figure 4.9, which shows the maximum positional error for each method of
registration.
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Figure 4.9: Maximum positional differences between expected and actual positions
of POIs following registrations of ADC maps to CT of phantom I, for small bladder
(solid colours) and larger bladder (hashed colours).
General discussion and implications
For all five DR settings the mean, standard deviation and range of the differences
between expected and actual POIs were consistently lower for the LB data. For
example, the mean post-DR POI differences were only 2.3 and 2.7 mm for the LB
and tumour respectively, but 2.9 and 3.4 mm respectively for the SB. This was
probably due to greater distortion prior to DR in the SB ADC maps compared to
those for LB, which is shown in figure 4.6. These images show the delineation of a
central slice of the SB and the LB following RR only to allow comparison of the CT
(solid line) and ADC map (dotted line) delineations of bladder (yellow) and tumour
(green) prior to DR. The distortion seen in the SB was visibly greater than for the
LB, as indicated by the arrows. This is also indicated by the lower DSC of 0.81
compared to 0.85 for the RRs of SB and LB respectively. There was no obvious
cause for this difference in distortion as the MRI scans of the two bladders were
acquired under the same conditions.
It was noted that the differences between expected and actual positions of
bladder POIs following DR tended to lie along the bladder surface itself, that is
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to say that the high DSC values seen in table 4.4 imply a greater improvement in
distortion than the results in figure 4.9 indicate. This is visually illustrated by figure
4.10 which shows the bladder ADC map ROI (dotted yellow) closely matching the
bladder CT ROI (solid yellow), but an example POI shown (dotted crosshair = ADC
map and solid crosshair = CT) indicates positional differences of approximately 3
mm, with both points lying along the bladder surface. This difference highlights a
limitation that the DR algorithm may not correctly map the target bladder voxels
onto the reference bladder voxels, although visually the ROIs appear correct. This is
due to the way in which the DR algorithm works, as the use of the hybrid algorithm
in RayStation without the intensity information (as this is designed for CT-CBCT
or MR-MR registrations) uses only a chamfer-matching technique. In this technique,
the system is looking at nearest points and minimizing distances between the two
delineations of the bladder. When the delineations are overlaid by the algorithm,
there is no further information or calculation within the algorithm to drive any
further deformation of the bladder. For dose painting approaches to radiotherapy
this limitation is potentially significant, otherwise the original benefit referred to
by Fowler [43] (and highlighted in Chapter 3) - that the use of ionizing radiation
has the virtue over drug or gene-based therapies that it reaches the cells that the
physical plan encompasses - may therefore not be achieved.
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Figure 4.10: Images showing CT (blue) and ADC maps (orange) following (a) rigid
registration (i.e. the original images are overlaid) and (b) deformable registration.
Bladder delineations are shown in yellow and tumour in green with CT delineation
indicated by solid lines and ADC by dotted lines. An example of POI differences
along the bladder surface is indicated with white cross-hairs. Note that whilst
contours closely align following DR, there remains a 3 mm difference along the
bladder surface.
In practice, tumours are likely to be visible on T2W-MRI as well as ADC
maps, and therefore some correction for the effect in figure 4.10 might be possible
in terms of correlating tumour delineation with the T2W (less-distorted) image set.
However, one of the purposes of investigating the use of ADC maps to directly inform
a radiotherapy treatment plan was as a first step in investigation of the utilization of
a dose painting strategy based upon ADC image intensities. If incorrect positioning
remains following mapping of the ADC to CT, this would mean that the clinically
visible volume will not have the same representation as with CT or T2W images
and so dose painting techniques would not be possible.
When using data from ADC maps to inform radiotherapy treatment planning
using the more standard method of dose prescriptions to delineated tumour volumes,
the values of most interest would be the maximum difference between expected and
actual POIs, as this information will allow a conservative estimation of the size of
additional (planning) margin which would be required to mitigate against target
positional uncertainties. In this case, the results from DR3, which used the hybrid
DR algorithm and the ROI focus set to the bladder, are the most promising. The
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maximum positional difference was 4.6 mm for DR3 and was the lowest across all
registrations. Using this DR, a margin of 5 mm could therefore be appropriate
to account for the positional uncertainties introduced by the use of DW-MRI. It
would be expected that this margin would be in addition to any others required
in order to account for bladder filling, changes in patient position and anatomy
and other uncertainties. It would therefore form an additional part of the gross
tumour volume/clinical target volume to planning target volume expansion. Note
that these results were obtained using a 3 T scanner, whereas MR-sim would usually
be performed using a 1.5 T scanner, and therefore this value is likely to represent a
conservative estimation of the required margin as distortions would be expected to
be greater using a 3 T scanner.
As the results found using phantom I showed distortions which remained
larger than desired for radiotherapy purposes, a further phantom was developed,
and a different method of correcting the distortions in DW-MRI was tested. Further
alterations were made to the phantom, in order to improve the design including
construction of a more realistic (non-spherical) bladder shape. The use of plastic
for bladder wall and fiducial markers was swapped for PVA and string respectively.
This served to make the bladder more tissue-equivalent and to minimise artefacts
from small air bubbles which had tended to lodge inside the plastic markers used in
phantom I. The work using phantom II is discussed in section 4.2.7.
4.2.6 Requirements for a second phantom
The aim of designing, constructing and imaging a new phantom was to test whether
a different method of correcting distortion in DW-MRI would produce improved
results. The method that had been used for phantom I relied upon deformable
registration software available within the TPS which is used for radiotherapy dose
distribution calculation. Therefore this software was CE-marked and known to be
robust with respect to its handling of images and attached patient information.
The method of distortion-correction which was intended to be tested via the use of
phantom II, however, does not form part of the software ordinarily used within the
pathway of radiotherapy treatments. It is an established method within research and
clinical diagnostic use of DW-MRI in some centres (as discussed in section 4.2.8),
but is not commonly used within routine clinical analysis of diagnostic images as di-
agnosis is usually possible without distortion correction. For example, no distortion
correction software is used by the centre at which this work was performed when
DW-MRI is used clinically for diagnosis of prostate cancer. Therefore, although
the software used is established, it is not as well-designed for use within the path-
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way required for radiotherapy treatment design, and there are some difficulties and
limitations associated with this; these will be discussed in 4.2.9.
As a second set of results was to be obtained, it was an opportunity to also
include a more realistic shape of bladder than the spheres previously used (these
changes will be discussed in section 4.2.7).
Distortion correction methods
The method of distortion correction used here was introduced in Chapter 2, section
2.2.3. The FSL software (FMRIB Analysis Group, Oxford, UK) was downloaded
from the FMRIB Software Library and installed and tested on an iMac (OS X
10.9.5). The functionality of ‘topup’ within FSL was used, in which the ‘blip up’
and ‘blip down’ images acquired with b = 0 are used to calculate a field map. This
field map was then used via ‘applytopup’ to correct the other diffusion-weighted
images with different b-values. These calculations produced distortion-corrected
images for each b-value used. The distortion-corrected images were generated by
the FSL software in NIfTI format, and were processed in MATLAB (v. 2016a,
MathWorks, Natick, NA, USA) to produce ADC maps according to the mathemat-
ical methods presented in Chapter 2 section 2.2.3. These distortion-corrected ADC
maps are referred to as ADC (FSL) in this thesis. In order that the ADC (FSL)
files could be used within the radiotherapy TPS, these files were then converted back
into DICOM format, again using MATLAB. This required stripping the header in-
formation from the NIfTI ADC (FSL) files and re-attaching the DICOM header
from the uncorrected ‘blip up’ ADC maps which had been automatically produced
on the scanner. This step would not be robust enough as currently implemented for
clinical patient images, but was sufficient for testing the work using a phantom.
4.2.7 Phantom II design and construction
Phantom II was designed and constructed as shown in figure 4.11. This figure shows
(a) a photograph and (b) and (c) cross-sectional diagrams of the design of a second
phantom to model a urinary bladder with internal tumour. Information regarding
the materials used are reported in table 4.5; these are similar to those used for
phantom I except that the bladder wall as well as the tumour was constructed using
PVA gel. This meant that the bladder wall material was more tissue-mimicking
than plastic, there could be a bladder wall of finite thickness (rather than 1 mm as
previously) such that POIs could be located on the internal and external bladder
wall surfaces, and the shape of the bladder could be made more similar to that of a
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human bladder. The acrylic block used originally to clamp the attachment rod of the
bladder in phantom I was retained, as it had been seen to result in slightly increased
distortion towards the top of phantom I and so could provide some indication of the
effect of nearby anatomical inhomogeneities such as bowel gas or bone.
Figure 4.11: Phantom II - second phantom designed and constructed to model a
bladder and internal tumour shown in (a) photograph and (b) and (c) cross-sectional
diagrams.
Features of the construction of phantom II were:
• The main phantom volume was filled with water.
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• The bladder was cast in two parts using PVA gel, with approximate dimensions
taken from the CT of a patient previously treated for MIBC (7.0 x 5.5 x 5.0
cm); the thickness of the bladder wall was as required for adequate rigidity
(0.5 - 1.0 cm) and therefore greater than that of a patient bladder (typically
0.3 cm [34]).
• The tumour was also PVA gel but with added Gadolinium contrast agent. The
volume of 10 cm3 was chosen such that it was similar to that expected for a
post-resection MIBC tumour as used by Wright et al. [58].
• Assembly of the bladder and tumour was performed using wet string to ensure
no air bubbles were introduced as they would cause additional distortion when
imaged using DW-MRI.
• Wooden location aids were affixed on either side of the bladder as for Phantom
I.
• The assembled bladder and tumour was suspended inside the container using
wet string attached to the wooden location aids.
• Intersections of string with bladder/tumour surfaces were used as fiducial/positional
markers for comparison across the imaging modalities. Five fiducials were in
cardinal positions on the inner and outer bladder wall surfaces, and four within
the tumour.
4.2.8 Phantom II imaging, processing and registration methods
Phantom II was imaged using CT, T2W-MRI and DW-MRI as for phantom I; CT
was performed using the same scanner and settings as for phantom I, but the MRI
scans were performed with slightly different settings (see table 4.6). These changes
(in particular the NEX values) were made in order that the required images to use
the distortion correction algorithm could be acquired - using firstly the clinical mode
of the scanner (‘blip up’ images) and also the research mode, in order to acquire the
‘blip down’ images. The ‘blip down’ images could only be acquired with NEX = 1,
and therefore all images were acquired with NEX = 1. This time the scans were
also performed using both 3.0 T (GE 3T Discovery MR750w scanner as previously)
and 1.5 T (GE 1.5T Optima MR450w scanner) MR scanners and so the images
acquired using the 1.5 T scanner required slightly different settings. As previously,
all settings were based upon those in clinical use at this centre for imaging of the
prostate. Axial DWI Focus setting with 3-D geometry correction was used in both
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Table 4.5: Construction of phantom II
Item Material Size Comments
Container Polypropylene
(PE) sphere
23 x 16 x 16 cm
Main filling liquid Water
Bladder wall PVA gel 7.0 x 5.5 x 5.0
cm
10 % PVA cryogel so-
lution with Gd cast
into 2 moulds; 3 freeze-
thaw cycles completed.
Thickness 0.5-1.0 cm for
rigidity
Tumour PVA gel, Gd
contrast agent





Localisation aids Wood Upper end 7.0
x 3.8 cm, lower
end 9.3 x 3.8 cm
The trapezoidal shape
of these wooden blocks
enabled accurate RR
between CT and MRI
Fiducials String




An acrylic block located
close to bladder enabled
testing of the effect of a
nearby inhomogeneity
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cases, and ADC map generation was performed automatically using the scanner
software for the generation of ADC ‘blip up’ and ‘blip down’ images.
Table 4.6: Settings used for T2W- and DW-MRI of phantom II.
1.5 T 3.0 T
Parameters T2W-MRI DW-MRI T2W-MRI DW-MRI
TR (ms) 6433 4000 6604 2081
TE (ms) 102.3 70.5 120.3 66
Slice thickness (mm) 2.5 2.5 2.5 2.5
Slice gap (mm) 0 0 0 0
Matrix size 256 x 224 140 x 70 352 x 288 140 x 70
FOV (cm) 24 x 24 24 x 24 24 x 24 24 x 24





b = 50 b = 50
b = 300 b = 300
b = 700 b = 700
b = 1000 b = 1000
†b-value is calculated using equation 2.14.
The operation of the scanners in the two modes, i.e. clinical mode and
research mode enabled acquisition of images with reversed phase-encode blips and
resulted in pairs of diffusion-weighted images with distortions going in opposite
directions, as can be seen in figure 4.13 (a) and (b). The DW images which had
been used by the scanner to produce these ADC maps were converted from DICOM
into NIfTI format using MRIcroGL10 [59] software for processing in FSL. The paired
DW images were imported into FSL, and the susceptibility-induced off-resonance
field was estimated using a method similar to that described by Andersson et al. [30]
as implemented in FSL and previously introduced in Chapter 2 section 2.2.3. The
two sets of DW images were thereby combined into a single distortion-corrected
one. This was done for each set of DW-MRIs (i.e. each b-value used) and then
the corrected images imported into MATLAB. A new ADC map was then created
manually within MATLAB following the methodology outlined in Chapter 2 section
2.2.3. An example distortion-corrected ADC map is shown in figure 4.13 (c), with the
equivalent ‘blip up’ and ‘blip down’ ADC maps shown in (a) and (b) for comparison.
MATLAB was then also used to convert the ADC (FSL) NIfTI image files back into
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DICOM format so that they could then be imported into RayStation TPS.
The CT, T2W-MRI and ‘blip up’ ADC maps were imported directly into
RayStation TPS from the scanners without further processing. The bladder outer
surface, tumour, location aids, positional markers and string were delineated on the
CT, T2W-MRI, and both ‘blip up’ and ‘FSL’ ADC maps. The locations of the
fiducial markers were marked with points of interest (POIs) at the intersection of
the string with the relevant bladder wall or tumour surface.
Rigid registration of the T2W-MRI to CT was performed manually using the
location aids to position accurately in three orthogonal directions and with respect
to three axes of rotation. This transformation was then applied to both ADC maps
resulting in the same rigid registration of each ADC map to CT.
4.2.9 Phantom II: Results and discussion
Representative cross-sectional images of phantom II on CT and T2W-MRI are shown
in figure 4.12, in which the bladder wall, tumour and string fiducials are visible
along with location aids. Figure 4.13 shows similar representative cross-sectional
slices to those in figure 4.12, but of the three different ADC maps generated ((a)
‘blip up’, (b) ‘blip down’ and (c) ‘FSL’, i.e. distortion-corrected with (d) T2W-MRI
for comparison). The distortions, particularly at the interface between water and
acrylic block or air at the top of the images are displaced in opposite directions
between the blip up and blip down ADC maps. It is less noticeable, but still visible
that the bladder itself appears shorter in the vertical direction in the ‘blip down’
image than in the ‘blip up’ image. The distortion in the ‘ADC (FSL)’ image shown
in (c) is visibly reduced.
Figure 4.12: Cross-sectional images of phantom II using CT and T2W-MRI.
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Figure 4.13: ADC maps where (a) ‘blip up’ and (b) ‘blip down’ refer to k-space
readout direction showing distortion primarily in the relevant readout direction; (c)
the ADC (FSL) map was recalculated following distortion-correction of acquired
DW-MRIs using FSL and (d) T2W-MRI for comparison.
Following rigid registration of the ADC image sets to CT, the location of
14 POIs marking fiducial locations were compared between the modalities. This
information is summarised in figure 4.14 which shows the mean and one standard
deviation distances between POIs located on the labelled image set compared to
their locations on CT.
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Figure 4.14: Mean and standard deviation of positional differences between expected
and actual positions of POIs following registrations of T2W-MRI and ADC maps
to CT of phantom II.
Of greater importance than the mean and spread of location agreement of
POIs for the purposes of radiotherapy, is the maximum disagreement in location of
the POIs. Figure 4.15 is a graph showing these maximum differences between POI
locations on CT and T2W-MRI, and CT and ADC maps.
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Figure 4.15: Maximum positional differences between expected and actual positions
of POIs following registrations of T2W-MRI and ADC maps to CT of phantom II.
The results in figures 4.14 and 4.15 show that for the T2W images at 3
T the discrepancy in POI location is less than 1 mm on average, and only 1.2
mm maximum. Similarly, at 1.5 T these results were 1.1 mm (mean) and 1.8 mm
(maximum) respectively. However, the equivalent results for ‘blip up’ ADC maps
show that whilst the mean location discrepancy is 2.2 mm, the maximum exceeded
6 mm at 3 T. At 1.5 T these results were 2.3 mm on average and 3.8 mm maximum.
Therefore, at both 3 T and 1.5 T the distortion seen in distortion-uncorrected (‘blip
up’) ADC maps would be unacceptable for the purposes of tumour delineation and
subsequent dose escalation in radiotherapy.
At 3 T, the locations showing poorest agreement corresponded to the fiducials
located at the furthest superior and inferior extremes of the bladder. A possible
reason for this could be that the centre of the scanned volume is positioned at the
centre of the bore longitudinally, and therefore any field inhomogeneities would be
worse for slices further from the centre of the phantom. One of these POIs also
shows the worst agreement at 1.5 T, although there are also several other points
with similar disagreement at 1.5 T (unlike at 3 T where all other points lie within
2.5 mm). At both 3 T and 1.5 T, the discrepancy occurs predominantly in the
z-direction, which is the direction in which positional information is encoded using
the phase of precession. This effect was more pronounced for the 3 T images, as
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would be expected. For the 1.5 T images, there are several points with 2 - 4 mm
discrepancy between POI locations, and more of these discrepancies lie in the x or
y-direction. It may be that these points were more difficult to accurately ascertain
as there was poorer contrast in the images acquired at 1.5 T, although this would
require further investigation to confirm.
Following distortion-correction of the DW-MRIs using the FSL software and
subsequent recalculation of ADC maps as discussed in section 4.2.8, the mean (and
maximum) discrepancies in fiducial locations were 1.3 mm (1.8 mm) at 3 T and
1.1 mm (1.7 mm) at 1.5 T respectively. These results are similar to those found
for the T2W images, and certainly below 2 mm in all directions. Therefore, using
this method to correct the distortion of DW-MRI and ADC maps for radiotherapy
delineation and dose escalation purposes appears feasible, providing the route of
image processing required could be made more robust to potential errors.
The acrylic block at the top of the phantom was located a distance from the
bladder similar to that expected for potential air/gas in patient rectum or bowel.
This was 1.3 cm from the bladder wall and nearest external bladder wall fiducial
marker, and 2 cm from the nearest internal bladder wall marker. Both points
show improvement in agreement in fiducial location following distortion correction,
with maximum discrepancies being 2.5 mm (uncorrected) reduced to 1.8 mm (post-
correction) at 3 T and 3.3 mm reduced to 1.5 mm at 1.5 T (both for the internal
marker, I1).
4.3 Summary and conclusions
Two phantoms were designed and constructed to determine the effect of distortions
in ADC maps of the positional information in cases of muscle-invasive bladder cancer
(MIBC). Imaging at 3 T of phantom I and processing using a commercially available
deformable registration software found that ADC maps were produced from DW-
MRI and transferred to a CT frame-of-reference with a 4.6 mm spatial accuracy.
This was a significant improvement compared to the initial accuracy of over 13
mm using rigid registration, but is still large for radiotherapy treatment planning
purposes.
Similar imaging at both 3 T and 1.5 T of phantom II found that ADC maps
produced directly from DW-MRI on the scanner and transferred to a CT frame-of-
reference reproduced location within up to 6.3 mm. However, when the DW-MRIs
were processed and corrected for distortion using FSL software before production
of ADC maps, the location of fiducials was reproduced within 1.8 mm for both 3 T
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and 1.5 T MRI scanners. This is similar to the reproducibility accepted clinically
for standard MRI techniques such as T2W-MRI. However, the workflow required for
this technique is not currently possible within a clinical framework as much offline
processing of images was required in order to produce the distortion-corrected images
and import into the TPS.
Work in later chapters of this thesis investigating the potential impacts of the
use of DW-MRI of bladder tumours for delineation of tumour (GTV) volumes will
therefore use both the initial results from phantom I (using deformable registration)
and phantom II (using offline distortion corrections) to accommodate uncertainties
in location originating from the use of DW-MRI. This means a conservative margin
of 5 mm will be used initially, and a less conservative margin of 2 mm will also be




probability for bladder cancer
The response of cells to radiation, and the resulting probability of local control of a
tumour (TCP) was introduced in Chapter 2 (section 2.1.3). This chapter develops
TCP models for MIBC to enable the subsequent comparison of dose distributions
in chapter 6.
5.1 TCP models
Several different mathematical functions have been used to model the probability of
tumour control given the delivered radiation dose. A useful introduction is provided
in a paper by Bentzen and Tucker [60], in which they describe how dose-incidence
data for a specific radiation effect (i.e. endpoint) follows a sigmoid curve. They
present the three most frequently used mathematical models: Poisson, logistic and
probit respectively. The work in this thesis builds upon a logistic model described by
Plataniotis and Dale [61] and refits their data using the Poisson model, for reasons
discussed later in this chapter.
All TCP models are limited in their ability to accurately predict TCP, for
two main reasons. Firstly, the clinical data on which the model is based will be
several years old in order to have the follow-up time to determine outcome data.
Therefore, the techniques and technology in use at the time of treatment delivery
may be different from those in current use, and it is difficult to know how important
these differences may be. For example, at the time of the BC2001 clinical trial [7]
the delivery techniques used did not routinely include daily CBCT for patient set
up, but such techniques are now in widespread use. Therefore, the partial bladder
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boost incorporated in the trial could potentially lead to better outcomes if performed
using current equipment as targeting of the boost volume would now arguably be
more accurate.
A second limitation of TCP models is that, historically, only the effect of
radiotherapy is taken into consideration [58, 62, 63, 64]. It is much less common
for TCP models to attempt to assess the effects of combined treatments such as
those including chemotherapy. This is a difficulty for many tumour sites, as often
the prediction of TCP will therefore be based on data acquired from clinical trials
which used only radiation therapy. However, in subsequent clinical practice patients
may also receive chemotherapy. Assessing the impacts of combined treatments is
not straight-forward [65].
There are also other limitations and difficulties involved in modelling TCP
including the inability to measure the ideal data points systematically such as would
be done for other experiments (i.e. varying dose across the possible range) as it would
obviously be unethical to do so outside cellular (laboratory) studies.
5.1.1 TCP model requirements for this project
The aim of this project was to investigate the effects of dose escalation on TCP for
simulated tumours akin to those expected to be found within the BladderPath trial.
To be used for this purpose, the TCP model must be able to account for differences
in tumour volume because the BladderPath trial omits the TURBT procedure, but
uses neoadjuvant chemotherapy, followed by radiotherapy (or other treatments in-
cluding surgery, although these treatments are not relevant to this project). The tu-
mour volume at the time of radiotherapy treatment under the BladderPath trial will
presumably be smaller than seen at diagnosis, owing to response to the chemother-
apy, but may not be as small as post-TURBT tumours. It is not yet known what a
representative tumour volume should be, and so it is pragmatic to model a range of
volumes and assess the effect of tumour volume as well as dose upon the resulting
TCP.
As BladderPath will include multimodality treatments, i.e. both radiother-
apy and chemotherapy, it is also desirable to be able to estimate the additional
effect of the chemotherapy as well as the effect of radiotherapy dose escalation upon
TCP. As noted above, this is not simple to achieve and there have been several ap-
proaches to the solution of this problem. A detailed review is given by Grassberger
and Paganetti [65], but there is currently no established method. In general, work
has assessed the potential impact of radiotherapy dose escalation using radiotherapy
data alone when investigating various adaptive radiotherapy treatment techniques
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for MIBC (for example Wright et al. [58], whose work is discussed in section 5.1.3).
Ideally, this project would follow this approach of using radiotherapy data alone, as
it is most established, but also incorporate an estimate of the additional effect of
chemotherapy.
5.1.2 Plataniotis and Dale’s logistic model
One paper which attempts to accommodate the effects of chemotherapy in addition
to radiotherapy for MIBC is that by Plataniotis and Dale [61], using the logis-
tic model. This model is frequently used in statistical applications and came into
widespread use in radiobiology following work by Suit et al. in 1965 [66]. In the





In this equation, u = a0 + a1D + a2Dd and d = dose per fraction, D = total dose
and an are constants.
In Plataniotis and Dale’s paper this standard approach was used to fit data
from radiotherapy-only (RT-only) trials and then used as a platform to quantify the
chemotherapy contribution in single-phase radiochemotherapy (RCT) trials. The
radiation-induced complete response (RCR) at 2 years post-treatment was the end-
point investigated, as it is reported most commonly by clinical trials. Complete
response is the disappearance of all signs of the tumour in response to treatment,
and is more readily measurable than other endpoints such as overall survival. RCR
was associated with a given dose, which may have been delivered using various frac-
tionation schemes across the different clinical trials. These differences were accom-
modated via the use of the biologically effective dose (BED) formula and converted
to equivalent dose in 2 Gy fractions (EQD2), where












Equation 5.2 is similar to equation 2.4 in which BED was originally defined in
chapter 2, but now explicitly includes the dose per fraction (d) and number of
fractions (n), as well as a factor k(T −Tk) to take account of potential repopulation
of tumour cells if delivery of dose is prolonged. In this factor, T is the overall
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treatment time in days, and Tk is the delay time in days before fast repopulation
of the cells in the tumour is thought to occur, and was taken to be 28 days by
Plataniotis and Dale. The factor k was taken to be 0.2 Gy.day−1 and the α/β ratio
was assumed to be 10 Gy.












where RCR = radiation-induced complete response at 2 years associated with a
given equivalent dose in 2 Gy fractions (EQD2), D50 is the dose in 2 Gy fractions
required for a 50% response and γ50 is the slope of the response curve (percentage
increase in response corresponding to a 1% increase in dose) at 50% response.
Figure 5.1: Scatterplot of RT-only observed complete response rates (RCR) against
equivalent dose in 2 Gy fractions (EQD2), together with the weighted best fit re-
sponse curve. Reproduced from figure 1 of Plataniotis and Dale [61].
Figure 5.1 is a reproduction of figure 1 from Plataniotis and Dale’s paper in
which a scatterplot of the RT-only observed complete response (CR) rates against
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EQD2 is shown, together with the best fit response curve which was weighted ac-
cording to the number of patients in each clinical trial. Figure 5.2 shows the same
data and fit, but with the clinical trials data in which patients received chemother-
apy as well as radiotherapy (radiochemotherapy, RCT). It can be clearly seen that
this data shows a trend of improvement in complete response, although there is a
wide spread thought to be due at least in part to the variations in chemotherapy
regimens used.
Figure 5.2: Scatterplot of RT-only (black circles) and RCT (red triangles) observed
complete response rates against equivalent dose in 2 Gy fractions (EQD2), together
with the weighted best fit to the RT-only data (black line). Reproduced from figures
1 and 2 of Plataniotis and Dale [61].
Plataniotis and Dale considered two alternative modes of operation for the
incorporation of chemotherapy into response: (a) a fixed chemotherapy-alone contri-
bution to complete response, or (b) a fixed degree of chemotherapy-induced radiosen-
sitization. The corresponding graphs are shown in figures 5.3 and 5.4 respectively.
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Figure 5.3: Scatterplot of radiochemotherapy (RCT) observed complete response
rates (red triangles) against equivalent dose in 2 Gy fractions (EQD2), together
with the weighted best fit using a fixed chemotherapy-alone contribution to complete
response (red solid line). The 95% confidence interval of the fit is shown by shading,
and the RT-only fit from figure 5.1 is shown for comparison (black line). Reproduced
from figures 1 - 3 of Plataniotis and Dale [61].
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Figure 5.4: Scatterplot of radiochemotherapy (RCT) observed complete response
rates (red triangles) against equivalent dose in 2 Gy fractions (EQD2), together with
the weighted best fit using a fixed degree of chemotherapy-induced radiosensitization
(red solid line). The 95% confidence interval of the fit is shown by shading, and the
RT-only fit from figure 5.1 is shown for comparison (black line). Reproduced from
figures 1 - 4 of Plataniotis and Dale [61].
In mode (i), chemotherapy provides a response rate independently of radio-
therapy and complete response (CR) was calculated from
CR = CCR+RCR(1− CCR) (5.5)
where CCR = chemotherapy complete response and RCR is given by equation 5.4
and can therefore be combined as














In the second possible mode of operation, Plataniotis and Dale postulated
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that chemotherapy may act purely as a radiation dose sensitizer and therefore the











where s is the dose sensitization coefficient and all other parameters are as previously
stated.
The resulting graphs produced from these two approaches (of incorporating
chemotherapy effects as having a fixed contribution or as a sensitizing agent) are
reproduced in figures 5.3 and 5.4 respectively. These figures show large differences
in fit at low doses, however the predicted response at these doses are not clinically
relevant (as treatment doses are in the range of the clinical trials data points).
The analysis by Plataniotis and Dale is novel in the way it attempts to incor-
porate the effects of chemotherapy as well as radiotherapy within the TCP models
for MIBC, and ideally this approach would be incorporated within any assessment
of the effect of dose escalation upon MIBC. Unfortunately, however, as there are no
parameters in the logistic model to enable direct control of the tumour volume, it
is not possible to use this model to assess the potential impact of dose escalation
within a BladderPath-based study. This is because it is not known whether tumour
volumes at the time of radiotherapy treatment in this study will be similar to those
for standard treatments, as tumours within the BladderPath treatment pathway
will not have undergone the TURBT procedure but will have been treated with
neoadjuvant chemotherapy. In this situation, the Poisson model would be useful, as
it contains parameters which enable the direct manipulation of tumour volume and
so investigations across a range of potential tumour volumes is possible.
5.1.3 Poisson Model
A detailed introduction to this model is given in The Handbook of Radiotherapy [11],
and the background discussed in this section can be found there unless otherwise
stated.













where N0 is the initial number of clonogens, d is the dose per fraction, D is the total
dose and α and β are the fitting parameters which affect the shape of the curve. This
model produces sigmoidal curves, with very steep slopes, as seen in the dashed curve
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in figure 5.5. As these slopes are steeper than those found in practice, the model
has been developed to incorporate inter-patient variation, where it is assumed that
α is distributed normally amongst the patient population with a standard deviation
σα. Figure 5.5 shows the effect of varying σα, with the two curves both having an
α of 0.35 Gy−1. Where the standard deviation in α is zero, i.e. σα = 0.00 Gy
−1 the
steep (dashed) curve is produced, and when σα = 0.08 Gy
−1 the shallower (solid)
curve is produced.
Figure 5.5: Tumour control probability (TCP) as a function of dose, adapted from
[67]. Both curves are calculated with α = 0.35 Gy−1, but with a standard deviation
σα = 0.00 Gy
−1 (dashed line) or 0.08 Gy−1 (solid line) respectively.
Wright et al. [58] have used the Poisson model in this way to fit a set of
MIBC clinical trials data, which they subsequently used to assess the effectiveness
of different adaptive bladder radiotherapy techniques. In chapter 2 (equation 2.1)




In their paper, Wright et al. assumed that the survival fraction over all volume













The probability of no surviving clonogens in a voxel (the voxel control probability,
VCP) is then given by
V CPi = exp (−VvoxρiSFi) (5.11)
where Vvox is the voxel volume and ρi is the density of clonogenic cells in the i
th












To include inter-patient variations in radiosensitivity, as discussed above,
Wright et al. assumed α followed a normal distribution with standard deviation
σα as presented originally by Nahum and Tait [67]. The α/β ratio was assumed to
remain constant with a value of 13 Gy (based on Pos et al.’s findings [62]). Hence












where g(α) is a Gaussian distribution. In the case of bladder cancer, the target
volume to be treated with radiation contains both primary tumour and the bladder
wall, as both may contain some clonogenic cells. The density of clonogenic cells will
be higher in the tumour volume than in the bladder wall, and incorporating both








k 6=i SFk)g(α)dα. (5.14)
Wright et al. used equation 5.14 to fit a set of MIBC clinical trials data
from Pos et al. [62]. These trials were RT-only and used an endpoint of 3 year
local control. In fitting the data, Wright et al. assumed a post-TURBT tumour
volume of 10 cm3 as being representative of an average volume, and a clonogenic
cell density within the tumour of 107 clonogens/cm3 as suggested by Webb and
Nahum [68]. They kept constant the total number of clonogenic cells in the whole
(bladder wall plus tumour) volume, whilst varying the relative density (i.e. greater
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or lesser proportions between the bladder wall and tumour itself. As stated, an α/β
ratio of 13 Gy was used from the Pos et al. paper, and constraints of 0% at 30
Gy and 95% at 100 Gy were used with a restricted nonlinear least square fit. The
work was then used by Wright et al. to compare different adaptive strategies for
radiotherapy of MIBC.
The combination of the work done by Plataniotis and Dale using the logistic
model, and by Wright et al. using the Poisson model gave rise to the approach taken
in this thesis. That is, the use of the Poisson model (in order to have explicit control
of the effects of tumour volume and clonogenic cell density), but also a separate,
additional attempt to incorporate the effects of chemotherapy upon TCP.
5.2 Fitting the Poisson model to TCP data
The aim of the work in this chapter was to refit the data used by Plataniotis and Dale
in their paper using the technique described by Wright et al. This would result in a
standard Poisson-based TCP model to predict outcomes from RT-only treatments.
The same methodology was then used to fit to the radiochemotherapy (RCT) data
fitted by Plataniotis and Dale. The intention of this was to be used as an adjunct
to the standard RT-only model in order to be able to better predict outcomes using
a dose escalatation technique which would include the use of chemotherapy and
require the ability to directly control for variations in tumour volume.
A MATLAB script was written which emulated the approach of Wright et
al., and was tested on the dataset used by Wright et al. and shown to reproduce the
results in Figure 1 of their paper [58]. All assumptions made within the MATLAB
code were based on those used by Wright et al., i.e. a post-TURBT average tumour
volume of 10 cm3, clonogenic cell density of 107 cm3 and constraints of 0% at 30 Gy
and 95% at 100 Gy were used with a restricted nonlinear least square fit and α/β
= 13 Gy. The output of the code was designed to find the value of αmean and σα
which would best fit the input trials data.
Following validation by reproduction of Wright et al.’s results, the α/β ratio
used by the code for fitting the (Plataniotis and Dale) data was altered to 10 Gy, in
order to be in keeping with the values used by Plataniotis and Dale in their fitting
using the logistic model and previously presented in figures 5.1 - 5.4. A review of
dose and fractionation schemes in the literature by Pos et al. [62] found that any
value for α/β in the range 10 - 15 Gy is appropriate, and that there is quite a large
uncertainty in this value.
96
5.2.1 Fitting methodology
The MATLAB code was used to methodically step through the possible values of
αmean and σα, to find the values which best fit the datasets using a restricted
nonlinear least square fit. The results of running this code are shown in figures
5.6 and 5.7 for the RT-only and RCT clinical trials data respectively (both from
Plataniotis and Dale [61]).
Figure 5.6: Graph showing how changing αmean and σα affects the root mean square
error (RMSE) when fitting RT-only clinical trials data from Plataniotis and Dale
[61] with the Poisson model.
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Figure 5.7: Graph showing how changing αmean and σα affects the root mean square
error (RMSE) when fitting radiochemotherapy (RCT) data from Plataniotis and
Dale [61] with the Poisson model.
Figure 5.6 shows how varying αmean and σα affects the root mean square
error (RMSE) when fitting the RT-only data from Plataniotis and Dale [61] using
the Poisson model. There is a wide plateau in the RMSE for the fits produced
with αmean in the range 0.31 - 0.33 Gy
−1 and σα in the range 0.09 - 0.11 Gy
−1.
The minimum RMSE produced was a value of 0.811 which occured when αmean =
0.32 and σα = 0.10. As these values are approximately central within the plateau
region, this appears reasonable. The values are similar to those found by Wright et
al. (αmean = 0.29 and σα = 0.08 respectively), although the endpoint used within
that study was 3 year local control, rather than 2 year local control as used here.
Figure 5.7 similarly shows how the RMSE varies with change in αmean and
σα but instead when fitting the RCT dataset from Plataniotis and Dale using the
Poisson model. There is again a wide plateau in values of αmean and σα which
produce the lowest RMSEs (approximately αmean between 0.34 - 0.36 and σα 0.09
- 0.11). The minimum RMSE of 0.981 was produced when αmean = 0.35 and σα =
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0.10. Again, these values are approximately central within the plateau region.
5.2.2 Estimation of model uncertainties
TCP models in the literature frequently do not estimate the uncertainty in the model
produced (for example Wright et al. report no estimate). This is perhaps partly
because it is understood that the data used to produce the models are incomplete,
and only exist in the range which is clinically acceptable to deliver to patients.
Hence there is inherently a wide uncertainty in any model.
In order to estimate a 95 % confidence interval for the models produced here,
the following method was used. The datapoints for both RT-only and RCT were
closely clustered in terms of the values on the x-axis (EQD2), as shown in figures 5.1
and 5.2. Therefore, the mean EQD2 over all the clinical trials in each case (RT-only
and RCT) was calculated, and assumed representative in this direction. The mean
and standard deviation in the TCP (i.e. y-direction) was then calculated, and the
combination used to produce points lying at mean EQD2 and mean TCP ± 2 s.d.
These points are listed in table 5.1.
Table 5.1: Points calculated for 95 % confidence interval (CI) curves to pass through
for RT-only and RCT data. Assuming no variation in dose and using spread in TCP
of trials datapoints to estimate mean ± 2 s.d. in TCP. Points stated as (EQD2 (Gy),
TCP (%)).
95% CI curve RT-only RCT
Upper (58.55, 98.33) (57.82, 84.41)
Lower (58.55, 62.18) (57.82, 44.27)
The same MATLAB code used to fit the data was then reused to manually generate
curves which would pass through each of the points in table 5.1 by varying αmean but
keeping σα fixed. In this way, curves approximating the expected 95 % confidence
interval curves were generated. The best fits and 95 % confidence interval curves are
shown in figures 5.8 and 5.9 in section 5.3 for RT-only and RCT data respectively.
99
5.3 Results and discussion: Fitting the Poisson model
to TCP data
5.3.1 Fit of Poisson model to RT-only data
Figure 5.8 shows the results of fitting the Poisson model as described to the RT-only
dataset used by Plataniotis and Dale. The graph shows the RT-only clinical trials
data (black circles) and Plataniotis and Dale’s logistic fit (black line) as previously
shown in figure 5.1 as well as the fit using the Poisson model with αmean = 0.32
and σα = 0.10 (thick green line). The 95 % confidence interval in the Poisson fit is
shown also (green shading).
Figure 5.8: RT-only clinical trials data (black circles) and logistic fit (black line)
reproduced from Plataniotis and Dale [61], along with the best fit using the Poisson
model (green line) produced using the MATLAB script and α = 0.32, σα = 0.10.
The 95 % confidence interval in the Poisson fit is also shown (green shading).
Figure 5.8 shows large differences in the fits for doses below ∼45 Gy. This
is not unexpected and is inherent to the models used (as discussed by Bentzen and
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Tucker [60]). These doses, however, are below those usually used for radiotherapy
treatments and therefore there are no clinical data in this region. The region of
interest for the purpose of this thesis lies from around 50 Gy and above. In this
region the maximum difference in TCP predicted by the logistic and Poisson models
is 7 %.
5.3.2 Fit of Poisson model to RCT data
Using the same approach as in section 5.3.1 for the RCT data, the results shown
in figure 5.9 were obtained. In this figure, the RCT trials data are shown by red
triangles and Plataniotis and Dales fits are shown by the dark red (sensitizer model)
and light red (fixed chemotherapy response model) solid lines. The best fit found
using the Poisson model with αmean = 0.35, σα = 0.10 is shown (purple line). The
95 % confidence interval in the Poisson fit is also shown (purple shading).
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Figure 5.9: RCT trials data (red triangles) and both logistic fits reproduced from
Plataniotis and Dale [61] (dark and light red lines), along with the best fit using the
Poisson model produced using the MATLAB script with αmean = 0.35, σα = 0.10
(purple line). The 95 % confidence interval in the Poisson fit is also shown (purple
shading).
The upper limit for the 95 % confidence interval shown in figure 5.9 for
the RCT Poisson fit appears large, in comparison to the other estimates. This is
probably due to the method used to estimate the curve, as the best fit curve itself
does not go quite through the mean value of the TCP datapoints at the location of
the mean dose of the datapoints; it lies further to the right than this point. This
makes the high estimate of the 95 % confidence interval appear to be overestimated
relative to the lower estimate of the 95 % confidence interval. Also, the large TCP
value that is required (98.3 % at a dose of 58.55 Gy) is such that a very steep
sigmoid curve is generated. Nevertheless, these curves serve to highlight a reasonable
estimate for the uncertainty involved in estimating TCP.
Figure 5.9 again shows large differences in the fits between logistic and Pois-
son models for doses below ∼45 Gy. In the region above 50 Gy the maximum
102
differences in TCP predicted by the logistic and Poisson models are ∼5 %. For the
RCT (sensitizer) model the differences in predicted TCP using the Poisson model
are <2 %.
5.3.3 Confidence in the models
Figure 5.10 shows all results for doses above 40 Gy, and the datapoints which corre-
spond to the clinical trial BC2001 [7] are highlighted. This trial used two fractiona-
tion schemes which were shown in table 3.1 and were found to have equivalent TCP
and toxicities and are two of the most commonly-used fractionation schemes in the
UK. The trial compared RT-only and RCT for both fractionation schemes; in figure
5.10 both RT-only (green circles) and RCT (purple circles) datapoints can be seen
to lie on either side of the relevant Poisson-fitted curves. This adds confidence that
the fits are reasonable at these doses.
Figure 5.10: Graph showing all trials data and all fits, with the 4 datapoints from
BC2001 [7] highlighted. Green circles indicate RT-only and purple indicates RCT.
The points for 55 Gy/20# and 64 Gy/32# fractionation schemes lie either side of
the appropriate Poisson-fitted curve in both cases.
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The use of the Poisson model to fit the RT-only clinical trials data from
Plataniotis and Dale is a standard approach, and produced fitting parameters which
are similar to those found by others for other datasets. The appropriateness of the
use of the Poisson model to fit the RCT dataset is less certain, however. For the
purposes of this work it is certainly useful to have a ‘best guess’ of the increase in
TCP which might be expected from the use of chemotherapy as well as RT, provided
this is done with the caveat that the approach is simply in addition to the standard
method, in order to gauge a reasonable estimate.
The data on which both TCP models (RT-only and RCT) are based is all for
patients who received RT (without/with chemotherapy) after a ‘maximal TURBT’
had been performed. This is the standard care for patients with MIBC at present,
however, the patients within the BladderPath trial will not receive the TURBT
procedure. At present, there are no data to indicate the TCP following neoadjuvant
chemotherapy without TURBT, followed by RT with or without chemotherapy -
this is part of what the BladderPath trial aims to test. Hence, there may well be
differences in outcome following the BladderPath protocol, and this is an inherent
limitation to any model used for this purpose.
5.3.4 Use of these models to calculate TCP
Having produced the two Poisson models via fitting to clinical trials data for both
RT-only and RCT, the next step was to alter the code to use treatment dose dis-
tributions to predict TCP. This would use the parameters of αmean and σα which
were found in section 5.2, and adapt the MATLAB code to read in the relevant dose
information from calculated dose distributions. The RayStation TPS can produce
text files which are generated by a Python script to produce differential dose volume
histograms (DVHs). These files contain information about how many voxels receive
each given dose, and the resolution of dose and voxel size can be chosen.
Firstly, the MATLAB script was adapted for the simple case where a 10
cm3 tumour volume was treated to a uniform dose of 64 Gy in 32 fractions (i.e.
EQD2 = 61.5 Gy using equation 5.2). This enabled testing that the script produced
the expected result (72.6 % and 81.5 % for RT-only and RCT respectively), as
this volume had been used to produce the fitted curve. Several further tests were
performed to ensure that the code worked as expected, for example that 10 x 1 cm3
tumour voxels produced the same result as a single voxel of 10 cm3 receiving the
same dose; and that a large decrease in dose for a small number of tumour voxels
had a noticeable (and expected) effect.
The code was then further developed to produce several results depending
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on the density of clonogens within the bladder wall. As for all previous work, it was
assumed that tumour clonogenic cell density was 107 cm−3, but the bladder wall
clonogenic cell density was allowed to vary between zero and 107 cm−3 (i.e. the
best and worst extremes) in logarithmic steps to see what effect this might have on
overall TCP.
The code was checked using a standard 64 Gy uniform plan to the whole
bladder within RayStation TPS, and which produced a text file containing the dDVH
data for the tumour and bladder wall. This file was used by the MATLAB code and
produced a predicted TCP within 1 % of the best fit curves in figure 5.8 (RT-only)
and figure 5.9 (RCT), i.e the Poisson best-fit curves. The code was also adapted
to produce estimates of the 95 % confidence intervals of these estimates, using
the parameters from the work discussed in section 5.2.2. All results subsequently
generated using this code are shown and discussed in Chapter 6 and 7.
5.4 Summary and conclusions
The approach used by Wright et al. [58] to fit a dataset of clinical outcomes data us-
ing the Poisson model was used to re-fit the datasets previously fitted by Plataniotis
and Dale using the logistic model [61]. The parameters required to best fit the data
were αmean = 0.32 and σα = 0.10 for the RT-only dataset, and αmean = 0.35 and σα
= 0.10 for the RCT dataset. These values were then included within two MATLAB
scripts (one for RT-only and one for RCT) which calculated predicted TCP from
an input differential DVH such as those produced by a treatment planning system
for a particular radiotherapy dose distribution. The functionality of these scripts
was tested with simulated DVH files and the DVH text file from RayStation from
a standard clinical dose distribution. Additional code produced estimates of the
95 % confidence interval TCP results for both RT-only and RCT models. Multiple
combinations of clonogenic cell density were tested; with the standard 107 clonogens
cm−3 within the GTV and varying between 0 and 107 cm−3 in the bladder wall.
The work presented in this chapter was intended to facilitate the calculation
of TCP for a range of dose distributions, in order to predict the ability to escalate




Isotoxic dose escalation of
simulated tumours
6.1 Introduction
The work presented in this chapter was inspired by a report by Warren et al. [69]
in which 21 patients with mid-oesophageal cancer were retrospectively selected fol-
lowing conventional treatment, and a theoretical dose escalation study performed.
Warren et al. used radiobiological modelling to calculate the required magnitude
of a boost dose to the tumour (plus a 0.5 cm margin) such that a clinically sig-
nificant increase in local control would be expected. The authors then calculated
dose distributions on this basis in all patients, as well as standard distributions for
comparison. They found that the dose escalation was achievable whilst continuing
to meet existing dose constraints for nearby OARs for 16 out of 21 patients, with
significant improvements in TCP and small increases in predicted toxicity.
The appproach taken in this chapter was similar to that of Warren et al, but
involved a systematic increase in escalation dose until acceptable OAR doses were
unachievable, followed by the calculation of the expected TCP. This meant that
it was possible to determine the dose at which escalation became unfeasible in a
variety of scenarios, rather than calculating a single dose for escalation based upon
a specific intended increase in TCP.
The Warren paper studied dose escalation to tumours which are visible on
CT, unlike post-TURBT bladder tumours. Therefore, in the work described in this
chapter, tumours were first simulated in a range of possible locations within the
bladder and with a range of volumes. The intention was to mimic a situation in
which tumour positional information would originate from DW-MRI and be trans-
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ferred to CT via image registration. Chapter 4 had separately sought to investigate
the accuracy with which such information might be transferred, using phantom stud-
ies. Initial results in Chapter 4 produced a conservative estimate of 5 mm for the
accuracy of such image data transfer, and subsequent work reduced this estimate to
2 mm. These values were each used within the study presented in this chapter, with
initial work using the former value of 5 mm and subsequent testing using 2 mm.
6.2 Development of a method to simulate tumours
The planning CT and daily CBCT imaging from a previously treated MIBC patient
was compiled and used for this section of work. The existing clinically-defined
delineations of bladder (i.e. outer bladder wall), bowel, rectum, and femoral heads
were retained. An internal 3 mm margin was created inside the bladder delineation
to grow a ‘bladder wall’ volume (the value of 3 mm was chosen as representative
of the values found by Jequier et al. [34]). When simulating a tumour volume
post ‘maximal TURBT’ the volume was assumed to be 10 cm3 as used by Wright
et al. [58]. Simulations of such post-TURBT tumour volumes were created in
six locations in the bladder (anterior, posterior, left, right, superior and inferior).
The delineated volumes were chosen such that their extents were approximately
symmetrical in each direction (see figures 6.1 and 6.2). All post-TURBT tumour
volumes were 10 cm3 and their thickness extended internally to 4 mm at the thickest
point. These simulated tumours were designed to represent post-TURBT tumours
such as those that would currently be treated in the standard way; an example
schematic is shown in figure 6.1. The figure shows the inner and outer surface of the
delineated bladder wall in yellow, and the simulated post-TURBT tumour volume
delineated in orange. This example shows a tumour located inferiorly in the bladder,
with noted symmetrical extent in the lateral (left and right) and anterior-posterior
directions.
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Figure 6.1: Schematic showing the coronal view of a simulation of an inferior post-
TURBT (10 cm3) tumour. Tumour extent is symmetrical as indicated in the lateral
and anterior-posterior directions.
A second group of tumours were then simulated, based on the first, but
in which an internal margin of 1 cm was used to increase their volume. Minor
adjustments (<1 cm3) were made to the volumes generated in each case so as to
ensure the volume of all six tumours was exactly 20 cm3. A third group of tumours
were simulated in the same way, but by growing the internal margin by a further
0.5 cm and manually adjusting the tumour volumes generated to be exactly 30 cm3.
A schematic diagram of one of the third group of tumours can be seen in figure
6.2. In this figure, the inner and outer surfaces of the bladder wall are delineated
in yellow, and the large simulated tumour in blue. This example shows a tumour
located posteriorly in the bladder, with symmetrical extent (as far as is possible
within the shape of the bladder itself) in the lateral and superior-inferior directions.
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Figure 6.2: Schematic showing the sagittal view of a simulation of a posterior large
(30 cm3) tumour. Tumour extent is shown to be approximately symmetrical in the
lateral and superior-inferior directions.
Following the described tumour simulation method, 18 tumours were simu-
lated in total, with three in each location (anterior, posterior, left, right, superior
and inferior). The three tumours in each location corresponded to small, i.e. post-
TURBT (10 cm3), medium (20 cm3) and large (30 cm3). Although it is possible
that some MIBC tumours could be larger than 30 cm3 at the time of presentation,
the purpose of this work was to model what might be possible using the Bladder-
Path pathway. In this pathway, patients receive neoadjuvant chemotherapy prior to
radiotherapy treatment. It is expected that the tumours will therefore shrink be-
tween presentation and radiotherapy treatment, due to response to chemotherapy.
As there is not yet any information available to show the degree to which shrinkage
occurs, the range of tumour volumes was chosen to cover the existing, small post-
TURBT volume, and two larger volumes in order to study the effect of variations
in tumour volume at the time of radiotherapy treatment.
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6.3 Radiotherapy treatment planning of simulated tu-
mours
The aim of this section of work was to determine how far dose escalation could be
driven without significant increase in toxicity, and to calculate the corresponding
increase in TCP. The approach taken was similar to that of the RAIDER clinical
trial (discussed in section 3.2.2). In RAIDER, the standard plan involves the whole
bladder receiving 64 Gy in 32 fractions (WBRT) and this is compared with 2 trial
arms. In both trial arms there are two PTVs, one incorporating the tumour (GTV)
which receives the highest dose, and one incorporating the rest of the bladder, which
is prescribed a lower dose of 52 Gy in 32 fractions. In the SART (standard dose
adaptive radiotherapy) arm the high dose PTV (containing the tumour volume)
still receives 64 Gy, and in the DART (dose escalated adaptive radiotherapy) arm
it receives an escalated dose of 70 Gy.
The work presented here proceeds in a similar manner, however with the
following differences:
• Reduced doses of 48, 52 and 56 Gy to the bladder wall are all studied, rather
than 52 Gy only
• A range of dose escalations to the tumour (high dose PTV) are studied rather
than only 70 Gy. The dose reached depends upon the achievability of that
particular treatment plan
• The expected TCP resulting from the dose escalation was also calculated.
To this end, the standard plan (in which a uniform dose of 64 Gy in 32
fractions was prescribed to cover the whole bladder volume) was compared with
systematically increased doses to the 18 simulated tumour volumes and reduced
doses to the rest of the bladder wall. The organ at risk (OAR) dose limits used
for this study were those used within the RAIDER trial and are shown in table
6.1. These values were chosen as they come from a current clinical trial and are
therefore accepted to be safe clinically. Values within the table are expressed in
terms of Vx where x is the dose in Gy which may be received by the volume in the
adjacent column. The last line of the table shows the dose constraint to normal
tissue (expressed as ‘body - PTV’) in terms of an optimal constraint of 105 % of
the prescription dose, and a mandatory constraint of 110 % of the prescription
dose. As the maximum prescription dose intended within RAIDER was 70 Gy, the
corresponding values of 73.5 Gy and 77 Gy were adopted as the maximum absolute
doses used for this work.
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Table 6.1: Organ at risk (OAR) dose constraints for 32 fraction schedule of RAIDER
(from Table 6a of RAIDER RT Guidelines [9]). Values given in terms of Vx where x
is the dose in Gy which may be received by the volume given in the adjacent column
of the table. For the bowel, two values of absolute volume are provided for each
dose - these are the optimal and mandatory levels.











Optimal (cm3) Mandatory (cm3)







Dx (cm3) % of prescription dose (PD) to OAR
Body - PTV D1 ≤ 105 % of PD ≤110 % of PD
The margins used to expand the bladder wall (CTV) and tumour (GTV)
to create PTVs were also taken from the RAIDER guidelines and are shown in
table 6.2. These margins correspond to those used in RAIDER for the standard
plans and the smallest of the adaptive plans, as they are the closest to relevance for
the ‘empty’ bladder technique used here. The CTV is the volume of bladder wall
receiving the reduced dose and this is expanded to produce the PTV. The GTV is
the simulated tumour volume, which is expanded to produce PTV2 which receives
the escalated dose. Mandatory and optimal dose limits for OARs as indicated in
tables 6.1 and 6.2 were used directly as defined in RAIDER. Where possible the
optimal dose limits were achieved, but mandatory limits were the backstop - if these
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could not be reached, this implied the dose escalation chosen was not possible. The
maximum dose escalation permitted was therefore found iteratively for each tumour
volume in each location.
Table 6.2: Table showing RAIDER expansion margins in mm for creation of PTVs
from GTV and CTV (taken from Tables 1 and 2 in RAIDER RT Guidelines [9]).
PTV refers to the reduced dose volume of the bladder and PTV2 refers to the dose
escalated volume containing the simulated tumour.
Lateral Anterior Posterior Superior Inferior
Standard plans
8 15 12 15 8
(CTV to PTV)
Dose escalated plans
5 5 5 5 5
(GTV to PTV2)
The margins used to expand the tumour (GTV) to high dose PTV (PTV2)
in RAIDER vary depending on the bladder volume. The margins are larger for
partially-filled bladders to accommodate the variability in bladder filling expected
during the course of treatment. The technique in use at this centre at the time of
this project was not based on the RAIDER technique, and involved uniform treat-
ment of a recently voided ‘empty’ bladder. Therefore only ‘empty’ bladder images
were available for this project. A GTV-to-PTV margin of 10 mm was initially used
for this study, within which 5 mm originated from the RAIDER recommendation
for GTV-to-PTV margin for empty bladders, and a further 5 mm from the initial
work in Chapter 4 which had shown tumour positional information from DW-MRI
could be transferred via registration to CT within this accuracy. It could be ar-
gued that these values could have been added in quadrature, or some other margin
recipe from the literature used (for example [70]). However, it was recognised that
as larger, partially-filled bladders would require larger margins than these ‘empty’
bladders in any case, it was decided that this work would be best performed using
the most conservative estimate (of a total margin of 10 mm). All other parame-
ters used, including CTV (bladder wall) to PTV (low dose PTV) expansion were
taken from RAIDER requirements. This latter value remained unchanged from
RAIDER requirements and was not increased to incorporate positional uncertain-
ties from DW-MRI, as the delineation of the external extents of the bladder would
still originate from the planning CT not the DW-MRI.
The work in Chapter 4 using phantom II had shown an accuracy of <2 mm
was achievable for transfer of positional data from DW-MRI to a registered CT.
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Hence, a subset of plans were generated in which a GTV to PTV margin of 7 mm
was used (i.e. 5 mm margins from RAIDER were retained, with an additional 2 mm
included, reduced from 5 mm). This allowed the effect of variation in margin to be
assessed as well as variations in tumour volume, dose to bladder wall and dose to
tumour (GTV).
Table 6.3: Table showing target dose objectives (taken from RAIDER table 5 of
RTGuidelines [9]) in terms of a percentage of the prescribed dose (PD). Dose con-
straints are provided in the form Dx where x is the percentage of the volume to
receive this dose.
Volume Dose Constraint Dx (%) Optimal Mandatory
PTV - PTV2
D98 ≥ 95 % of PD ≥ 90 % of PD
D50% ± 1 % of PD -
PTV2
D98 ≥ 95 % of PD ≥ 90 % of PD
D50 - ± 1 % of PD
D2 ≤ 105 % of PD ≤ 107 % of PD
The doses prescribed to generate each radiotherapy treatment plan were
based on those listed in table 6.3. This table indicates the two dose constraints used
for the reduced dose part of the bladder (48, 52 or 56 Gy). For example, for the
plans in which the bladder wall should receive 52 Gy, it was required that 50 %
of the PTV received between 51.48 - 52.52 Gy, and that 98 % received ≥49.4 Gy
(ideally) or, if that was not achievable then ≥46.8 Gy was acceptable. The three
dose constraints for the dose escalated volume (PTV2) were calculated in the same
way.
The reduction in dose to bladder wall was chosen so that the bladder wall
dose of 52 Gy (as used in RAIDER), was compared with a lower (48 Gy) and higher
(56 Gy) dose to investigate the effects of doing so. This was to assess the effect on
TCP, and also regarding the ease of generation of the various dose distributions.
Escalation doses to tumours were increased from the standard 64 Gy in steps of
4 Gy until a constraint was unachievable. The maximum dose possible was then
individually determined to the nearest 1 Gy. For example, for anterior tumours the
dose was increased from the standard 64 Gy to 68 Gy, then 72 Gy. This latter dose
was not achievable and so 71 Gy was tested and found to be achievable.
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Methodology used for generation of dose distributions (treatment plan-
ning)
The calculation of dose distributions for all 18 tumour volumes and multiple dose
levels for low dose (PTV) and high dose PTV (PTV2) respectively was performed in
RayStation. Within this TPS, the assessment of treatment plans can be performed
via the use of clinical goals. These are essentially criteria to enable the user to rapidly
ascertain whether the current dose distribution meets the required parameters (i.e.
OAR and PTV dose ranges). The clinical goals are set via a maximum or minimum
percentage or absolute dose to a percentage or absolute volume. For example ‘no
more than 2 % of the high dose PTV may receive ≥74.9 Gy’. If this requirement
was not met by the dose distribution, it would be highlighted for the user. The
clinical goals do not directly drive the optimization of the dose distribution; this is
performed manually by the user via the selectable optimization functions. Table 6.1
informed the clinical goals used for all OARs, and table 6.3 those for the PTVs.
Export of DVHs and TCP calculations
Following creation of all dose distributions, the differential dose volume histograms
(DVHs) were exported using a Python script in RayStation, for each plan in which
all mandatory clinical goals had been met. This script generated a text file in
which the number of voxels in the bladder wall and tumour receiving each dose was
recorded. Doses were set to be binned in 0.1 cGy steps, and voxel volumes were
2× 2× 2 mm3. The files were used by the MATLAB code developed in Chapter 5
to calculate the expected TCP for a range of clonogen densities within the bladder
wall, and with a density of 107 cm−3 within the simulated tumour. Both the RT-
only and RCT Poisson-based TCP models were used to predict TCP, as discussed
in Chapter 5.
6.4 Results and discussion
The results are discussed here for the following sections of work:
• Dose escalation using 10 mm margins (5 mm RAIDER plus 5 mm from work
presented in chapter 4) and RT-only TCP calculations,
• Dose escalation using reduced (7 mm) margins (5 mm RAIDER plus 2 mm
from chapter 4) and RT-only TCP calculations,
• All results following RCT TCP calculations.
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6.4.1 Dose escalation for simulated tumours with 10 mm margins
and RT-only TCP calculations
Figure 6.3: Effect of tumour (GTV) location within the bladder upon maximum
achievable dose escalation. The standard plan is indicated by a red line for compar-
ison.
Using margins of 10 mm in total for the GTV to high dose PTV expansion, a set of
results was obtained in which the bladder wall was prescribed either 48, 52 or 56 Gy.
PTV2, containing the simulated tumour, was prescribed increasing doses from the
standard 64 Gy, in 4 Gy steps. When a dose became unachievable whilst meeting
the required constraints, steps of 1 Gy were used to determine the highest possible
dose for which all mandatory clinical goals remained achievable. It was found that
this maximum dose was dependent on tumour location within the bladder, and was
largely unaffected by either the reduced bladder dose value, or the volume of the
tumour. Figure 6.3 shows this effect, with the maximum dose achieved for each
tumour location, which remains constant for all bladder wall prescription doses and
all tumour volumes. In this figure, the red line indicates for comparison, the dose
prescribed in a standard plan of 64 Gy regardless of tumour location. It can be
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seen that the dose escalation to anterior and superior tumours is more limited than
for the inferior tumours in particular. This is due to the proximity of the bowel
to tumour in the superior and anterior regions of the bladder, and so the dose to
this OAR is higher for the same prescribed tumour dose. Nevertheless, these results
show that dose escalation beyond the 70 Gy prescribed in RAIDER is possible if
tumours are located anywhere other than in the most superior region of the bladder,
and escalation to 78 Gy is possible for inferior tumours.
Figure 6.4: Effect of tumour volume on TCP using the standard technique of uniform
irradiation of the whole bladder to 64 Gy in 32 fractions. For the standard dose
distribution, the TCP is shown as a mean for small tumours (10 cm3) in dark red,
medium tumours (20 cm3) in red and large tumours (30 cm3) in pale red. Tumour
clonogen density was kept constant at 107 cm−3, whilst bladder wall clonogen density
was varied from 100 - 107 cm−3 as the true value is not known but will lie within
this range. The mean TCP for all small tumours (dark red) is consistently ∼4%
higher than for large tumours (pale red).
Figure 6.4 shows the effect of tumour volume on TCP when using the stan-
dard technique of uniform irradiation of the whole bladder to 64 Gy in 32 fractions.
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The clonogen density within the tumour was kept constant (at 107 cm−3, as previ-
ously in Chapter 5 and by Wright et al. [58]) in all cases. The graph shows the effect
of varying the clonogen cell density within the bladder wall from 1 to 107 cm−3 in
logarithmic steps. TCP can be seen to remain reasonably constant for all clonogen
densities, and varies by around 4 % between small (dark red) and large (pale red) tu-
mours. This was 71 % for small and 67 % for large tumours respectively on average
for all tumour locations. The effect is due to the increased total number of clonogens
within the larger tumour volume, even though the density remains constant. Only
when the clonogen density in the bladder wall is 107 cm−3 does the TCP begin to
decrease, although the effect is small (the average TCP for clonogen density of 107
cm−3 is 63 % across all volumes). This is probably due to a small proportion of the
bladder wall receiving the lowest dose within the range permitted. Inspection of the
DVH shows that 100 % of the bladder wall receives 63 Gy, 72.02 % receives 64 Gy,
and 0.5 % receives 65 Gy. The ∼28 % of the bladder wall which receives slightly
less than 64 Gy therefore begins to limit the TCP when the clonogen density is so
high.
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Figure 6.5: Effect of reducing dose to the bladder wall (BW) to 48 Gy (dashed
lines), with dose to tumour maintained at 64 Gy and compared to the standard
uniform dose of 64 Gy to the whole bladder (solid lines). All lines show the mean
TCP calculated for the displayed tumour volumes. Tumour clonogen density was
kept constant at 107 cm−3, whilst bladder wall clonogen density was varied from
100 - 107 cm−3 as the true value is not known but will lie within this range.
Figure 6.5 shows the effect of reducing the planned dose to the bladder wall
(BW) to 48 Gy whilst maintaining the 64 Gy prescription to the tumour (dashed
lines), with the results for the standard plan from figure 6.4 also shown for com-
parison (solid lines). All lines show the mean TCP for the relevant tumour volume,
as the effect is consistent for all tumour locations. In figure 6.5 the TCP predicted
for the treatment plans with reduced dose to the bladder wall remains the same as
for the standard plans, provided the bladder wall clonogen density is less than ∼104
cm−3. When the bladder wall clonogen density is greater than ∼104 cm−3, the TCP
decreases significantly as it is dominated by the effect of the reduced dose to the
bladder wall. The TCP in this latter region is also no longer affected by the size of
the tumour, whereas for clonogen densities below 104 cm−3 the effect shown first in
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figure 6.4 is maintained (where TCP is ∼4 % higher for small tumours than large
tumours).
Figure 6.6: Effect of reducing dose to the bladder wall (BW) to 48, 52 or 56 Gy
respectively, with dose to tumour maintained at 64 Gy and compared to the standard
uniform dose of 64 Gy to the whole bladder. The effect of the reduced doses to
bladder wall of 48, 52 or 56 Gy respectively is indicated via the annotations. Tumour
clonogen density was kept constant at 107 cm−3.
Figure 6.6 shows the effect of varying the magnitude of the permitted reduc-
tion in dose to the bladder wall, i.e. to 48 Gy, 52 Gy and 56 Gy respectively whilst
maintaining the dose of 64 Gy to the tumour. As previously in figures 6.4 and 6.5,
the tumour clonogen density was kept constant at 107 cm−3 whilst bladder wall
clonogen density was varied from 100 - 107 cm−3 as the true value is not known but
will lie within this range. It can be seen that these results follow the same pattern
as seen in figures 6.4 and 6.5 regarding the effect of tumour volume. The effect dom-
inates in the region where bladder wall clonogen cell density is below ∼104 cm−3
and TCP is ∼4% higher for small tumours than large tumours. Where the bladder
wall clonogen density is above ∼104 cm−3 the magnitude of the prescribed dose to
the bladder wall again begins to dominate, and the effect of tumour volume is no
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longer visible. These effects occur at slightly greater clonogen densities for higher
doses to bladder wall (i.e. ∼105 cm−3 for the plans delivering 56 Gy to the bladder
wall).
Figure 6.7: Effect of increase in tumour dose to 68 Gy compared with the 64 Gy
plans. The effect of the reduced doses to bladder wall of 48, 52 or 56 Gy respectively
is indicated via the annotations. Tumour clonogen density was kept constant at 107
cm−3 and bladder wall clonogen density was varied from 100 - 107 cm−3.
Figure 6.7 highlights how increasing the dose to the tumour impacts upon
the portion of the curve where clonogen density is below 104 cm−3. In this graph,
the TCP is seen to increase from 67-71 % at 64 Gy to 74-78 % at 68 Gy (in both
cases the range in dose is due to the range in tumour volumes). The plateau value
of TCP increases with the increase in dose as would be expected, but at greater
clonogen densities in the bladder wall, the reduced dose to the bladder wall continues
to dominate as already seen in figures 6.5 and 6.6. Similar TCP values are seen
regardless of tumour dose and are instead dependent on bladder wall dose. Indeed,
a similar pattern of results to those shown in figures 6.6 and 6.7 were found for all
tumour dose escalation values. Figure 6.8 shows tumour doses of 64 Gy, 68 Gy and
78 Gy. The same pattern is seen in which the TCP plateau region when bladder
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wall clonogen density is <104 cm−3 increases with tumour dose, and the effect of
bladder wall dose is dominant where bladder wall clonogen density is >104 - 105
cm−3.
Figure 6.8: Tumour dose escalations of 64, 68 and 78 Gy. The effect of the reduced
doses to bladder wall of 48, 52 or 56 Gy respectively is indicated via the annotations.
Tumour clonogen density was kept constant at 107 cm−3, and bladder wall clonogen
density was varied from 100 - 107 cm−3.
The increase in the predicted TCP within the plateau region with system-
atically escalated tumour dose is shown in figure 6.9. The points marked show the
mean predicted TCP over the plateau region (bladder wall clonogen density 1 -
103 cm−3) for the various tumour escalation doses investigated. Tumour escalation
doses achieved were dependent on tumour location within the bladder, as seen in
figure 6.3. For example, maximum tumour dose achievable for superior tumours
of all volumes was limited to 70 Gy (owing to their proximity to the bowel). The
corresponding predicted TCP using the RT-only Poisson model was 78.4 - 80.9 %,
with the lower TCP value predicted for the large tumour and higher TCP predicted
for the small tumour. Similarly, for the anterior tumours the maximum achievable
dose was 71 Gy, for posterior, left and right tumours 72 Gy, and for inferior tumours
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78 Gy. These doses were converted to EQD2 using equations 5.2 and 5.3 and can
be seen in figure 6.9 plotted in relation to the RT-only Poisson model produced in
chapter 5.
Figure 6.9: Mean predicted TCP using the RT-only Poisson model for small, medium
and large tumours for the range of doses with EQD2 of 61.5 - 78.3 Gy (corresponding
to prescribed doses 64 - 78 Gy) and compared with the RT-only Poisson model curve
developed in chapter 5.
Figure 6.9 shows that the results predicted by the use of the RT-only Poisson
model behave as expected. For standard treatment plans generated for small tu-
mours (i.e. post-TURBT with a volume of 10 cm3) receiving 64 Gy in 32 fractions,
the model predicts a TCP of 71.0 %, which agrees well with the RT-only curve itself
(TCP of 72.1 % at 61.5 Gy EQD2, i.e. 64 Gy/32 fractions). As planned doses were
increased to the small tumours, the predictions remained along the RT-only curve
(indeed, the point at EQD2 61.5 Gy showed the maximum difference of 2.1 %, with
a mean difference of 0.1 % across all points). These small differences are likely to
originate from two sources. Firstly, both the RT-only curve itself and the data-
points plotted, are generated using calculations in which a Gaussian is sampled 104
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times. Therefore there may be limited variability in the results obtained between
one calculation and another (this was ∼0.2 % when tested).
Secondly, and more importantly, the individual voxels of the treatment plans
will receive slightly different doses than the prescription (planned) dose. The treat-
ment planning method used allowed specified proportions of a volume to receive
certain ranges in dose via the setting of clinical goals. For example, where tumour
dose escalation to 70 Gy was required, the dose to 50 % of the tumour PTV was set
to lie within ± 1 % of 70 Gy (i.e. 69.3 - 70.7 Gy). In addition, the dose to 98 % of
this volume must be ≥ 90 % of 70 Gy (63 Gy) and no more than 2 % of the volume
is to receive ≥ 74.9 Gy. Similar ranges of acceptable doses were used to generate
all of the plans (as discussed in section 6.2 and according to the values quoted in
table 6.3). This variation in the voxel doses underlying the TCP predictions will
cause small deviations from the values expected, when compared with the quoted
prescription dose alone.
At all points marked on figure 6.9, the predicted TCP for large tumours
remains ∼2 - 4 % lower than for the small tumours (and similarly below the RT-
only curve which assumed a post-TURBT tumour volume of 10 cm3).
Bladder wall prescribed dose
The results presented in figures 6.5 to 6.9 indicate that the reduced dose to bladder
wall (of 48, 52 or 56 Gy), only impacts upon the predicted TCP if clonogen cell
density in the bladder wall lies above ∼104 cm−3. However, in terms of the ability
to escalate dose to the tumour, the prescribed bladder wall dose is not particularly
important, as these plans were achievable regardless (it is noted, however, that the
52 Gy plans were more readily achievable).
Tumour location within the bladder and limiting OARs
When tumours were located in the superior region of the bladder, it was not possible
to escalate doses above 70 Gy (as shown in figure 6.3). This was the case regardless
of the dose prescribed to the bladder wall. The dose was limited by the requirement
to deliver less than 70 Gy to a maximum volume of 10 cm3 of the bowel, although in
general for most plans the other dose constraints from table 6.1 were still achievable.
Similar effects were found for anterior tumours of all volumes when the dose to
tumour was escalated beyond 71 Gy. These results are unsurprising, as the bowel
lies closest to the superior and anterior portions of the bladder. Figure 6.10 shows
how close the bowel (shown in purple) lies in relation to a simulated superior tumour
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(shown in bright green). PTV2 (dark green), which contains the tumour, overlaps
with the bowel.
Figure 6.10: The location of a superior tumour close to the bowel results in lower
achievable maximum dose escalations than for tumours in other locations within the
bladder.
For tumours located in the posterior, left and right regions of the bladder,
the maximum dose escalation achieved was 72 Gy. Again, this was regardless of
tumour volume or dose prescribed to the bladder wall. As previously discussed for
superior and anterior tumours, the limitation was the dose constraint of 70 Gy to
<10 cm3 of the bowel. These tumours were able to receive a slightly increased dose
than the superior and anterior tumours before this requirement was breached, as
they are further from the bowel.
Further illustrating the effect of proximity to the bowel, dose escalation to
78 Gy was achievable for the inferior tumours before dose constraints became un-
achievable. These tumours lie the furthest from the bowel, which lies superior and
anterior of the bladder. For these dose distributions, the limiting dose constraint
was that of 1 cm3 of all normal tissue (‘body - PTV’ in table 6.1) to not receive
more than 110 % of the prescription dose. This had been limited to a maximum of
77 Gy as is used within RAIDER.
These results show that the potentially achievable TCP varied between 67 -
71 % if there was no dose escalation to the GTV (i.e. for a standard plan with a
uniform 64 Gy to the whole bladder), to 86 - 88 % for inferior tumours escalated
to 78 Gy. Doses (and hence TCP) for tumours located within other regions of the
bladder fell within this range, as can be seen in sections ‘Tumours with 10 mm GTV
to PTV margins’ and ‘Standard plan’ within table 6.4.
Overall, these results show that the current clinical trials such as RAIDER,
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Table 6.4: The maximum dose to which tumours located in the various regions of
the bladder were escalated whilst continuing to meet all mandatory clinical goals.
Also shown is the corresponding calculated TCP using the RT-only Poisson TCP
model developed in chapter 5. Results for plans with reduced GTV to PTV margins
and for tumours with reduced superior extent are included. The increases in TCP
are shown between small tumours compared to the standard plan. All TCP values
shown were calculated using the plateau region of TCP averaged over bladder wall
clonogen density 100 - 103 cm−3.
Tumour Maximum RT-only TCP (%)
Location Prescribed large - small tumour
Dose (Gy) (increase)
Standard plan for comparison
Any 64 67.0 - 71.0 (N/A)
Tumours with 10 mm GTV to PTV margins
Anterior 71 78.8 - 82.2 (11.8)
Posterior 72
80.9 - 83.4 (13.9)Left 72
Right 72
Superior 70 78.4 - 80.9 (11.4)
Inferior 78 86.2 - 87.8 (19.2)
Tumours with reduced GTV to PTV margins (7 mm)
Anterior 73
81.9 - 84.9 (14.9)Posterior 73
Left 73
Superior 71 79.5 - 82.8 (12.5)
Inferior 84 90.0 - 91.2 (23.0)
Tumours with reduced superior extent and 7 mm margins
Posterior 74 80.9 - 85.6 (13.9)
Left† 74 83.5 (16.5)
†only medium sized tumour investigated in this case.
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in which doses to tumour volume are escalated to 70 Gy, are perhaps the realistic
limit of current techniques for superior and anterior tumours. However, tumours
located in other parts of the bladder may be escalated to higher doses whilst meeting
the same OAR dose constraints, producing greater increases in TCP. In particular,
inferior tumours could be escalated furthest, with doses of 78 Gy producing increased
TCPs of 86 - 88 % compared to 67 - 71 % for standard plans of 64 Gy.
6.4.2 Dose escalation for simulated tumours with 7 mm margins
and RT-only TCP calculations
Initial work presented in section 6.4.1 used the original estimate from chapter 4 of 5
mm for geometrical distortion in DW-MRI data. This was interpreted as an uncer-
tainty in image positional information from registered DW-MRI to CT of up to 5
mm, hence resulting in a total GTV to PTV (PTV2) margin of 10 mm. The addi-
tional 5 mm was that shown in table 6.2 and taken from RAIDER recommendations
[9] to account for variations in bladder position and movement.
The work using phantom II in Chapter 4 sections 4.2.7 - 4.2.9 showed that
margins of 2 mm can account for the residual positional uncertainties involved in
the use of DW-MRI for imaging bladder tumours, if additional image acquisition
and processing is performed using software such as FSL. Therefore, a further subset
of work was repeated using GTV to PTV margins of 7 mm (where 2 mm accounts
for DW-MRI distortion and the previous margin of 5 mm from the RAIDER clinical
trial accounts for bladder variations). The results of this work are shown in the third
section of table 6.4 (‘Tumours with reduced GTV to PTV margins (7 mm)’ ). They
show that the dose to which each tumour can be escalated is slightly increased with
the margin reduction, as might be expected. The dose increases are mostly very
modest (70 to 71 Gy for superior tumours, 71 to 73 Gy for anterior tumours, and
72 to 73 Gy for posterior and left tumours)1. However, the final dose achieved for
inferior tumours of all volumes was 84 Gy before the normal tissue dose constraint
of <1 cm3 to receive 77 Gy was breached. This is a very high dose and greater than
that used clinically for most treatment sites, however it does serve to illustrate the
degree to which the location of the tumour in the bladder is the central issue of
importance in dose escalation of bladder tumours.
1As previous results for all lateral tumours were equivalent, only the left tumours were repeated
with smaller margins.
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Figure 6.11: Inferior tumour shown in bright green, with mid-green PTV2 (7 mm
margin) and dark green PTV2 (10 mm margin). The indicated region falling between
PTV2 (7 mm margin) and the red PTV (containing whole bladder) is where high
dose gradients are located in the 84 Gy plans.
Figure 6.11 indicates the reason for the large increase in dose that was pos-
sible for the inferior plans with reduced GTV to PTV2 margins. This figure shows
a sagittal view of the bladder (yellow), containing simulated inferior tumour (bright
green). The two PTV2s used are shown in dark green (10 mm margin) and mid-
green (7 mm margin) respectively. The indicated region lying between PTV2 (7
mm margin) and the PTV covering the whole bladder (shown in red) allows a rapid
decrease in dose to occur within a PTV region, rather than outside it (as when the
10 mm margin is used). Figure 6.12 compares the generated dose distributions of
(a) the 78 Gy plan using a 10 mm margin with the whole bladder shown, and (b) the
same 78 Gy plan shown magnified with just the high dose region, and (c) high dose
region only of 84 Gy plan using the 7 mm margin. The region of high dose gradient
in (b) occurs just outside the whole bladder PTV (red), rather than just inside as in
(c). This difference was the reason that the normal tissue dose constraint of <1 cm3
to receive 77 Gy was achievable at a much higher prescribed dose for the reduced
GTV margin.
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Figure 6.12: (a) 78 Gy plan to inferior tumour (whole bladder shown), (b) 78 Gy
plan to inferior tumour (only high dose region shown magnified), (c) 84 Gy plan
to the same inferior tumour also magnified. Inferior tumour shown in bright green,
with mid-green PTV2 (7 mm margin) and dark green PTV2 (10 mm margin). The
indicated region falling between PTV2 (7 mm margin) and the red PTV (containing
whole bladder) contains a high dose gradient in (c), but this gradient is outside the
whole bladder PTV in (b). The effect leads to a higher achievable dose to PTV2
using 7 mm margins before the normal tissue dose constraint of <1 cm3 to receive
77 Gy is breached.
Tumour simulation and superior extent of tumours
Owing to the similar results for superior, anterior, posterior and lateral tumours,
with very different results for the inferior tumours, the methodology used for simu-
lating tumours was reassessed. It was noted that the simulated tumours had been
produced such that the volumes, although located in the required regions of the
bladder tended to extend towards the superior-inferior directions for the anterior,
posterior and lateral tumours. As the superior-inferior location of the tumours had
been found to be so influential in the dose to which the high dose PTV might be
escalated, a subset of results were repeated for posterior and left GTVs, with re-
duced extent in the superior direction. Anterior tumours were themselves already
located very close to the bowel regardless of superior extent, and so were not in-
vestigated further. All previous results for left and right tumours were equivalent
and therefore only left tumours were repeated. In these further tests, the tumour
volumes were altered to reposition the most superior 1 cm onto more inferior CT
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slices, as illustrated in figure 6.13. In this figure a left tumour is shown as originally
simulated in green, and after the most superior 1 cm was removed and added to the
inferior edge (purple).
Figure 6.13: Left tumour shown re-simulated with reduced superior extent. Original
location shown in green, with re-simulated tumour shown in purple.
The results of this repeated subset of plans are shown in the final section
of table 6.4 ‘Tumours with reduced superior extent and 7 mm margins’ in which
it can be seen that doses of 74 Gy were achieved for all tested plans and GTVs,
resulting in TCPs of 80 - 84 %. This meant that the maximum tumour escalation
doses of 72 Gy found for posterior, left and right tumours are very dependent upon
the degree to which those tumours extend superiorly, and hence their proximity
to the bowel. This would of course also vary between patients owing to variations
in internal anatomy. The original left tumours were approximately 0.2 cm from
the most inferior portions of the bowel, whereas in these latter plans with altered
GTVs, the left tumours were approximately 0.7 cm from the most inferior extent of
the bowel. The equivalent figures for the posterior tumours were 0 cm and 0.3 cm
respectively.
6.4.3 TCP calculations using the RCT Poisson model
All results discussed so far have referred only to those produced using the RT-only
Poisson model to calculate expected TCP. This section discusses the effect using the
RCT Poisson model instead. The model sought to provide a best estimate for the
expected increased TCP when patient treatment involved the use of chemotherapy
in addition to radiotherapy. The same dose distributions were used as in sections
6.4.1 and 6.4.2, but TCP calculations were performed using the RCT model.
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The trends seen using the RCT model were similar to those already discussed
regarding the RT-only model, but with higher calculated TCP as would be expected.
For example, in figure 6.14 the results of tumour doses of 64 Gy and either 48, 52
or 56 Gy planned to the bladder wall, along with those from the standard plan
show patterns similar to those seen in figure 6.6. The plateau values using the RCT
model are 77-80 % compared to 67-71 % for the RT-only model. As before, the
higher TCP values within the range relate to small tumours and the lower to the
large tumours. The TCPs seen for bladder wall clonogen densities of 105 - 107 cm−3
follow the same pattern, with the bladder wall doses of 48, 52 or 56 Gy dominating
the TCP although the absolute values of TCP are ∼10 % higher using the RCT
model.
Figure 6.14: Effect of reducing bladder wall (BW) dose to 48, 52 or 56 Gy respec-
tively, with dose to tumour maintained at 64 Gy and compared to the standard
uniform dose of 64 Gy to the whole bladder (see annotations). TCP was calculated
using the RCT Poisson model and tumour clonogen density was kept constant at
107 cm−3, whilst bladder wall clonogen density was varied from 100 - 107 cm−3.
The effect of increasing the tumour dose from 64 Gy to 78 Gy was again seen
to affect the plateau region of the curves, and can be seen in figure 6.15.
130
Figure 6.15: Effect of increase in tumour dose from 64 to 68 and 78 Gy compared
with the standard plan (64 Gy) (see annotations). TCP was calculated using the
RCT Poisson model and tumour clonogen density was kept constant at 107 cm−3,
whilst bladder wall clonogen density was varied from 100 - 107 cm−3.
Figure 6.16 shows the impact on dose escalation beyond 68 Gy on the TCP
in the region with bladder wall clonogen density of 1 - 103 cm−3 using both the
RT-only model (as seen in figure 6.9) and RCT Poisson models. As previously,
doses were converted to EQD2 using equations 5.2 and 5.3. The TCPs calculated
for small tumours using the RCT model follow the original RCT curve produced
in chapter 5 as would be expected. The largest difference between the datapoints
plotted and the original RCT curve is 1.8 % and the mean difference is 0.1 %.
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Figure 6.16: Mean TCP predicted using the RT-only and RCT Poisson models for
small, medium and large tumours for the range of doses with EQD2 of 61.5 - 78.3
Gy (corresponding to prescription doses 64 - 78 Gy) and compared with both the
RT-only and RCT Poisson model curves.
A summary of all the data presented in this chapter is given in table 6.5,
which shows the maximum doses achievable within the various regions of the bladder,
and the corresponding calculated TCPs using both the RT-only and RCT Poisson
TCP models. The effects of reducing the margins required to accurately map tumour
location from DW-MRI to CT from 5 mm to 2 mm is shown in the sections ‘Tumours
with 10 mm GTV to PTV margins’ and ‘Tumours with reduced GTV to PTV
margins (i.e. 7 mm)’ respectively. The effect of reducing the superior extent of
tumours located in the posterior and left regions of the bladder are shown in the
section ‘Tumours with reduced superior extent and 7 mm margins’.
Table 6.5 shows all results for TCPs calculated using the RCT model along-
side those already presented in table 6.4 using the RT-only model. This shows that
the TCP calculated using the RT-only model for standard plans and is 67.0 - 71.0 %,
which rises to 76.9 - 80.1 % using the RCT model. For the tumours which received
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Table 6.5: The maximum dose to which tumours located in the various regions of
the bladder were escalated whilst continuing to meet all mandatory clinical goals.
Also shown is the corresponding calculated TCP using both TCP models developed
in chapter 5. Results for plans with reduced GTV to PTV margins and for re-
positioned tumours (reduced superior extent) are included. The increases in TCP
are shown between small tumours compared to the standard plan and using the
same TCP model. All TCP values shown were calculated using the plateau region
of TCP averaged over bladder wall clonogen density 100 - 103 cm−3.
Tumour Maximum RT-only TCP (%) RCT TCP (%)
Location Prescribed large - small tumour large - small tumour
Dose (Gy) (increase) (increase)
Standard plan for comparison
Any 64 67.0 - 71.0 (N/A) 76.9 - 80.1 (N/A)
Tumours with 10 mm GTV to PTV margins
Anterior 71 78.8 - 82.2 (11.8) 86.4 - 88.6 (9.5)
Posterior 72
80.9 - 83.4 (13.9) 87.9 - 89.6 (11.0)Left 72
Right 72
Superior 70 78.4 - 80.9 (11.4) 85.9 - 87.9 (9.0)
Inferior 78 86.2 - 87.8 (19.2) 91.7 - 92.9 (14.8)
Tumours with reduced GTV to PTV margins (i.e. 7 mm)
Anterior 73
81.9 - 84.9 (14.9) 88.8 - 90.8 (11.9)Posterior 73
Left 73
Superior 71 79.5 - 82.8 (12.5) 86.8 - 89.2 (9.9)
Inferior 84 90.0 - 91.2 (23.0) 94.2 - 95.0 (17.3)
Tumours with reduced superior extent and 7 mm margins
Posterior 74 80.9 - 85.6 (13.9) 87.9 - 91.5 (11.0)
Left† 74 83.5 (16.5) 90.0 (13.1)
†only medium sized tumour investigated in this case.
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the lowest dose escalation (superior tumours), these results rose to 78.4 - 80.9 %
and 85.9 - 87.9 % respectively using the RCT model. For tumours located in the
left, right or posterior portions of the bladder, the results using the RT-only and
RCT models were 80.9 - 83.4 % and 87.9 - 89.6 % respectively, although these were
quite variable, depending both upon the GTV-PTV margin used and the degree to
which the tumours were allowed to extend in the superior direction.
When the margins used to create the high dose PTVs from the GTVs were
reduced from 10 mm to 7 mm, the dose could be increased by a further 1 Gy whilst
meeting the same clinical goals. This led to TCPs of 81.9 - 84.9 % and 87.9 -
89.6 % using the RT-only and RCT models respectively. A subset of these volumes
(posterior small, medium and large, and left medium) were also adjusted to extend 1
cm less far in the superior direction, with the volume kept constant (i.e. repositioned
over the other CT slices). These results showed that dose could again be escalated
by a further 1 Gy (74 Gy total), producing calculated TCPs of 80.9 - 85.6 % and
87.9 - 91.5 % for the RT-only and RCT models respectively.
The highest TCP was consistently found for the inferior tumours, as the
doses to which they could be escalated were the greatest. For GTV to PTV margins
of 10 mm these doses were 78 Gy resulting in TCPs of 86.2 - 87.8 % and 91.7 -
92.9 % using the RT-only and RCT models respectively. When the GTV to PTV
margin was reduced to 7 mm, the achievable dose escalation rose to 84 Gy resulting
in increases in TCP to 90.0 - 91.2 % and 94.2 - 95.0 % respectively (although it is
recognised that this is above the doses usually used clinically).
6.4.4 Toxicity
For OARs such as the femoral heads, the doses received even with these high dose
escalations are still quite low, as the dose to the rest of the bladder is reduced com-
pared with the standard technique. For example, the dose to 50% of the femoral
heads was consistently within the range 18.5 - 25.5 Gy for all plans including stan-
dard and dose escalated (84 Gy) plans. This compares well with the maximum
accepted in table 6.1 of 50 % of femoral heads to receive <50 Gy.
The doses which were most limiting to dose escalation were twofold:
1. Bowel: Maximum volume receiving 70 Gy (where the optimal constraint was
0 cm3 and mandatory was 10 cm3)
2. Normal tissue: No more than 1 cm3 of the volume Body - PTV should receive
73.5 Gy (optimal) or 77 Gy (mandatory).
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Dose escalation was limited by (1) for superior, anterior, posterior and lateral
tumours. For inferior tumours the limitation was (2).
Owing to the large (>200) number of plans generated for the results presented
in this chapter, the plans were unlikely to be of the high standard required for
clinical use, particularly as parameters other than purely meeting dose constraints
are considered when determining clinical acceptability. For example, the visible
appearance of the dose distribution and the presence of any regions of high dose
outside the target volume are considered, and these aspects were not part of the
analysis included here. It is also arguable that these plans would not be truly
‘isotoxic’, that is that the likelihood of complications arising from treatment would
not necessarily be the same for all discussed dose distributions including the standard
plan, as there is such variation in the location of doses delivered. Nevertheless, all
of the plans met the basic requirements for plans produced within a current clinical
trial, and the general trends discussed remain.
Doses of 78 Gy (as found to be achievable for inferior tumours), are high
compared with general clinical fractionation schemes within the pelvis. Standard
fractionation schemes for the prostate, for example, are 60 Gy in 20 fractions or
74 Gy in 37 fractions. Therefore, although this dose appeared feasible from the
perspective of meeting OAR dose constraints, from the perspective of clinical use,
further work would be required to establish safety and toxicity at lower doses first.
6.5 Summary and conclusions
Dose escalation to a partial bladder volume incorporating the GTV plus margin
could increase local control for MIBC by 9.0 - 19.2 % compared to the standard
uniform treatment depending on tumour location and TCP model used for calcula-
tion. The increase is lowest for superior tumours and when using the RCT model






In the previous chapter we saw that it was possible to escalate radiotherapy doses to
some bladder tumours in such a way as to significantly increase the predicted TCP.
This was possible without requiring the surrounding organs at risk to receive greater
doses than would be acceptable within the RAIDER clinical trial. Ideally, the next
step of work would be to determine the feasibility of delivery of such escalated doses
in practice. This is not a straightforward task, however, as shall be discussed within
this chapter.
The work reported here uses patient CBCTs acquired at the time of (stan-
dard) bladder radiotherapy delivery to infer the doses that would have been received
had the escalated doses been delivered instead. It is recognised that there are many
caveats in terms of the ability to use these images for this purpose, as shall be
discussed. Nevertheless, this work is in essence a blueprint using the technology
currently available to highlight the methodology required for future work using im-
proved technology. Such technology would include the use of MR via an MR-linac
rather than CBCT, to enable accurate assessment of soft tissue structures such as
the bladder and bowel immediately prior to treatment delivery.
7.2 Calculation of accrued doses on CBCTs
Within the RayStation TPS there is a module (‘Treatment Adaptation’) which is
intended to enable assessment of doses delivered to the patient based on CBCT(s)
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acquired of that patient. The clinical use of this module largely concerns changes
to the patient anatomy (for example weight loss) during the course of radiotherapy
treatment. If these concerns arise, then a CBCT may be imported into the TPS and
the planned dose distribution recalculated using the image intensities (HU) within
the CBCT rather than the original planning CT. A DR is used to map the CBCT
to the original planning CT, and then the doses calculated using the CBCT can
also be mapped back to the original planning CT and doses to the various organs
compared with those intended.
There are several sources of uncertainty involved in the standard clinical use
of this technique:
• The increased scatter due to the cone-beam acquisition of the CBCTs means
that the HU on CBCT images are not as accurate as for CT. This is accom-
modated partially within RayStation by assigning bulk densities to air, lung,
adipose tissue, soft tissue and bone which are then used within dose calcula-
tions.
• The increased scatter and resulting poorer image quality of the CBCTs means
that it is more difficult (and sometimes not possible) to distinguish soft tissue
details corresponding to delineated organs on CT.
• Owing to these difficulties in determining soft tissue details and also limitations
of DR algorithms, knowing the location of OARs and corresponding doses they
receive is subject to uncertainty.
In clinical use at the centre this work was performed at, this technique is used only
for assessment of absolute doses for tumours treated within the head and neck. In
particular, the dose to the PTV is checked, and locations of the relevant OARs
(spinal cord and brainstem) with respect to the PTV are assessed, along with the
calculated delivered dose to these OARs. As the uncertainties listed above are
greater within the pelvis, this technique is only currently routinely used for the
assessment of relative dose differences within the pelvis.
Although the intended use of the Treatment Adaptation module is for mid-
treatment assessment (and hence resulting treatment adaptation), it is also possible
to use the toolkit to assess the doses that would have been received had other dose
distributions been delivered instead. It is possible to accumulate doses on multiple
CBCTs and then sum these doses to infer the delivered dose distribution from
the whole treatment course, in order to compare with the original planned dose
distribution. This is the approach that has been taken within this chapter, in order
to infer the feasibility of delivery of the technique.
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7.3 Methods of data extraction and analysis
Daily CBCT images were acquired for the patient whose planning CT was used
for the work reported in chapter 6 during the course of their standard treatment.
These images were imported into RayStation TPS, and RR was performed using
the shifts applied at the time of treatment delivery by the radiographers based on
their pre-treatment image registration.
As the CBCTs were acquired using smaller FOVs than the planning CT,
some geometrical tools were used to recreate the external contour of the patient for
the missing parts of the patient anatomy. These volumes were set to the density
of water. DRs were created from each CBCT to the CT; this used the hybrid DR
and included the use of image intensities (i.e. this is the expected clinical use of the
algorithm studied in chapter 4).
This resulted in 10 DRs of daily CBCTs to the planning CT, with mapped
delineations of all organs including the bladder, and simulated internal tumours.
Delivered doses were then calculated on each CBCT and deformed back using the
DRs to the planning CT for comparison with the planned dose distribution. This was
performed for a subset of treatment plans - these were chosen to be representative
of the variations covered in chapter 6. Therefore medium volume tumours and a
planned dose of 52 Gy to the whole bladder were used in all cases (other than the
standard plan), as neither tumour volume nor dose to the rest of the bladder had
significantly affected the escalation dose achievable and these were the middle values
used. The extremes of findings in chapter 6 were included, i.e. inferior and superior
tumours with the relevant maximum achievable doses in each case (i.e. 78 Gy and 70
Gy respectively). As the results for superior and anterior were very similar, this was
not repeated for an anterior tumour, but a posterior tumour with reduced margins
(7 mm) was also tested as representative of right/left and posterior tumours (the
results of which were similar in chapter 6). Therefore the following plans were used
in addition to the standard plan of 64 Gy to the whole bladder, to accumulate dose
on CBCTs:
• Superior medium tumour - 70 Gy planned to tumour and 52 Gy to whole
bladder,
• Inferior medium tumour - 78 Gy planned to tumour and 52 Gy to whole
bladder,
• Posterior medium tumour with reduced (7 mm) margins - 73 Gy to tumour
and 52 Gy to bladder.
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The DVHs for these inferred dose distributions were extracted and used for
calculation of delivered TCP following the same methodology and MATLAB codes
as described in chapters 5 and 6.
7.4 Results and discussion
This section reports the various different dose distributions recalculated on CBCTs
using the shifts were applied at the time of treatment delivery (and are hence here-
after referred to as ‘delivered’ - as they were not delivered in reality, but the best
estimate of what would have been delivered). The standard plan with 64 Gy to the
whole bladder is the most similar to the dose distribution which would have actually
been delivered to the patient, although the technique in use at the time of treatment
used different margins to expand the bladder into the PTV.
7.4.1 Standard plan - 64 Gy to whole bladder
Figure 7.1 shows the original 64 Gy standard plan calculated on the planning CT for
(a) a transaxial, (b) sagittal and (c) coronal view of the patient. Doses are shown
as a percentage of a single fraction delivery of 2 Gy.
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Figure 7.1: Original planned dose distribution calculated on the planning CT for a
single (2 Gy) fraction using the standard 64 Gy plan. Images show (a) transaxial,
(b) sagittal and (c) coronal views.
For comparison, the re-calculation of the fraction dose on a CBCT image is
shown in figure 7.2. As in figure 7.1, the three orthogonal views of the patient are
shown. Note that the images are of poorer quality, and that a smaller volume of the
patient was imaged.
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Figure 7.2: Re-calculated dose distribution on the CBCT for a single (2 Gy) fraction
using the standard 64 Gy plan. Images show (a) transaxial, (b) sagittal and (c)
coronal views.
Figure 7.3 shows the differences between the planned standard (64 Gy) dose
distribution and the ‘delivered’ standard (64 Gy) dose distribution, in (a) transaxial,
sagittal and (c) coronal views. The dose differences are those generally expected:
around the edges of the patient anatomy small differences between patient anatomy
at the time of original planning CT and the daily imaged anatomy cause surface
dose differences, which are most clearly seen in (a) the transaxial view. Often
patients experience weight loss during the treatment, and this and any other small
differences in positioning will be visualised in this way. The positional differences
in the treatment couch are also seen and highlighted in (a) and (b).
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Figure 7.3: Differences between original planned dose distribution and the dose dis-
tributions which would have been delivered using the standard 64 Gy plan, based
on re-calculation on a CBCT image acquired immediately prior to treatment. Dif-
ferences shown for (a) transaxial, (b) sagittal and (c) coronal views of the patient.
Discrepancies are indicated owing to surface variations of the patient and couch.
Figure 7.4 shows the differences between the recalculated dose distribution
from figure 7.2 mapped back onto the planning CT via the DR, and compared with
the original planned dose distribution.
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Figure 7.4: Differences between original planned dose distribution and the dose
distributions which would have been delivered using the standard 64 Gy plan, based
on re-calculation on a CBCT image acquired immediately prior to treatment which
are then mapped back onto the orignal planning CT using the DR. Differences shown
for (a) transaxial, (b) sagittal and (c) coronal views of the patient.
The dose differences seen within the patient CT volume are much greater
than would be expected from the images seen in figures 7.1, 7.2 and 7.3. There is
an increased dose to the region superior and slightly anterior to the PTV (shown
delineated in red), and a corresponding decrease to the region inferior of the PTV
as indicated in the figure. This appears to show that the DR is incorrectly mapping
the dose back onto the planning CT. Figure 7.5 shows an overlay of the DR mapping
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vectors onto the planning CT. Vectors are colour coded with red corresponding to
a shift of 1 cm and yellow 0.5 cm, as indicated in the key. There are several regions
showing large vectors, as annotated in the figure.
Figure 7.5: Deformable registration (DR) mapping vectors between CBCT and CT
shown overlaid upon the planning CT for (a) transaxial, (b) sagittal and (c) coronal
views.
Where there were known to be differences in the location of the patient
surface owing to weight loss, these vectors are not surprising. There are also large
vectors in the regions of bones, which may be due to small differences in position or
rotational changes in leg positions. Neither of these would be likely to affect the doses
mapped to the bladder or nearby OARs as they are not close to these structures.
144
There are, however, large vectors close to the bowel and in particular regions of
bowel gas that have moved between the planning CT and CBCT. Obviously, these
regions should not need to be shifted as they are in fact part of the same organ,
but as the DR algorithm is designed to map intensities this is a difficulty in the
use of such as algorithm for this part of the anatomy. The magnitude of the DR
vectors in the region of the bladder wall is approximately 0.5 cm (yellow). This is
not correct when the two datasets are visualised, for example, as can be seen in
figure 7.6. In this figure, the delineations from the planning CT are shown overlaid
onto the CBCT and show good agreement with the anatomy seen on the image,
apart from the superior and anterior parts of the bladder and neighbouring bowel.
Figure 7.6: CBCT in (a) transaxial, (b) sagittal and (c) coronal views. The delin-
eated volumes are overlaid from the original planning CT and are as follows: right
femur (pink), left femur (red), bowel (purple), rectum (blue) and bladder wall (yel-
low). Most delineations are in good agreement with the image intensities seen in
the CBCT image, apart from the superior and anterior parts of the bladder and
neighbouring parts of the bowel.
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Analysis of the CBCT images shows that the bladder filling is greater in
general on the CBCTs than the planning CT, and this shifts the overlying bowel
also. This difference is shown in figure 7.7.
Figure 7.7: CBCT in (a) transaxial, (b) sagittal and (c) coronal views. The delin-
eated volumes are mostly overlaid from the original planning CT and are as follows:
right femur (pink), left femur (red), bowel (purple), rectum (blue) and bladder wall
(yellow). Delineations on the CBCT of the bladder and bowel are shown in dotted
magenta and dotted pale blue respectively.
Bladder filling was seen to be greater on all of the CBCTs acquired of this
patient than on the planning CT. Large variations in filling are expected, and is the
historical reason for the requirements for relatively large CTV-PTV margins for the
bladder. The difference in bladder shape was not, however, picked up by the DR.
Increased bladder filling pushes the overlying bowel superiorly and anteriorly, and
this was also not picked up by the DR, although the DR did try to map parts of
the bladder onto other parts of the bladder owing to movement of bowel gas.
For these reasons, the assessment of the feasibility of delivery of the dose
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distributions calculated in chapter 6, cannot be accurately assessed by directly using
the ‘Treatment adaptation’ functionality of RayStation as it requires the use of the
DR. Instead, a single CBCT was used in which manual alteration of the bladder and
bowel delineations was performed. As was seen in figure 7.7, the bladder is readily
visible on the daily CBCT and the differences in filling are apparent between those
from the original CT (yellow), and those visible by eye (magenta). The bowel is
not, however, as readily visible owing to the poorer image quality using CBCT.
Therefore, rather than attempting to delineate it manually, the only alterations
made to the bowel were to remove it from the regions which were distinguished as
bladder, and ensure that all volumes of gas (which are readily visibile owing to the
low density) were included in the bowel contour. Otherwise, the existing structure
from the planning CT was retained.
The DVHs corresponding to the various volumes delineated were calculated
using the CBCT and compared with those originally planned. Figure 7.8 shows the
DVH for the standard 64 Gy plan.
Figure 7.8: Cumulative dose-volume histograms for femoral heads (red and ma-
genta), rectum (blue), bowel (purple), bladder wall (yellow) and bladder PTV (dark
red). Planned and ‘delivered’ doses are shown as dashed and solid lines, respectively;
where manual delineations were performed these are shown dotted.
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The pairs of coloured lines in figure 7.8 show the various delineated struc-
tures, with solid lines indicating the ‘delivered’ dose, and dashed indicating the
planned dose. The femoral heads (red and magenta) receive doses similar to those
expected, and the rectum (blue) receives a slightly lower dose than expected. The
bowel (purple) appears to receive a higher dose (solid line) than planned (dashed),
but the manually altered delineation (dotted purple) falls between the two. It is
difficult to be confident that this is an accurate representation of the doses received,
owing to the uncertainties in delineation of the bowel volume on CBCT, but it does
give confidence that the apparent overdose of the bowel indicated by the solid line
is probably not correct, as this structure includes volume that is in fact the bladder.
Although the PTV (dark red) receives lower doses than planned in part, the blad-
der wall (yellow) itself still receives the planned dose (this is the intention of the
relatively large margins used to produce the PTV). The manual delineation of the
bladder wall (dotted yellow) overlays the planned (solid) line, showing the bladder
wall receives the planned dose even taking into account the change in bladder filling.
7.4.2 Superior tumour - 70 Gy
This section relates to the use of the planned dose distribution in which 70 Gy was
prescribed to a medium tumour in the superior region of the bladder, with 52 Gy
to the rest of the bladder. The same methodology as discussion in section 7.4.1 was
used for the analysis of the feasibility of delivery of this dose distribution.
As this simulated tumour was in the superior region of the bladder, and it
had already been established that the superior and anterior portion of the bladder
had moved between the planning CT and CBCT, the delineation of the superior
simulated tumour was adjusted, so that it included the superior portion of the
bladder wall that had been altered manually. The inferior edge of the tumour was
adjusted similarly towards the superior direction such that the total volume of the
tumour was unchanged.
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Figure 7.9: Dose distributions which would have been delivered using the 70 Gy to
medium superior GTV plan, based on re-calculation on a CBCT image acquired at
the time of treatment for (a) transaxial, (b) sagittal and (c) coronal views. Simulated
superior tumour is shown in green.
Figure 7.10 shows the resulting differences between planned and ‘delivered’
doses via cumulative DVHs for the various organs. As discussed for the standard
plan, most organs such as the femoral heads again receive doses similar to those
expected, with the rectum receiving a slightly reduced dose. The manual alterations
in the bowel resulted in a calculated bowel dose closer to that predicted, as shown by
the overlaying purple dashed (planned) and dotted (‘delivered’ manually delineated)
bowel curves. The bladder wall curves (yellow) show similar doses for planned
(dashed) and manually delineated ‘delivered’ (dotted). The simulated superior GTV
(pale green) shows similar results for planned (dotted) and ‘delivered’ (solid) doses,
although the ‘delivered’ is around 1 Gy lower at its’ furthest deviation.
The curves in figure 7.10 denoted by ‘GTV+2mm’ and ‘GTV+5mm’ show
the doses ‘delivered’ to volumes produced by isotropic expansion of the GTV (i.e.
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superior medium tumour volume). This was done to assess what dose would have
been received by the actual tumour volume if the volume modelled had originated
from DW-MRI, and been inaccurate by either 2 or 5 mm (corresponding to the
results from Chapter 4 regarding geometric uncertainties in DW-MRI). As these
curves both closely overlay that of the delineated GTV, this implies that the margin
used (10 mm in this case) was sufficient to ensure coverage of the required volume.
Figure 7.10: Cumulative dose volume histograms for femoral heads (red and ma-
genta), rectum (blue), bowel (purple), bladder wall (yellow), and simulated superior
tumour (i.e. GTV) (green). Planned doses are shown dashed, ‘delivered’ doses are
solid lines and where delineations have been performed manually on the CBCT these
are shown dotted for an improved estimate of ‘delivered’ doses. Expanded GTVs to
assess the potential ‘worst case’ effect of geometric distortion in GTV delineation
are shown for GTV+2mm and 5mm in dotted bright green and green, respectively.
Table 7.1 shows the resulting change in TCP using the ‘delivered’ DVHs for
calculation for the RT-only and RCT models developed in chapter 4. In both cases
these results are 0.3 % lower than predicted in chapter 6.
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Table 7.1: Expected and ‘delivered’ (i.e. what would have been delivered had this
plan been used clinically) TCPs according to the RT-only and RCT models devel-
oped in chapter 4.
TCP (%) RT only model TCP (%) RCT model
Plan Planned ‘Delivered’ Planned ‘Delivered’
Superior 70 Gy 78.6 78.3 (-0.3 %) 86.2 85.9 (-0.3 %)
Inferior 78 Gy 87.3 87.2 (-0.1 %) 92.3 92.5 (0.2 %)
Posterior 73 Gy 83.4 82.6 (-0.9 %) 89.7 88.9 (-0.9 %)
7.4.3 Inferior tumour - 78 Gy
The procedures previously described in section 7.4.1 were performed for the planned
dose distribution in which 78 Gy was prescribed to an inferior simulated medium-
sized tumour. Figure 7.11 shows a sagittal view of the calculated dose distribution
on the CBCT.
Figure 7.11: Dose distributions which would have been delivered using the 78 Gy
to medium inferior GTV plan, based on re-calculation on a CBCT image acquired
at the time of treatment. Dose distribution shown on sagittal views with simulated
inferior tumour shown in green.
Figure 7.12 shows the resulting differences between planned and ‘delivered’
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doses via cumulative DVHs for the various organs. As previously seen, ‘delivered’
doses are similar to planned, although the delivered dose to the right femoral head
is slightly higher than planned in this case. Again, the manually delineated bladder
and bowel show results more closely matched with those planned than the vol-
umes produced by the deformable registration. The simulated inferior GTV and
expanded volumes (GTV+2mm and GTV+5mm) all receive very similar doses to
those planned to the tumour volume. Table 7.1 shows the resulting TCP was cal-
culated within 0.2 % of original predicted values.
Figure 7.12: Cumulative dose volume histograms for femoral heads (red and ma-
genta), rectum (blue), bowel (purple), bladder wall (yellow), simulated medium
inferior tumour (green). Planned doses are shown dashed, ‘delivered’ doses are solid
lines and where delineations were performed manually on the CBCT for an improved
estimate of ‘delivered’ doses, these are shown dotted. Expanded GTVs to assess the
potential ‘worst case’ effect of geometric distortion in GTV delineation are shown
by dotted lines for GTV+2mm and 5mm in bright green and green respectively,
although as these closely overlay the GTV the lines are indistinguishable from each
other.
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7.4.4 Posterior tumour with 7 mm margins - 73 Gy
The planned dose distribution in which 73 Gy was prescribed to the simulated pos-
terior medium-sized tumour was analysed in the same way as previously described
in section 7.4.1. This plan had been produced using reduced margins for GTV to
PTV expansion, of 7 mm rather than 10 mm, i.e. incorporating a predicted geo-
metric uncertainty within DW-MRI of 2 mm rather than 5 mm. Figure 7.13 shows
the sagittal view of the ‘delivered’ dose distribution.
Figure 7.13: Dose distribution which would have been delivered using the 73 Gy
to medium superior GTV plan, based on recalculation on a CBCT image acquired
at the time of treatment. This plan used reduced margins (7 mm compared to
previous 10 mm) to create the PTV containing the tumour. Dose distribution
shown in sagittal view with simulated posterior GTV in green.
Figure 7.14 shows the resulting differences between planned and ‘delivered’
doses via cumulative DVHs for the various organs. The femoral heads received
doses similar to those expected, and the rectum a slightly reduced dose as for pre-
vious plans. The bowel doses were higher using the DR mapped bowel volume,
but the manually altered volume was again closer to the planned curve. The blad-
der wall planned and ‘delivered’ doses are similar, although this is reduced slightly
when the bladder was manually delineated. The simulated posterior GTV shown
in green receives a very similar dose to that planned, although the expanded GTV
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(GTV+2mm, shown in bright green) receives a slightly lower dose than planned.
Table 7.1 shows the resulting changes to TCP calculation: as expected using the
reduced PTV margins this produced the greatest change in TCP; however this was
only -0.9 % using both models.
Figure 7.14: Cumulative dose volume histograms for rectum (blue), femoral heads
(red and magenta), bowel (purple), bladder wall (yellow), simulated posterior GTV
(green). Planned doses are shown dashed and ‘delivered’ by solid lines; where de-
lineations were performed manually on the CBCT for an improved estimate of ‘de-
livered’ doses, these are shown dotted. An expanded GTV is shown to assess the
potential ‘worst case’ effect of geometric distortion in GTV delineation and is shown
by a dotted bright green line (GTV+2mm).
7.4.5 Limitations of this method
The method described in this chapter which was used to assess the feasibility of
delivery of dose escalated radiotherapy used simulated tumours. In the case of the
inferior and posterior tumours, the location inferred for the daily positioning of these
simulated tumours was likely to be reasonably accurate, as there was little movement
of the bladder wall in these regions. However, for the simulated superior tumour
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there is greater uncertainty whether the inferred position at time of treatment would
be correct, as this had required manual adjustment. Nevertheless, it appears that
the margins used in all cases to produce the relevant PTVs were sufficient that the
tumours themselves would have received similar doses to those intended.
The method used a coarse test of growing a margin around the original
simulated tumour to attempt to assess whether the tumour would still have received
the intended dose had the inferred position from DW-MRI been incorrect by the
maximum predicted by the bladder phantom work report in Chapter 4 (i.e. 5
mm and 2 mm respectively). It is obviously unlikely that the tumour would be
uniformly larger by this amount, however, the results from the plans using 10 mm
GTV-PTV margins all produced very similar DVHs for the expanded GTVs to the
original GTVs. The posterior plan using reduced margins of 2 mm showed a slightly
reduced dose to part of this expanded GTV volume, but this had a <1 % effect on
the calculated TCP.
The positioning of the bowel was difficult to assess, as again this is not
well visualised on the CBCT. The method used involved removal of bowel from
regions manually delineated as bladder, but added obvious volumes of bowel gas.
This produced results in which doses were similar to those planned. Therefore the
’delivered’ doses appear similar to those accepted within the RAIDER clinical trial,
however this is still subject to some degree of uncertainty.
The simulated tumours and the positions they were manually deformed to
would not necessarily be those expected by the deformation of the outside wall of
the bladder. Perhaps less deformation of a tumour would in fact be expected, as
Lotz et al. found that tumours tend to be more rigid than the bladder itself [71].
All results were based upon the positioning chosen by the radiographers
treating the patient - and using the treatment plan and PTV margins in clinical
use at that time. Therefore it is possible that different positioning would have
been chosen had these different plans been in use instead, or with the knowledge
for example that the tumour was in the inferior/superior/posterior portion of the
bladder. Certainly, should this be tested using MR imaging at the time of treatment,
the ability to visualise the tumour itself would be expected to improve dose delivery
to closer match the intended distribution. Therefore it could be argued that these
results indicate a worst case rather than realistic estimate of the dose that would be
delivered in that case.
Developments to build upon the work outlined in this chapter would benefit
greatly from the ability to assess bladder and tumour location immediately prior
to or during radiotherapy treatment delivery using MRI, owing to its superior soft
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tissue contrast. Many of the uncertainties relating to positional information are not
possible to improve using the currently available technologies of CT and CBCT, but
with the development of MR-linacs these issues should be possible to overcome.
7.5 Summary and conclusions
The approach taken in this chapter, of using treatment adaptation assessment within
RayStation TPS to assess the feasibility of delivery of dose escalated treatments
was limited by the ability of CBCT to visualise soft tissue, as well as the need for
simulation of tumours. However, it sets outs a blueprint for what could be done
using the same approach but using MR-sim of real tumours and an MR-linac.
Within the limitations stated, the delivery of the prescribed doses developed
in chapter 6 appear feasible. Further work is necessary using MR to visualise tumour
at the time of treatment delivery and to assess the impact upon organ at risk doses,




The original aim of this work was to study the use of DW-MRI and resulting ADC
maps with regard to their application for use within the radiotherapy treatment
of MIBC. It was intended that the project would investigate the magnitude and
effects of geometric distortion within DW-MRI upon the uncertainties in positional
information of bladder tumours. The ways these uncertainties might be mitigated
or accommodated in the design of radiotherapy dose distributions was to be inves-
tigated. The idea lying behind this project, was the potential to ultimately improve
treatment outcomes for patients with MIBC. This would be achieved by increasing
the radiotherapy dose prescribed, but without additional toxicity from such treat-
ment because the use of DW-MRI would enable improved targeting of the tumour
volume.
There is growing interest and investment in the use of MRI within radiother-
apy imaging and treatment planning, as well as at the time of treatment delivery via
hybrid systems such as MR-linacs. Several such systems are already in clinical use
in many centres across the world [72], although at present much of the use of MRI
is still in the realms of conventional T1- and T2-weighted imaging, rather than the
‘functional’ or ‘multi-parametric’ MRI that this thesis addresses. However, there are
already the beginnings of investigations into the clinical use of MRI sequences for
adaptation of radiotherapy treatments to various types of response [27, 28, 46]. The
work in this thesis aims to add to this area of endeavour, and highlight what could
be achieved with such technology for the particular tumour site of the bladder.
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8.1 Summary of the work
Chapter 4 showed in principle that positional information acquired in DW-MRI of
bladder tumours could be transferred to CT with a conservative estimate of 5 mm
accuracy if the only attempt to correct for geometric distortion is made within the
treatment planning system itself using deformable registration algorithms.
Subsequent work, also reported in chapter 4, tested how well an established
method within the diagnostic MR setting worked to correct for geometric distortion
in DW-MRI performed for the purposes of radiotherapy treatment planning. The re-
sults of this investigation found that the positional information could be transferred
from DW-MRI to CT with a conservative estimate of 2 mm accuracy, although the
workflow involved is not at present suitable for clinical use.
Chapter 5 used data from a paper by Plataniotis and Dale [61] in which
patients with MIBC had received treatment only with radiotherapy and which the
authors had fitted using a logistic TCP model. The chapter reported on the refitting
of this data with the Poisson model following Wright et al.’s approach [58]. A second
fit was also produced, to a further dataset from Plataniotis and Dale’s paper in which
patients had received chemotherapy as well as radiotherapy. This was done in order
to produce a model which may better estimate outcomes for patients receiving both
radiotherapy and chemotherapy.
The results from Chapters 4 and 5 were then used to predict TCP for a
range of simulated bladder tumours with different volumes and locations within
the bladder. It was found that the tumour location was of primary importance
for the extent to which dose could be escalated, as proximity to the bowel was
the main limitation. Variations in tumour volume were of secondary importance,
although an effect was seen (as expected), in which larger tumours resulted in slightly
lower TCP. Results using the model in which only the effects of radiotherapy were
included, showed that TCP could be expected to increase by at least 9 % (for
superior tumours, in which the dose escalation was the most limited), and up to
>19 % for the most inferior tumours (owing to their greater distance from the
bowel). The corresponding figures using the TCP model which incorporated the
additional effects of chemotherapy showed smaller relative increases in TCP, but
the absolute values of TCP were around 10 % higher.
The effects of variations in margin sizes used to produce PTVs from GTVs,
showed some minor differences for most tumour locations, but a large effect for
inferior tumours. Also, the effect of small changes in tumour location (i.e. shifting
the superior border of lateral or anterior/posterior tumours inferiorly by 1 cm)
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showed small effects on the dose to which tumours could be escalated (an increase
of around 1 Gy).
Finally, work reported in chapter 7 using the CBCT daily imaging, attempted
to ascertain the doses the treatment volumes might have received in practice. This
work showed that the tumour received similar doses to those planned, and would
have resulted in similar calculated TCPs to those originally predicted. There was
some uncertainty in bowel location using the CBCT images, owing to the poorer
image quality, and this could mean that the bowel received higher doses than orig-
inally planned, although manual delineations indicated that this was not likely the
case. As the dose escalation was already pushing OAR doses close to tolerance, this
is however an important finding which indicates that further work should be done
to assess the effect prior to a clinical trial for such dose escalation techniques. This
would ideally be performed using MRI which would show the required soft tissue
contrast as well as tumour location.
Overall, this work set out to explore the possibility of the use of DW-MRI
within the radiotherapy pathway. It addressed and quantified one of the main
potential limitations in the use of DW-MRI (i.e. geometric distortion) and its’
accommodation within radiotherapy treatment planning. The probability of local
control of the tumour in MIBC was modelled and then used to infer the magnitude
of potential increase should this change of treatment technique be used clinically. A
blueprint for assessment of the feasibility of delivery of the treatment was developed,
which showed that delivery of the change in technique appears feasible, as far as can
be assessed using this available technology. Further work using a similar approach
with MR rather than CT is the next step in developing this work.
8.2 Vision
The work within this thesis has indicated that it should be possible to improve the
local control of MIBC, by at least 9 %, and up to 19 % depending upon tumour
location and TCP model used. This is a large potential improvement in outcomes for
patients given that there have been minimal improvements in outcomes for MIBC
over several decades. The next steps required to enable the implementation of this
work into clinical practice are detailed in section 8.3. This section aims to first paint
a picture of how the technique could be implemented.
There are three main possibilities for the application of the work reported
in this thesis. Firstly, using DW-MRI in the same manner as shown here to de-
sign radiotherapy dose distributions but only using the additional information from
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DW-MRI alongside conventional CT scans via image registration. In this way, there
would be a minor change in the methodology of radiotherapy treatments for MIBC,
and which would not require any additional technology beyond that already widely
available but there would likely be some degree of increased tumour control, partic-
ularly for those tumours which happened to lie towards the inferior portion of the
bladder. A shortcoming of this approach is that the tumour may not be visible on
CBCT at the time of treatment delivery, particularly towards the end of a course of
treatment owing to response.
A second possible way to incorporate the findings within this thesis into
clinical practice, would be to largely use the described methodology, but without
the additional acquisition of CT for planning purposes. Instead, an anatomic MRI
using standard MRI sequences could be performed along with the DW-MRI, and
these images could be processed to enable direct radiotherapy planning on these
images. This full MR-sim approach would mean that some uncertainty in the ini-
tial patient set-up could be reduced, as all images for treatment planning would be
acquired in a single imaging session and the uncertainties involved in image registra-
tion (which propagate through the treatment process) would be minimised. Since
many radiotherapy departments are beginning to use MR-sim, this is an approach
which is likely to be possible in the near future, although the same shortcomings as
previously noted would apply.
Thirdly, in addition to the use of MR-sim, the patient could also be treated
on an MR-linac. In this scenario, the daily positioning for treatment could incorpo-
rate the acquisition of DW-MRI as well as conventional T1/T2 imaging. This could
potentially allow the further reduction of margins for expansion of GTV to high dose
PTV, as the GTV would now be directly visible at the time of treatment. Indeed,
it would also be possible that the daily adaptation of treatment could incorporate
tumour positional variations, variations in bladder filling, and also individual pa-
tient response to treatment via assessment of the quantitative information contained
within ADC maps. This potential scenario was the original vision for exploration
through the work in this thesis.
8.3 Future work
This section aims to outline the further work required to enable clinical implemen-
tation of the technique developed in this thesis. The main areas of work are:
1. Technical developments in image processing - either in-house, by TPS manu-
facturers, MR scanner and/or MR-linac manufacturers,
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2. MR-sim and ideally MR-linac use for visualization of real MIBC tumours pre-
treatment,
3. Further investigation of radiotherapy dose escalation of MIBC tumours using
real MR images and assessing resulting OAR doses,
4. Outcomes from BladderPath trial showing the effect of removing TURBT from
the treatment pathway would ideally be required to assure that this is at least
non-inferior to the current standard pathway.
The workflow required to use ADC maps within the radiotherapy treatment
planning process is at present cumbersome and unsuitable for clinical use. As noted
in (1), this problem could be addressed by (a) in-house development of appropriate
software, (b) TPS manufacturers incorporating distortion correction of DW-MRI
within the TPS, much as they have deformable registration algorithms, or (c) MRI
manufacturers directly addressing the issue via their scanner software. Any or all of
these methods could enable the safe and robust transfer of DW-MRIs via DICOM,
and for validated software within the radiotherapy department to then enable the
clinical use of such images. Such software would also be highly desirable within
an MR-linac platform, to enable the DW-MRI to be performed, and a distortion-
corrected image registered with pre-treatment images for daily treatment adaptation
prior to treatment delivery.
Radiotherapy dose escalation to MIBC should be further investigated, using
images of actual tumours and multi-parametric MRI for radiotherapy treatment
planning and pre-treatment positioning assessment where possible. Further work is
necessary to ascertain the potential effect on OAR doses resulting from any dose
escalation. Initial work could involve planning studies of those patients accrued
through the BladderPath clinical trial, to see whether
(a) similar results are obtained across a wider patient cohort,
(b) plans can be generated upon MRI scans directly,
(c) a full (theoretical) workflow for the treatment process can be achieved,
ideally leading to
(d) a clinical trial in which patients receive escalated doses based on their MRI
without TURBT within the patient pathway.
A further step would involve follow-up of patients during and after treatment in
which the response of tumours on DW-MRI and ADC maps would be seen. The
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outcomes could then facilitate design of a clinical trial using an MR-linac which
would enable on-treatment adaptation of radiotherapy treatment plans.
This vision of radiotherapy treatments based on tumour response as well
as location within the bladder represents a major shift towards fully individual-
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